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This chapter describes the clinical picture of the Prader-Willi Syndrome (PWS), and the 
different genetic defects that cause the syndrome. Additionally, the endocrine and 
metabolic aspects, psychological issues and sleep-related breathing abnormalities are 
described. It provides previously reported results on growth hormone (GH) treatment 
in PWS children. Finally, the objectives, study design, and in- and exclusion criteria of 
the Dutch multicenter GH trial are summarized.
1.1.1  Background
The characteristic features of Prader-Willi syndrome were fi rst documented by Prader, 
Labhart and Willi in 1956, as “Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchidismus 
und Oligophrenie nach myotonieartigem Zustand im Neugeborenenalter” [1]. PWS is 
a neurogenetic disorder characterised by a number of signs and symptoms, including 
muscular hypotonia, psychomotor delay, obesity, hypogonadism, and short stature. 
The estimated birth incidence varies from 1:10 000 to 1:30 000 live births, and the 
reported overall population prevalence of PWS, based on epidemiological studies, 
varies between 1: 38 395 to 1: 52 000 [2-4]. The differences between these numbers 
might be caused by different methodological approaches and by including patients 
with clinical diagnosis or with genetically confi rmed diagnosis of PWS. PWS is not 
associated with social-economic status and the distribution between both sexes is 
considered equal. Some studies, however, report a slightly higher prevalence among 
boys, which might be the result of more diffi cult recognition of hypogonadism in 
young girls. PWS is considered the most common syndromal cause of severe obesity.
1.1.1.1  Clinical features of PWS change with age
The clinical characteristics of the PWS are age-dependent. Originally, two clinical 
phases were distinguished: an infantile hypotonic phase and a childhood obese phase. 
Whitman et al added a third adolescent phase, with particular behavioural features 
[5], and Donaldson et al [6] extended this model with a foetal and neonatal phase.
1.1.1.2  Foetal and neonatal phase
Decreased foetal movements are commonly reported and there is an increased 
incidence of breech delivery and of delivery by caesarean section. These abnormalities 
have been related to hypotonia in neonates with PWS [6], but also foetal hypothalamic 
dysfunction has been suggested to play an important role [7]. At birth, PWS neonates 
have severe hypotonia mainly affecting the neck [8,9] (Figure 1), and have a weak 
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or absent cry [10]. Due to this severe hypotonia and poor sucking refl ex, feeding 
via a nasogastric sonde is usually required. Hypoplasia of the external genitalia is 
common in both sexes: Boys often have cryptorchidism, a hypoplastic scrotum and 
a decreased penile length. Girls may have hypoplastic labia, but this is less obvious 
and easily missed. Sticky saliva may also be a helpful pointer to the clinical diagnosis 
[9], and neonates may have temperature instability [11]. With the availability of rapid 
genetic testing and recommendations to exclude the diagnosis of PWS in any neonate 
with hypotonia, feeding diffi culties and low refl exes [12], the diagnosis is now usually 
confi rmed in the neonatal period. 
1.1.1.3  Infant phase
After the neonatal stage, hypotonia becomes gradually less marked, although infants 
with PWS remain to have feeding diffi culties, and failure to thrive. Psychomotor 
development is delayed, in particular gross motor development and speech development 
[13]. Body composition is abnormal, with a low lean body mass (LBM) and a high body 
fat percentage, even in infants who are underweight and have failure to thrive [14,15]. 
Although also present in the neonatal phase, typical dysmorphic features become 
more pronounced in the infant and childhood phase: a narrow bifrontal diameter, 
almond shaped eyes, a thin downturned upper lip, and a narrow nose. Many childeren 
with PWS have hypopigmentation, fair hair and blue eyes [16].
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Figure 1. Hypotonia in an infant with Prader-Willi Syndrome Adapted from U. Eiholzer, 
Prader-Willi Syndrome: Coping with the disease – living with those involved, Karger, Edt, 
Dr. E. Zangger (with permission).
1.1.1.4  PWS in childhood
In childhood, the hypotonia improves, although diffi culties relating to physical activity 
remain present. The original feeding diffi culties improve and excessive appetite with 
hyperphagia may develop, which may result in extreme obesity, if not controlled 
by dietary measures. Children with PWS have an abnormal body composition, with 
a relatively high body fat percentage and a low LBM, which contributes to exercise 
intolerance. Due to muscle imbalance, children with PWS may have genu valgum and 
often develop scoliosis [8]. Scoliosis may be present in childhood, but becomes more 
common and pronounced in adolescence. Their hands and feet are small. They have 
poor growth and behavioural abnormalities may occur, such as temper tantrums and 
obsessive compulsive behaviour, often in relation to food. Skin picking may be present, 
which is related with their decreased pain sensitivity. Other cutaneous symptoms 
consist of easy bruising and marked erythema after a hot bath. Autism-like symptoms 
are common in PWS children. Many have mild to moderate learning disability, but 
some children are able to attend normal schools [17].
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1.1.1.5  PWS in adolescence
Puberty may be delayed, incomplete or even absent in adolescents with PWS, although 
some have precocious puberty [18]. Pubertal delay may be caused by a combination 
of both hypothalamic dysfunction and primary hypogonadism. Spontaneous growth 
velocity is impaired, and the pubertal growth spurt might be lacking, which contribute 
to a decreased adult height. In adolescence, behavioural abnormalities may become 
worse, in particular in relation to daily life routines [5]. Most patients with PWS have 
mental disability, although there is a wide variation. Psychosis may occur, in particular 
in children with uniparental maternal disomy (UPD). 
1.1.1.6  PWS in adulthood
The combination of mental disability, excessive appetite with associated food-seeking 
behaviour, often resulting in extreme obesity, and psychiatric and behavioural 
abnormalities makes it usually impossible for an adult with PWS to live independently 
[13,17]. Median adult height is 145-150 cm for women and 155-162 cm for men [13,19, 
20]. Secondary sex characteristics are often absent or incomplete [13,17] although 
pregnancy, resulting in the birth of a healthy baby girl has been reported, in 1 PWS 
woman [21], whereas another one gave birth to a child with Angelman syndrome (AS) 
[22]. The incidence of scoliosis in adult PWS patients is high [17]. The adult population 
of today was usually diagnosed relatively late, when obesity was already present. 
So far no studies are available on the clinical picture of PWS patients who had been 
diagnosed early in life by genetic testing and who were treated from infancy onwards, 
with diet, exercise and hormonal substitution. Complications of severe obesity, such 
as diabetes mellitus type II or respiratory insuffi ciency do frequently occur and may 
lead to an early death [17]. However, if severe obesity can be avoided, patients with 
PWS may have a reasonable life expectancy [23].
1.1.2  Pathophysiology: the role of the hypothalamus
Most symptoms of the PWS are considered to result from hypothalamic dysfunction 
[7]. The hypothalamus is important in the regulation of many processes, including 
body temperature, activity level, appetite, body weight, and breathing. In addition, 
the hypothalamus regulates the release of hormones from the anterior lobe of the 
pituitary gland, which is often dysregulated in PWS patients (Endocrine and metabolic 
aspects). The higher incidence of breech delivery and caesarian section in PWS may 
be the result of foetal hypothalamic dysfunction. In addition, in PWS a decreased 
cell number and a lower volume of oxytocin-expressing neurons in the hypothalamic 
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paraventricular nucleus, the putative satiety neurons, have been reported and might 
be the basis of the insatiable hunger and obesity [245]. Abnormal temperature control, 
excessive daytime sleepiness and rapid eye movement (REM) sleep abnormalities as 
have been described in PWS, have been related to hypothalamic dysfunction [25] 
as well as abnormal chemoreceptor function in PWS [26]. In a subgroup of patients, 
Magnetic Resonance Imaging (MRI) studies showed an absence of the posterior pituitary 
bright spot. The posterior pituitary bright spot represents the neuropituitary and its 
presence confi rms the integrity of the hypothalamic-pituitary axis [27].
1.1.3  Genetic background
In 1981, PWS was reported to be related to a deletion in chromosome 15 in a subgroup 
of patients [28]. Subsequently, it was discovered that the deletion in PWS affected 
only the paternally inherited chromosome 15 [29]. In 1989, Nicholls et al found that in 
most of the remaining patients maternal disomy was the underlying genetic defect, 
suggesting genetic imprinting of the PWS region of chromosome 15 [30] (Figure 2). 
Gene imprinting is a mechanism by which part of a chromosome is “imprinted” or 
silenced during gametogenesis, which leads to a different expression according to 
the parent of origin. In some rare cases, PWS is considered to result from a mutation 
in the imprinting control region (imprinting center mutation, ICM), which causes a 
defect of paternal imprinting of chromosome 15 genes [31,32]. 
A deletion, a disomy or an ICM in the same region on the maternal chromosome, 
results in a completely different syndrome (AS).
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Figure 2. Schematic presentation of the different genetic defects in PWS. (A) represents 
a normal imprinting of the paternal (P) and maternal (M) regions of 15q11-13. In paternal 
chromosome 15, PWS genes are active (open square) and AS genes are imprinted (silenced, 
solid circle), whereas in maternal chromosome 15, PWS genes are imprinted (solid square) 
and AS genes are active (open circle). (B) represents the possible genetic defects, resulting 
in lack of expression of paternal genes in PWS (a paternal deletion, a uniparental maternal 
disomy (UPD), or an imprinting defect, due to a imprinting center (IC) mutation (ICM), 
respectively.
Adapted from H. Kokkonen; Genetic changes of chromosome region 15q11-13 in Prader-
Willi syndrome and Angelman syndrome in Finland ISBN951-42-7027-4 URL: http//herkules.
oulu.fi /isbn9514270274
1.1.4  The link between genotype and phenotype
Several mouse models of PWS have been developed, with maternal disomy or paternal 
deletions of the PW region, or mutations in the imprinting center. These mice have a 
consistent phenotype of failure-to-thrive, hypotonia, neonatal lethality, and growth 
retardation [33], but not of hyperphagia and obesity. For most genes, however, the 
link between genotype (Figure 3) and phenotype has not yet been established.
SNURF-SNRPN (imprinting center)
The promoter and fi rst exon of the SNURF-SNRPN gene appears to be the imprinting 
center in the PWS region [34]. The imprinting center has a role in erasing the 
grandmaternal imprint and establishing the paternal imprint during spermatogenesis, 
and in postzygotic maintenance of the paternal imprint [33].
Maternally imprinted genes
Maternally imprinted genes are normally only expressed in the paternally inherited 
chromosome, and are therefore lacking in PWS.
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Necdin 
Necdin (neurally differentiated embryonal carcinoma-cell derived factor) is involved 
in the neural differentiation and survival. Necdin defi cient neonatal mice have severe 
neonatal respiratory distress, with an abnormal rhytm-generating center in the 
medulla [35]. Most mice don’t survive the neonatal period, but the ones that do, have 
increased skin-scraping activity, improved spatial learning and structural abnormalities 
in the hypothalamus, which resembles the PWS phenotype [36]. Necdin defi cient mice 
show a reduction in both hypothalamic oxytocin producing and luteinizing hormone 
releasing hormone (LHRH) producing neurons [36]. A potential role for the Necdin (and 
other) genes in the other PWS symptoms outside the brain, such as small hands and 
feet, growth retardation, hypotonia, articulation defects, dysmorphic mouth, viscous 
saliva, and genital hypoplasia, are indicated by mouse models [37,38]. 
Paternally imprinted genes
Paternally imprinted genes are expressed only in the maternally inherited chromosome, 
and might therefore be over-expressed in PWS patients with UPD.
UBE3A
Patients with UPD are reported to have signifi cantly higher scores on verbal IQ tests, 
but not performance IQ tests and a higher risk of developing psychotic disorders in 
adult life than patients with a paternal deletion [39]. This is suggested to result from 
an overexpressing of the Ubiquitin protein ligase E3A (UBE3A) gene, which is located 
in the paternally imprinted AS region. Since UBE3A is expressed only on the maternally 
inherited chromosome 15, UBE3A may be overexpressed in patients with UPD [40]. 
Non-imprinted genes
Hypopigmentation of skin, hair and eyes is more frequent in patients with a paternal 
deletion [41]. Hypopigmentation is caused by the loss of expression of the non-
imprinted P gene which is also involved in oculocutaneous albinism [42].
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Figure 3. Human chromosome 15q11-13. Common deletion breakpoints (BP1, BP2, BP3), 
and imprinting center (IC). Adapted from H. Kokkonen; Genetic changes of chromosome 
region 15q11-13 in Prader-Willi syndrome and Angelman syndrome in Finland ISBN951-42-
7027-4 URL: http//herkules.oulu.fi /isbn9514270274
1.1.5  Diagnosis
Clinical diagnostic criteria were developed by Holm et al [11] for the diagnosis in 
children aged 0 to 3 years and from 3 years to adulthood (Table 1). The PW71 (D15S63) 
methylationtest is presently the method of choice for rapid diagnostic testing of 
patients suspected of having PWS [43]. The PW71 methylation test, using methylation-
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sensitive restriction enzymes, is based on the observation that the D15S63 (PW71) 
locus in chromosome 15q11-13 is methylated on the maternally derived chromosome, 
but unmethylated on the paternally derived chromosome [43]. The PW71 methylation 
test does not differentiate between paternal deletion, maternal disomy or ICMs. 
Further characterisation of the genetic defect is required to distinguish between 
those defects. The estimated recurrence risk is lower than 1%. In case of an imprinting 
center mutation the recurrence risk is higher [44]. 
Table 1: Consensus diagnostic criteria: Holm et al (Pediatrics 1993;91:398-340)
Major criteria
Neonatal and infantile central hypotonia with poor suck, gradually improving with age.1. 
Feeding problems in infancy with need for special feeding techniques and poor weight gain/2. 
failure to thrive.
Excessive or rapid weight gain on weight-for-length chart (excessive defi ned as crossing 2 3. 
centile channels) after 12 months but before six years of age.
Characteristic facial features with dolichocephaly in infancy, narrow face or bifrontal diameter, 4. 
almond shaped eyes, small appearing mouth, with thin upper lip, down-turned corners of the 
mouth (3 or more required).
Hypogonadism – with any of the following, depending on age:5. 
(a)  genital hypoplasia, male: scrotal hypoplasia, cryptorchidism, small penis and/or testes for age 
(<5th percentile); female: absence or severe hypoplasia of labia minora and/or clitoris.
(b)  delayed or incomplete gonadal maturation, with delayed pubertal signs in the absence of 
intervention after 16 years of age (male: small gonads, decreased facial and body hair, lack of 
voice change; female: amenorrhoea, oligomenorrhoea after age 16).
Global developmental delay in a child younger than 6 years of age: mild to moderate mental 6. 
retardation or learning problems in older children.
Hyperphagia/food foraging/obsession with food.7. 
Deletion 15q11-13 on high resolution (>650 bands) or other cytogenetic/molecular abnormality 8. 
of the PWS chromosome region, including maternal disomy.
Minor criteria
Decreased foetal movement or infantile lethargy or weak cry, improving with age.1. 
Characteristic behaviour problems: temper tantrums, violent outbursts and obsessive-2. 
compulsive behaviour; tendency to be argumentative, oppositional, rigid, manipulative, 
possessive, and stubborn; perseverating, stealing and lying (5 or more of these symptoms 
required).
Sleep disturbance or sleep apnoea.3. 
Short stature for genetic background by age 15 (in the absence of growth hormone 4. 
intervention)
Hypopigmentation: fair skin and hair compared to family.5. 
Small hands (<25th centile) and/or feet (<10th centile) for height age.6. 
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Narrow hands with straight ulnar border.7. 
Eye abnormalities (esotropia, myopia).8. 
Thick, viscous saliva with crusting of corners of mouth.9. 
Speech articulation defects.10. 
Skin picking.11. 
Supportive fi ndings
High pain treshold.12. 
Decreased vomiting.13. 
Temperature instability in infancy or altered temperature sensitivity in older children and 14. 
adults.
Scoliosis and/or kyphosis.15. 
Early adrenarche.16. 
Osteoporosis.17. 
Unusual skill with jigsaw puzzles.18. 
Normal neuromuscular studies.19. 
Major criteria are scored as 1 point, minor criteria as ½ point each. In children <3 years, a total of 5 
points, of which at least 4 major criteria are required for diagnosis. In children >3 years, a total of 8 
points, of which at least 5 major criteria are required for diagnosis
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1.1.6  Growth and body composition in PWS
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Figure 4. Reference curve indicating height-for-age and BMI-for-age in healthy boys and 
girls (straight line) and for boys and girls with PWS. Adapted from (19) and Growthanalyser 
(www.growthanalyser.org)
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Birth weight, but not birth length is signifi cantly reduced in PWS. Growth during 
the fi rst months of life may be compromised by feeding diffi culties secondary to 
the muscular hypotonia. Catch-up in length is rare, even when nutrition becomes 
adequate or even excessive, and some loss of height SDS during the fi rst three years 
of life has been reported. A close to normal growth rate, however, can be maintained 
until puberty (with the 50th percentile of the PWS growth curve, corresponding to the 
3rd percentile of the reference population), when a gradual decline from the reference 
curves starts [20,45]. A distinctive pubertal growth spurt is rare, and mean adult 
height is 155 to 162 cm in males and 145 to 150 cm in females [13,19,20].
Until a height of about 90 cm, nearly all PWS patients have a body weight within 
the normal range for the general population. After the initial feeding diffi culties, 
obesity is common, generally starting at age 2-5 years and, if uninhibited, proceeding 
to extremes. When a height of about 120 cm is reached, nearly all patients have 
surpassed the normal weight-for-height range [20]. 
1.1.6.2  Body composition
LBM is signifi cantly lower in PWS patients than in healthy normal-weight or obese 
individuals, which resembles a growth hormone defi cient state [46,47]. PWS patients 
have signifi cantly higher adiposity and lower LBM in the limbs, whereas trunk fat 
percentage is similar compared to normal weight subjects [46]. Bone mineral content 
(BMC) is signifi cantly lower in PWS patients than in healthy normal-weight and obese 
subjects [46]. These abnormalities are more severe in patients over 12 years, indicating 
a role of hypogonadism in the abnormal body composition [46]. When the diagnosis 
of PWS is established in the newborn period, parents are prepared for the risk of 
obesity, and with food restriction weight can often be maintained within normal 
limits. However, studies of body composition by Dual Energy X-ray absorbtiometry 
(DXA) have shown that even under these conditions, the ratio between fat and LBM is 
still elevated in PWS children due to subnormal muscle mass and a relatively high body 
fat percentage. Even in young, underweight infants, body fat percentage is relatively 
high [14,15]. 
Besides GH defi ciency, hypogonadism, and increased energy intake, a decreased 
energy expenditure and reduced physical exercise may play a role in the development 
and maintenance of obesity in PWS. Total energy expenditure in PWS subjects is 
low compared to healthy obese controls, and compared to predicted metabolic rate 
based on height, and weight [47]. The difference between energy expenditure in PWS 
children and controls could largely be explained by the small fat free mass as found 
in PWS [47,48].
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1.1.7  Endocrine and metabolic aspects
1.1.7.1  Hypothalamic-pituitary axis
The hypothalamus regulates the release of hormones from the anterior pituitary. 
These hormones are growth hormone (GH), gonadotrophins (LH/FSH), thyrotropin 
(TSH), prolactin (PRL), and corticotropin (ACTH) (Figure 5). The endocrine status of 
children with PWS is characterised by a hypothalamic dysfunction. Hypoplasia of the 
pituitary gland is reported in a subgroup of PWS patients [18], which might refl ect the 
hypothalamic insuffi ciency. Also a size reduction or even a complete absence of the 
posterior pituitary bright spot was found in 4 out of 15 patients [27]. The posterior 
pituitary bright spot is synonymous with the neuropituitary and its presence confi rms 
the integrity of the hypothalamic-pituitary axis. 
1.1.7.1.1  Growth hormone (GH) and Insulin-like growth factor I (IGF-I)
Most attention has been paid to the GH-IGF-I axis. Many studies reported that PWS 
individuals have a lower spontaneous 24-hour GH secretion [49] and a lower response 
to GH provocation testing with arginine, clonidine, or insulin-induced hypoglycaemia, 
compared to lean controls, but not compared to obese controls [45,49-52]. In non-
syndromal obese children, stimulated GH levels and 24-hour GH secretion are also 
low. They are considered not to have GH defi ciency, but to have a down-regulated 
GH secretion, which is reversible after weight loss [53]. Therefore the question was 
raised whether the low GH secretion in PWS was the result of true GH defi ciency, 
or secondarily to obesity. In healthy obese children and adolescents, IGF-I levels are 
high or normal [54,55]. In contrast, in PWS children, IGF-I levels are low, which is 
similar to patients with GH defi ciency [56]. Other arguments for GH defi ciency in 
PWS are short stature, small hands, feet and abnormal body composition, low insulin 
levels and the dramatic response to GH treatment, resembling the GH defi cient state 
[49,57,58]. Most authors concluded that GH defi ciency in PWS is most likely the result 
of a hypothalamic dysfunction [49,52,57].
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— Energy expenditure
— Timing of birth
Figure 5. The hypothalamus regulates the release of hormones from the anterior pituitary. 
GHRH: Growth hormone releasing hormone; CRH: Corticotropin releasing hormone; 
LHRH: Luteinizing hormone releasing hormone; TRH: Thyrotropin releasing hormone; GH: 
Growth hormone; ACTH: Corticotropin; LH: Luteinizing hormone; FSH: Follicle stimulating 
hormone; TSH: Thyrotropin; PRL: Prolactin
1.1.7.1.2  Gonadal dysfunction and cryptorchidism
Puberty is often delayed or incomplete. Cryptorchidism is common in boys with 
PWS, and they may have hypoplastic external genitalia. Girls often have hypoplastic 
labia minora, which may be more subtle and easily missed. These abnormalities are 
compatible with decreased function of the hypothalamus-pituitary-gonadal axis and 
were generally considered of hypothalamic origin. Alternatively it was suggested that a 
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lack of abdominal pressure due to extreme hypotonia might play a role in cryptorchidism 
as well [59]. Several reports demonstrated hypogonadotropic hypogonadism in a 
subgroup of children, with low response of LH and FSH to GHRH administration [45,60]. 
However, others reported signs of hypergonadotrophic hypogonadism [61]. Recently, 
a combination of low LH levels, indicating hypothalamic hypogonadism and high FSH 
and low Inhibin B, indicating a primary defect in Sertoli and/or germ cell maturation 
or an early germ cell loss, was reported in PWS boys [62]. Therefore some, but not 
all, of the PWS patients may have hypogonadotrophic hypogonadism, whereas others, 
in particular males, may have primary gonadal failure. It is not known whether the 
latter is the result of uncorrected or late correction of cryptorchidism, which often 
occurs in PWS boys. 
1.1.7.1.3  Thyroid hormone axis
Studies concerning thyroid hormone levels in PWS children are very limited. Congenital 
hypothyroidism has been reported in one PWS girl [63]. In some studies, however, 
baseline TSH levels have been reported to be normal, and TSH response to TRH 
stimuli has been reported to be high-normal [45,60], indicating a mild hypothalamic 
hypothyroidism in some PWS patients. However, these studies reported thyroid 
function in mostly obese adult PWS patients.
It has been suggested that GH therapy has an inhibitory effect on the hypothalamo-
pituitary-thyroid axis [64,65] and might increase peripheral conversion of T4 to T3 [66-
68]. Some studies report low fT4 levels requiring replacement therapy in individual 
PWS subjects [18,69,70].
1.1.7.1.4  Adrenal axis
Premature adrenarche has been reported in PWS patients [71] and is one of the 
supportive fi ndings of clinical diagnosis [11]. As a group, PWS children have increased 
adrenal androgen levels [72]. It has been suggested that this is the result of the PWS 
associated obesity, which may lead to hyperinsulinism, and increased serum IGF-I 
levels, which may in turn increase adrenal androgen levels resulting in premature 
adrenarche. High leptin levels might stimulate CRH. Recently, adrenal androgen levels 
in PWS were indeed found to be correlated with insulin, leptin and IGF-I [72]. However, 
in contrast to non-syndromal obesity, PWS children have low insulin and IGF-I levels, 
probably due to insuffi cient GH secretion. 
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1.1.7.2  Carbohydrate metabolism, lipid metabolism and cardiovascular risk 
 factors
As a group, PWS individuals have lower fasting insulin levels, and higher insulin 
sensitvity than a weight comparable group [73-77]. Suggested mechanisms for the 
higher insulin sensitivity are GH defi ciency [58] and an abnormal body fat distribution 
compared to simple obesity, as has been described in PWS female adults [78]. In PWS 
women, insulin sensitivity was higher and hepatic insulin extraction was increased 
compared to women with simple obesity. Nevertheless, a subgroup of PWS individuals 
do develop insulin resistance and the absolute prevalence of diabetes mellitus type 2 
(DM2) in adult PWS subjects is 25% [79]. The mean age at onset is 20 years.
Adiponectin is an anti-infl ammatory adipocytokine that has been inversely related 
to adiposity and insulin resistance [80-83], and is thought to be protective with regard 
to DM2 and cardiovascular disease [84]. Adiponectin levels increase during weight 
loss [85]. Adiponectin levels in obese adults with PWS are high, compared to simple 
obesity [86-89] and low [86,89] or similar [88] compared to lean adult controls. So 
far, no published data concerning adiponectin levels in pre-pubertal, not severely 
overweight PWS children compared to normal-weight healthy controls are available. 
1.1.8  Cognition, behaviour and psychotic illness
1.1.8.1  Cognition
IQ tests indicate that IQ in PWS is usually in the ranges of 50-85, with 25% having an 
IQ over 70 [90,91]. In a UK population study, it was shown that the global ability was 
near-normally distributed, but shifted downwards by about 40 IQ points for patients 
with both deletion and UPD. The most likely cause of the intellectual impairment 
is a genetic defect within the PWS region. It is now generally accepted that, as a 
group, PWS people have poor short-term memories, defi cits in sequential processing, 
and perform better on visuo-spatial tasks and have exceptional skills with jigshaw 
puzzles [92,93]. The latter is accepted as one of the supportive fi ndings for the 
clinical diagnosis of PWS [11]. However, more recently, it was shown that scores on 
2 WISC subtests (Object assembly and Block design) were lower in subjects with 
both deletion and disomy, than in a reference group with mental disability for other 
reasons. Furthermore, IQ was not related to weight and did not decline with age [93]. 
Systematic differences between patients with paternal deletions and UPD have been 
found. Patients with disomy have higher verbal abilities than those with deletions 
[94], and they have particularly diffi culties with the Coding subtest. These differences 
might result from different expression of genes on chromosome 15, in patients with 
UPD compared to deletions [94].
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1.1.8.2  Behaviour
Many behavioural abnormalities have been reported in PWS, such as temper 
tantrums, mood instability, self-injury and skin picking, excessive daytime sleepiness, 
impulsiveness, repetitive speech, obsessional symptoms and unusual routines [95-98]. 
Skin-picking, in combination with decreased sensitivity to pain, is more frequently 
observed with increasing age. Some children with PWS have clear signs of autism, 
some have signs of borderline autism. The obsessive behaviour of children with PWS 
becomes evident when trivial alterations in routines occur, such events may provoke 
a tantrum. These symptoms are very specifi c for PWS and could not be explained by 
their mental disability and obesity [30-33].
1.1.8.3  Psychosis
Until 1997, several case reports were published of PWS patients who suffered from 
psychosis. In order to establish whether this was a part of the PWS behavioural 
phenotype, an international collaboration was proposed and several cases of psychotic 
PWS patients were collected [99], which indicated a non-chance relationship between 
PWS and psychoses. The latter has now been confi rmed in a population study. This 
study showed that the prevalence of psychosis in PWS subjects with deletions, only 
just exceeded the prevalence reported for affective disorders in adults with learning 
disabilities, but of the adults with UPD, 62% had psychosis. The authors postulated 
that an abnormal pattern of expression of a maternally or paternally imprinted gene 
on chromosome 15 might lead to development of psychotic symptoms in PWS [40].
1.1.9  Sleep and breathing abnormalities
Sleep disorders, such as excessive daytime sleepiness and rapid eye movement 
(REM)-sleep abnormalities have been reported [100]. Respiratory abnormalities, such 
as hypoventilation [101-103], decreased pulmonary function [104], obstructive and 
central sleep apnea [105-108], and abnormal ventilatory and arousal response during 
hypercapnia both during wakefulness and during sleep [100,105,108,109] have been 
described in PWS. Studies evaluating sleep-related breathing in PWS by overnight 
complete polysomnography are limited. These studies show a wide range of incidence 
and nature of sleep-related breathing abnormalities. Most likely, the discrepancies 
between these studies are caused by the selection of patients: most studies included 
both children and adults, with or without obesity. Many patients were evaluated 
after referral to the sleep clinic for symptoms suggesting sleep-related breathing 
disorders. 
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A few months after start of the Dutch GH trial, several reports were published 
on sudden death in PWS children during GH treatment, most of which were related 
to breathing abnormalities (obstructive apnea, complications of upper respiratory 
tract infections). A causal relationship with GH treatment was suggested [110-112]. 
Unexpected death, however, has also been described in non-GH-treated children with 
PWS (113). In fact, Whittington et al. reported an overall death rate of 3% per year in 
a PWS population in one of the Health Regions in UK [4]. 
1.1.10  Associations between sleep-related breathing disorders, cognition, 
 behaviour and psychomotor development
In healthy children, increasing attention has been drawn to the association between 
sleep-disordered breathing and neurobehavioural abnormalities, in particular 
symptoms of Attention-Defi cit/Hyperactivity Disorder (ADHD). Associations between 
sleep-disordered breathing and cognition, school performance and psychiatric and 
behavioural co-morbidities are consistently reported, and seem to be at least partial 
reversible [114-116]. In PWS patients, no reports on the associations between sleep-
related breathing disorders and cognition or behaviour were available at the time we 
started the study.
1.2 Growth hormone treatment
Twenty years ago, GH treatment has fi rst been suggested to improve growth velocity 
in children with PWS [117]. Until now, several studies have shown that GH treatment 
improves height velocity in PWS children [49,51,118-120], resulting in a normal height-
for-age, if started before puberty. A few GH-treated patients had reached fi nal height, 
which was within the ± 2 SDS of their target height [121]. In addition, GH treatment 
has been shown to improve (but not normalise) body composition, with an increase 
in LBM and a decrease in body fat percentage, as had been measured with doubly 
labelled water [118] or DXA [49,70,122]. In 2000, GH was registered for PWS children. 
It might well be that the anabolic and lipolytic effects of GH treatment are far more 
important for the children than the increase in height velocity. In previous studies, 
GH treatment improved muscle strength and physical performance [52,69,122], and 
parents reported that their child was more active in daily life [50, 52,69,122]. The latter 
remain to be objectively confi rmed. In addition, preliminary reports indicated that 
GH treatment prevented deterioration of behaviour [123]. In several studies parents 
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reported that their child was more alert, had a more stable temperament and was 
easier to handle [69,119,123]. In contrast, it was reported that after discontinuation of 
GH treatment, children were more unhappy, more tired and less active. After stop of 
GH they had more temper tantrums and were more diffi cult to handle [69,123].
Recently, the question was raised whether start of GH treatment in infancy, 
might stimulate psychomotor development. Due to the increased awareness of 
paediatricians and neonatologists of the clinical presentation of PWS in infancy 
combined with the availability of the methylation test for rapid and reliable diagnosis, 
PWS is now usually diagnosed in infancy. Data on the effects of GH treatment on 
psychomotor development in PWS infants and toddlers are, however, limited. Eiholzer 
at al demonstrated a normalisation of LBM after 30 months of GH treatment in 18 PWS 
infants (<2 years) [124]. These children started walking freely at an earlier age than 
PWS children without GH, reported in literature [125]. Unfortunately, this study had 
no randomised controlled design. So far, there is only one controlled study on motor 
development in PWS infants during GH treatment, demonstrating an improvement 
in body composition, and suggesting an improvement in motor development if GH is 
started at an early age [126]. Long-term reports (> 1 year) of controlled GH studies in 
PWS, are however not available. 
Figure 6. (a) An adolescent with PWS before the era of early diagnosis and GH treatment. 
(b) A different generation. Adapted from U. Eiholzer, Prader-Willi Syndrome: Coping with 
the disease – living with those involved, Karger, Edt, Dr. E. Zangger (with permission)
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1.3 Growth hormone treatment and safety issues
1.3.1  Sleep-related breathing disorders
After recent reports of unexpected death in children and adults with PWS [110,111,113, 
127] renewed attention had been drawn to the described respiratory abnormalities. 
Some of the unexpected deaths were related to sleep apnea, obstruction or upper 
respiratory tract infections. Some of the deceased children, were treated with GH. 
By some clinicians a causal relationship between GH treatment and unexpected death 
was suggested [110-112]. Pfi zer, the pharmaceutical company that has a license for 
GH treatment of PWS children sent out a safety warning, stating that PWS children 
with respiratory abnormalities and obesity should be excluded from GH treatment. 
At the start of this study, only 3 reports were available concerning the effects of GH 
treatment on respiratory parameters in PWS children. Lindgren et al found improved 
CO2-responsiveness in 9 PWS children after 6-9 months of GH compared with baseline 
[128]. Myers et al demonstrated that inspiratory and expiratory muscle strength 
improved in 20 PWS children, aged 4 to 16 years after 12 months of GH compared 
with 10 controls [70]. Haqq et al reported in a double blind placebo-controlled cross-
over GH study a decrease in apnea hypopnea index after 6 months of GH in 12 PWS 
children, aged 4.5 to 14.5 years, although this did not reach statistical signifi cance 
[129]. More data are however required on the effects of GH on breathing. 
1.3.2  Scoliosis 
Scoliosis in PWS is common, starts in childhood and becomes worse during adolescence. 
Many adolescent patients have orthopaedic problems such as lumbago, walking 
diffi culties, contractures etc. Muscle hypotonia might contribute to the severity of 
scoliosis. Increased height velocity, as is evidently present during GH therapy, is 
generally considered as one of the exacerbating factors of scoliosis [130]. On the 
other hand, increased muscle mass and muscle strength during GH treatment might 
compensate for the effects of height velocity. Preliminary retrospective studies 
showed that GH therapy does not induce scoliosis, and that early start of GH therapy 
may not be an exacerbating factor of scoliosis [131]. However, prospective studies on 
the effects of GH on progression of scoliosis are required.
1.3.3  Thyroid hormone levels
Growth hormone might interact with the thyroid hormone axis, either via a direct 
inhibition of TSH secretion or via an increased peripheral conversion of T4 to T3. 
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Prospective studies on the effects of GH treatment on thyroid hormone function in 
children with PWS are, however, not available, but some studies report low fT4 levels 
requiring replacement therapy in individual PWS subjects  during GH [18,69,70].
1.3.4  Risk factors for DM2
GH treatment has been associated with decreased insulin sensitivity [132]. Recently, 
a higher incidence of insulin resistance and DM2 has been reported in GH-treated 
children, compared to the normal references [133]. These authors warned that 
children with a higher risk for developing DM2, such as PWS children, are more prone 
to develop DM2 during GH treatment. Monitoring of glucose homeostasis during GH 
treatment in these children is therefore warranted.
1.4 Aims of the study and outline of the thesis
This thesis presents a detailed description of several studies on growth, metabolism, 
psychomotor development, cognition, behaviour and breathing in PWS children. 
These children were enrolled in the Dutch GH study in PWS children. For a detailed 
description of the study, the reader is referred to Appendix A
Growth and body composition (Chapter 2)
We aimed to investigate whether GH improves growth velocity and contributes to the 
maintenance of normal weight-for-height in PWS children compared with randomised 
controls. In addition, we evaluated the effects of GH on body composition and body 
proportions.
Psychomotor development in infants with Prader-Willi Syndrome (Chapter 
3)
We aimed to evaluate if GH treatment improves mental and/or motor development, when 
started at a very early age. We hypothesized that initiation of GH treatment in infancy 
stimulates acquisition of gross motor skills, such as sitting and standing independently, 
walking, and climbing stairs. In addition, we postulated that an improvement of 
motor development stimulates the infant to explore his/her environment, and will 
subsequently improve mental development. We performed Bayleys Scales of Infant 
Development (BSID II) to evaluate mental and motor development. 
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Breathing disorders (Chapter 4)
The aim of this part of the study was to determine whether sleep-related breathing 
disorders do occur in young, pre-pubertal PWS children, and if so, how frequently. 
In addition, we evaluated whether GH treatment worsens sleep-related breathing 
disorders. We performed complete nocturnal polysomnography both before and 
during GH treatment. In addition, we reviewed literature on respiratory abnormalities 
in PWS, and the effects of GH on breathing disorders, and sleep-related breathing 
during upper respiratory tract infections. 
Associations between sleep-related breathing, cognition, psychomotor 
development and neurobehavioural abnormalities (Chapter 5 and 6)
In healthy children and adults consistent relations have been found between sleep-
disordered breathing and neurobehavioural abnormalities. Since sleep-disordered 
breathing, neurobehavioral abnormalities, and cognitive defi cits are common in PWS, 
we evaluated the associations in PWS.
In addition, we evaluated in infants whether psychomotor development is affected 
by sleep-disordered breathing, particularly obstructive sleep apnea syndrome (OSAS), 
as was recently shown for healthy infants. 
Thyroid hormone function (Chapter 7)
The aim of this part of the study was to evaluate the thyroid hormone function in a 
large group of pre-pubertal PWS children, and whether GH treatment affects thyroid 
hormone function.
Adiponectin levels and insulin sensitivity (Chapter 8)
As GH treatment induces insulin resistance, we aimed to evaluate serum adiponectin 
levels both before and during GH treatment. Adiponectin was chosen because it is 
strongly related to insulin sensitivity and is considered cardioprotective. 
In chapter 9, the general discussion, our data are discussed in relation to the 
present literature. Chapter 10 summarizes our fi ndings in English, and chapter 11 
presents a Dutch summary.
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Appendix A
In- and exclusion criteria and design of the study, entitled “Multicenter, randomised 
controlled growth hormone study in children with Prader-Willi Syndrome: effects on 
growth, body composition, activity level and psychosocial development”
A.1 Patients
Inclusion criteria:
Genetically confi rmed diagnosis of PWS  —
Age between 6 months and 16 years at start of the study —
Maximal bone age of less than 14 years in girls, or 16 years in boys —
Exclusion criteria:
Severe degree of scoliosis >15-20º —
Non cooperative behaviour —
Extremely low dietary intake of less than minimal required intake according to  —
WHO
Medication to reduce weight (fat) —
If female >13 years of age: a positive pregnancy test —
In children over 3 years of age: height > 0 SDS unless weight-for-height is > 2 SDS. —
Previously treated with GH —
A.2  Study Design
Group 1
Infants
Infants, with age between 6 months and 3 years at start of study, after randomisation 
for age, were divided into 2 groups
1.a. GH treatment group (50% of infants)
 Infants were treated with GH 1 mg/m2/day s.c. from start of the study.
1.b.  Control group (50% of infants)
Infants were followed as control patients during the fi rst year of the study. 
After one year of follow-up, GH treatment 1 mg/m2/day s.c. was started.
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Control 
start 12mo
GH 1 mg/m2/day
GH 1 mg/m2/day
Group 2
Pre-pubertal children
Pre-pubertal children with PWS, aged 3-12 years in girls, 3-14 years in boys, after 
randomisation for BMI, were divided into 2 groups
2.a.  GH treatment group (50% of children)
Children were treated with GH 1 mg/m2/day s.c. + dietary advice + training. 
Three months prior to the study dietary advice and training were started.
2.b. Control group (50% of children) 
No GH treatment, but children received dietary advice + training i.e. control 
group for 24 months. After 3+24 months children in group 2.b started GH 
treatment in a dose of 1 mg/m2/day s.c.
Control 
start 24mo
GH 1 mg/m2/day
GH 1 mg/m2/day
-3 mo
start diet and exercise 
Group 3
Pubertal children 
If puberty did not start spontaneously in children with PWS with chronological age at 
or above 12 years in girls and at or above 14 years in boys puberty was induced. All 
pubertal children were treated with GH.
3.a.  GH treatment group  1 mg/m2/day (50% of adolescents)
Pubertal children were treated with GH 1 mg/m2/day s.c. + dietary advice 
+ training. 
Three months prior to the study dietary advice and training were started.
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3.b.  GH treatment group 1.5 mg/m2/day (50% of adolescents)
Pubertal children were treated with GH 1.5 mg/m2/day s.c. + dietary advice 
+ training. 
Three months prior to the study dietary advice and training were started.
start 24mo
GH 1 mg/m2/day
GH 1.5 mg/m2/day
-3 mo
start diet and exercise 
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2.1 Abstract
Background: Prader-Willi Syndrome (PWS) children have impaired growth, and 
abnormal body composition. Previous one-year controlled studies showed improvement 
of height and body composition during growth hormone (GH) treatment. 
Objective: To evaluate growth, body composition, and body proportions during GH 
treatment in a large group of PWS children.
Design/Patients: We performed a randomised controlled GH trial in 91 pre-pubertal 
PWS children (42 infants, 49 children, aged 3-14 years). Infants were randomly assigned 
to GH treatment (GH group; 1 mg/m2/day; n=20), or no treatment (control group; 
n=22) for 1 year. Children >3 years were randomly assigned to GH treatment (GH 
group; 1 mg/m2/day; n=27) or no treatment (control group; n=22) for 2 years. 
Methods: Anthropometric parameters were assessed 3-monthly. Body composition 
was measured by Dual Energy X-ray Absorptiometry.
Results: Height, body mass index (BMI), and head circumference completely 
normalised during 1 and 2 years of GH in infants and children, respectively. Body 
fat percentage and body proportions improved in GH-treated children, but did not 
completely normalise. Lean body mass, for height and sex, did improve compared 
with the control group. Insulin like growth factor I (IGF-I) levels increased to levels 
above the normal range in most children.
Conclusions: Thus, 2 years of GH in PWS children normalises height, BMI and head 
circumference, and improves body composition, and body proportions. PWS children 
are highly sensitive to GH, suggesting that monitoring of serum IGF-I is indicated.
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2.2 Introduction
Prader-Willi Syndrome (PWS) is a genetic disorder, caused by either a microdeletion 
on the paternally derived chromosome 15q11-13 or a uniparental maternal disomy 
affecting the same region [1]. In rare cases, PWS is due to an imprinting center 
mutation [2], which results in silencing of genes that are normally active in the 
paternally inherited chromosome 15q11-13. PWS is characterised by muscular 
hypotonia, psychomotor delay, short stature and feeding diffi culties in infancy. After 
the age of 2-4 years, excessive appetite may result in rapid weight gain and obesity. 
Most of the characteristic features of PWS are thought to result from hypothalamic 
dysfunction [3].
Several endocrine abnormalities have been reported, including growth hormone 
(GH) defi ciency and hypogonadotropic hypogonadism [4]. Twenty years ago, GH 
treatment was suggested to improve growth velocity in children with PWS [5]. 
Nowadays, studies are available, showing that GH treatment improves growth velocity 
notably in GH-defi cient PWS children [6-8], or in PWS children treated irrespective of 
their GH-status [9]. In addition, body composition improved, i.e. body fat percentage 
decreased and lean body mass (LBM) (expressed as kg) increased during 1 year of 
GH treatment [7,10]. From the methodological point of view, it is striking that those 
studies did not adjust LBM for sex- and age dependency or, more importantly, for 
height at baseline and during GH treatment. Consequently, these studies might 
have reported an underestimation of LBM for height and an overestimation of the 
effect of GH treatment on LBM. There is only one study describing LBM adjusted for 
height in PWS children, but that was a non-controlled trial [11]. In previous studies, 
the incidence of overweight is high. Today, due to early diagnosis and intervention, 
severe obesity can often be prevented in PWS children, resulting in a different clinical 
presentation.
We therefore evaluated a large group of 91 PWS children, according to a one- 
and two-year controlled design in infants and children, respectively. We investigated 
effects of GH on growth, LBM adjusted for height, and body fat percentage, head 
circumference, and body proportions.
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2.3 Patients and Methods
Patients
Ninety-one patients were included in our randomised controlled GH trial. Forty-two 
children below 3.5 years at start of study (“PWS infants”) were treated in a one-year 
controlled study. Forty-nine pre-pubertal children over 3.5 years at start of study (“Pre-
pubertal PWS children”) were treated in a two-year controlled study. All participants 
fulfi lled the following inclusion criteria: (1) genetically confi rmed diagnosis of PWS; (2) 
age between 6 months and 14 years at start of study; (3) bone age less than 14 years 
(girls) or 16 years (boys); (4) pre-pubertal at start of study, defi ned as Tanner breast 
stage < 2 for girls and testicular volume less than 4 ml for boys [12], or with age below 
12 or 14 years in girls or boys, respectively. Patients with non-cooperative behaviour 
or patients receiving medication to reduce fat were excluded. Children were regularly 
seen by a dietician and a physiotherapist. The caloric intake and activity level of all 
children were standardised at 3 months prior to start of study, and recommendations 
were given. Compliance to diet and exercise was evaluated by the research nurse 
(MvE), in close collaboration with the dietician and, if indicated, the physiotherapist. 
All children were naïve to GH treatment at the start of study. They were included 
irrespective of their GH secretory status. After stratifi cation for age and BMI, all 
participants were randomly assigned to GH treatment (GH group) or no GH treatment 
(control group). The GH group received Genotropin® (somatropin) GH 1 mg/m2/day 
s.c. (Pfi zer).
The study protocol was approved by the Medical Ethics Committees of the 20 
participating Dutch centers. Written informed consent was obtained from the parents 
and children over 12 years of age.
Methods 
Anthropometry
At baseline, and at 3-monthly intervals, anthropometric measurements were 
performed. Standing height (or supine length, when appropriate) and sitting height 
(only in children >3.5 years) were obtained using a Harpenden stadiometer and a 
sitting height table. Weight was measured on an accurate scale. Left foot length, 
left tibia length and span width were measured according to Cameron [13], using a 
Harpenden anthropometer. The mean of 3 measurements was used for analysis. All 
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measurements were obtained by two observers (DF, MvE). Height, body mass index 
(BMI), and head circumference were expressed as standard deviation (SD) scores, 
adjusting for age and sex [14,15]. BMI and SD scores of BMI, height, sitting height, 
head circumference, foot length, span width, and tibia length were calculated with 
Growthanalyser, Version 3.0. (www.growthanalyser.org)
Body composition
Dual Energy X-ray Absorptiometry (DXA, type Lunar Prodigy, GE Healthcare) was 
performed in all children and total fat mass, fat percentage, and LBM were measured. 
Fat mass, fat percentage and LBM were transformed into SD scores adjusting for sex 
and age (LBMage) [16]. Since body composition, particularly LBM, is strongly related to 
height, LBM expressed as SD-score for age and sex might result in an underestimation 
in short stature. Besides, we were interested to know whether GH had an effect on 
LBM beyond the catch-up in height. For these reasons, LBM was also expressed as SDS 
for height and sex (LBMheight). The LBMheight SD scores were computed by comparing LBM 
of PWS children with LBM of healthy children with the same height and sex. Reference 
values were obtained using the same instrumentation and software [16]. Because 
reference data for DXA (Lunar Prodigy) were not available for children aged 0-4 years, 
only children >4 yrs were included in this analysis.
IGF-I and IGFBP-3
Blood samples were collected in the morning after a 12h overnight fast, immediately 
centrifuged and stored at -20° until assayed. Samples were pooled, and assayed in one 
session, to minimize variation. 
Serum insulin like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) were 
measured using a specifi c RIA in one laboratory [17]. The intra-assay coeffi cient of 
variation (CV) was 4% and the inter-assay CV was 6%. For IGF-I and IGFBP-3, sex- 
and age-matched Dutch references were available. Because of the age- and sex 
dependency IGF-I and IGFBP-3 levels were transformed to SD scores. 
Statistical analysis
Statistical analysis was performed by the Statistical Package for Social Sciences (Version 
11.0, Chicago, IL). Most of our data were not Gaussian distributed. We therefore 
expressed data as median (interquartile range, iqr), and we used non-parametric 
tests. Differences compared with baseline within groups were calculated using 
Wilcoxon signed rank test. Differences in change compared with baseline between 
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groups were calculated using Mann Whitney U tests. We used Bonferroni’s correction 
for multiple testing for both inter- and intra-individual testing. We used the binomial 
test to compare results of SD scores in PWS children with healthy reference data (0 
SDS). Values between -2 SDS and +2 SDS are considered within the normal range. 
Correlations were calculated using Spearman’s rank correlation coeffi cient (rho).
2.4 Results
Infants
Clinical characteristics
Table 1 lists the clinical data of 42 PWS infants and toddlers. After 1 year, 31 of them 
were re-evaluated (11 did not yet complete 1 year of study). After 1 year the control 
group also started with GH. After 2 years, 24 of them were re-evaluated (7 did not 
yet complete the second year of study). Infants with repeated measurements had 
similar SD scores of BMI and height compared with infants who did not fi nish 2 years 
of study yet. Infants with repeated measures were, however, older (p=0.025), which 
might refl ect early diagnosis of PWS during recent years. One infant of the GH group 
was treated with thyroxin replacement therapy to correct low fT4 levels prior to start 
of GH. Fifteen infants had a paternal deletion, 13 a uniparental maternal disomy, and 
in 14 PWS was confi rmed by a positive methylation test, albeit the underlying genetic 
defect was yet unknown. 
Height, BMI and head circumference
At start, BMI was not signifi cantly different from 0 SDS, but all other median SD scores 
were signifi cantly below 0 (Table 1). Anthropometric parameters were similar in the 2 
groups (Figure 1 a-c). Median head circumference SDS was relatively high compared to 
height SDS; -0.8 (-1.6 to -0.3) versus -2.3 (-2.8 to -0.7) in the GH group, and -1.1 (-1.8 
to -0.5) versus -2.1 (-3.2 to -1.0) in the control group.
In the GH group, height SDS increased from -2.3 (-2.8 to -0.7) to -1.0 (-1.9 to 0.10) 
(p < 0.005) after 1 year, and to -0.4 (-1.1 to 0.0) (p < 0.001) after 2 years. After 2 years 
of GH, all infants had a height SDS above -2 SDS. In the control group, height SDS 
remained low in the fi rst year, at start -2.1 (-3.2 to -1.0), and after 1 year -1.8 (-3.5 
to -1.4) (not signifi cant), but height increased to -1.2 (-2.3 to 0.1) (p < 0.01), when GH 
was started in the second year (Figure 1a). Head circumference SDS showed a similar 
trend from -0.8 (-1.6 to -0.3) to 0.0 (-0.9 to 0.7) (p<0.005) to 0.4 (-0.5 to 1.1) (p<0.005) 
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in the GH group, and from -1.1 (-1.8 to -0.5) to -0.8 (-1.6 to -0.3) (p<0.05) to 0.0 (-0.6 to 
0.6) (p<0.01) in the control group (Figure 1c). BMI SDS increased progressively in both 
groups, but remained within the normal range in most patients (Figure 1b). 
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Figure 1 a-c: Anthropometric data in PWS infants, during 2 years follow-up. In the fi rst year 
only the GH group received GH, during the second year both groups were treated. Data 
are expressed in SDS for age and sex and represented by boxplots. The lower boundary 
is the 25th percentile and the upper boundary is the 75th percentile. The line in the box 
represents the median. Lines are drawn from the smallest observed value to the largest 
observed value that is not an outlier. Open circles are outliers. Signifi cantly different 
compared with baseline 1p<0.05, 2p<0.01, 3p<0.005, 4p<0.001. Signifi cantly different change 
in GH group vs. control group: height SDS after 12 mo (p<0.001) and after 24 mo (p<0.05), 
head circumference after 12 mo (p<0.001).
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IGF-I and IGFBP-3 levels
IGF-I levels rapidly increased during GH treatment to levels with a median above 
+2 SDS (Table 1). After 1 year of GH treatment, 8/13 infants (62%) had an IGF-I level 
> +2 SDS, and after 2 years, 5/7 (71%). In the control group, IGF-I levels only increased 
during GH in the second year, with 6/7 (86%) infants having an IGF-I level > +2 SDS. 
IGFBP-3 levels increased during GH treatment and remained low during the fi rst year 
in the control group. However, as IGFBP-3 levels were within the normal range during 
GH, the IGF-I/IGFBP-3 ratio increased from -0.9 (-2.0 to -0.4) to 2.3 (1.7 to 3.4) (p<0.01) 
to 2.4 (1.7 to 3.3) (p=0.056) in the GH group and from -0.3 (-1.7 to 0.6) to -1.1 (-2.1 to 
0.0) to 2.5 (2.0 to 3.5) (p= 0.056) in the control group.
Pre-pubertal children (3-14 years)
Clinical characteristics
Of the 49 pre-pubertal PWS children, 2 were excluded from the present analysis. 
In one patient, GH dose was reduced because IGF-I levels increased to +5 SDS. A 
second patient had spinal surgery for scoliosis, used CPAP for sleep-related breathing 
disorders, and Risperdal after he had 2 psychotic episodes, all prior to start of GH. As 
a result, 47 children were eligible for baseline analysis (Table 2). After 1 year, 42 were 
re-evaluated (21 in the GH group and 21 in the control group), and after 2 years 40 
of them were re-evaluated (20 in the GH group and 20 in the control group). Children 
with repeated measurements had similar SD scores of BMI and height compared with 
those who did not fi nish 2 years of study yet. Three children (1 in the GH group and 
2 in the control group) received thyroxin replacement therapy prior to start of GH to 
correct low free T4 levels. 
Twelve children had a paternal deletion, 14 had a uniparental maternal disomy, 
and 5 had an imprinting center mutation. In 16 patients, PWS was confi rmed by a 
positive methylation test, but the underlying genetic defect was unknown. 
Height, BMI and body proportions
At start of study, BMI was signifi cantly higher than 0 SDS (Table 2). Ten out of 47 children 
(21%) were considered overweight. All other median SD scores were signifi cantly below 
zero. Head circumference SDS, however, appeared to be relatively high compared 
to other anthropometric parameters. At start, height SDS and BMI SDS were highly 
correlated (r = 0.44, p<0.005), but neither height SDS nor BMI SDS were related to IGF-I 
SDS. Baseline anthropometric parameters were not signifi cantly different between 
the GH- and control group. 
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During GH treatment, median height SDS increased compared with baseline from 
-2.0 (-3.1 to -1.7) to -1.2 (-1.5 to -0.6) (p<0.001) after 1 year, and to -0.6 (-1.1 to -0.1) 
(p<0.001) after the second year. In the control group, who did not receive GH for 2 
years, height SDS remained low (GH group vs. control group p<0.001 and p<0.001, 
after 1 and 2 years, respectively) (Figure 2a). BMI SDS decreased signifi cantly (p<0.001) 
during the fi rst year of GH treatment and then stabilized, at a level that was not 
signifi cantly higher than 0 SDS (p=0.08 and p=0.12 after 1 and 2 years respectively), 
whereas in the control group BMI remained signifi cantly higher than 0 SDS (Figure 
2b). Head circumference increased signifi cantly to completely normal values during 
GH treatment (p<0.001 and p<0.005 compared with baseline, after 1 and 2 years 
respectively) (Figure 2c), whereas tibia length, foot length, arm span, and sitting 
height signifi cantly improved, but remained signifi cantly lower than 0 SDS (Table 3). 
Body composition
At start of study, lean body mass corrected for age and sex (LBMage), and for height and 
sex (LBMheight) were signifi cantly below 0 SDS and body fat percentage was signifi cantly 
higher than 0 SDS in the total group. During GH treatment, LBMage SDS increased from 
-1.7 (-3.0 to -1.0) to -0.5 (-1.3 to 0.7) (p<0.005) after 1 year, and to -0.1 (-1.3 to 0.6) (p = 
0.10 compared with baseline) after 2 years, resulting in a LBMage not signifi cantly below 
0 SDS after 1 and 2 years of GH treatment (Table 3, Figure 3a). In the control group, 
LBMage SDS declined over time from -1.9 (-3.4 to -1.2) to -2.1 (-4.1 to -1.3) (p<0.05) to 
-2.5 (-3.8 to -1.4) (p<0.005) after 2 years and body fat percentage remained high. 
However, LBMheight SDS did not signifi cantly increase in the GH group from -1.7 (-3.8 to 
-0.6) to -1.5 (-2.3 to -0.7) (NS) to -1.9 (-2.4 to -1.4) (NS). Notably, in the control group 
there was a progressive and signifi cant decrease in LBMheight SDS from -1.4 (-2.9 to 0.9) 
to -1.9 (-2.9 to 0.0) (p<0.05) to -2.3 (-2.7 to -1.3) (p<0.005), resulting in a signifi cantly 
different change in LBMheight between the GH group and the control group after 1 (p 
< 0.05) and 2 (p < 0.05) years. Body fat percentage SDS decreased signifi cantly from 
2.1 (1.7 to 2.7) to 1.5 (0.7 to 2.1) (p<0.005) to 1.9 (0.7 to 2.3) (p < 0.005), but body fat 
percentage was still signifi cantly higher than 0 SDS, after 1 and 2 years of GH. Trunk 
fat (%) signifi cantly decreased in the fi rst year of GH, and increased in the second year 
to a level still signifi cantly below baseline. In contrast, in the control group, trunk fat 
increased gradually, resulting in signifi cantly higher levels after 2 years.
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Figure 2 a-c: Anthropometric data in pre-pubertal PWS children, during the 2-year 
controlled study. Data are expressed in SDS for age and sex and represented by boxplots. 
Signifi cantly different compared with baseline 1p<0.05, 2p<0.01, 3p<0.005, 4p<0.001. 
Signifi cantly different change in GH group vs. control group: height SDS after 12 mo 
(p<0.001) and after 24 mo (p<0.001), BMI SDS after 12 mo (p<0.001) and after 24 mo 
(p<0.005), head circumference after 24 mo (p<0.05).
IGF-I and IGFBP-3 
IGF-I SDS was signifi cantly lower than 0 at start of study (Table 1). After 1 year of GH 
treatment, IGF-I SDS had signifi cantly increased, and remained high. After 2 years, 
17/19 children (89%) had IGF-I SDS above +2. IGF-I SDS remained low in the control 
group, with levels below 0 SDS during 2 years. During GH treatment IGFBP-3 also 
increased, but not to the same SDS as IGF-I. 
Safety aspects
GH was well tolerated. Compared with randomised controls, GH treatment did not 
induce disadvantageous effects on carbohydrate metabolism, sleep-related breathing 
disorders and thyroid hormone levels. The results of these safety aspects have been 
published separately [18-20]. 
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Figure 3 a-d: Body composition in pre-pubertal PWS children, during the 2 years controlled 
study. Data are expressed in SDS for age and sex or SDS for sex and height and represented 
by boxplots. Signifi cantly different compared with baseline 1p<0.05, 2p<0.01, 3p<0.005, 
4p<0.001. Signifi cantly different change in GH group vs. control group: LBMage SDS after 12 
mo (p<0.001) and after 24 mo (p<0.001); fat mass SDS after 12 mo (p<0.001) and after 24 
mo (p<0.01); body fat percentage after 12 mo (p<0.001) and after 24 mo (p<0.001), and 
LBMheight SDS after 12 mo (p<0.05) and after 24 mo (p<0.05)
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2.5 Discussion
Our study demonstrates that height, BMI, and head circumference signifi cantly 
increased in GH-treated infants and children, resulting in a complete normalisation 
after 2 years of GH in pre-pubertal PWS children. Also length of foot and tibia, arm 
span, sitting height and body fat percentage improved in GH-treated children. LBM, 
corrected for sex and age, signifi cantly improved. LBM corrected for height and sex 
(LBMheight) did not increase during GH treatment, but signifi cantly declined in non-
GH-treated controls, resulting in a signifi cantly positive effect on body composition 
in the GH group compared with the control group. During GH treatment, IGF-I levels 
increased to levels above normal ranges in many patients. Also, IGFBP-3 increased, 
but to a lesser extent, resulting in an increased IGF-I/IGFBP3 ratio.
At baseline, we found a strong positive correlation between height SDS and BMI SDS. 
This is in favour of the hypothesis that growth in PWS represents a combination of 2 
opposite mechanisms: an acceleration of growth by obesity and a growth retardation 
due to insuffi cient GH secretion [21]. 
Median height SDS and IGF-I SDS, prior to start of GH treatment, were relatively 
low compared with previously reported levels [7,10,22]. This may be explained by 
the fact that our PWS children were not severely overweight in contrast to previously 
reported studies. In non-syndromal obese children, stimulated GH values are low as 
well as the 24-hour GH secretion, but IGF-I levels are high or normal [23,24]. It might 
be that in more severely obese PWS children, the low IGF-I levels are counteracted by 
the obesity-related IGF-I increase.
Head circumference SDS was less depressed than median SD scores of height, foot 
length, arm span and sitting height. This was in contrast to our expectations, because 
usually, in syndromal short stature, head circumference and other anthropometric 
parameters are equally impaired. Our results are in line with previous studies in young 
PWS children [25,26]. 
Two years of GH treatment resulted in a normal median height SDS, whereas height 
SDS in non-GH-treated children remained low. This is in line with previous studies [10, 
21,27], although so far, no 2-year controlled studies were available. 
The most important effect of GH, in our opinion, is the improvement of LBM. 
The low LBM in PWS most likely refl ects a reduced muscle mass, and may therefore 
contribute to clinical hypotonia, poor physical performance, and as a result, reduced 
energy expenditure [4]. LBM corrected for age and sex (LBMage) increased during GH 
treatment from levels below normal to levels not signifi cantly different from 0 SDS. 
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Although LBM corrected for height and sex (LBMheight), did not increase during GH 
treatment, LBMheight did signifi cantly decrease in the control group, which means that 
GH is benefi cial for improving LBM. The decrease in LBM in non-GH-treated PWS 
children is in line with previous studies [28]. In previous GH studies, LBM was expressed 
in kg, not taking into account height-dependency of LBM. Only one study expressed 
LBM in SDS (for both height and age) in GH-treated PWS subjects compared with 
baseline [11]. The authors suggested that the increase in LBM in 12 overweight PWS 
subjects was growth-related and that the initial defi cit of LBM cannot be compensated 
for by GH. This study was, however, a non-controlled study. Our study is the fi rst one 
showing that, although LBMheight did not increase in the GH group, the LBMheight did 
improve compared with the control group, indicating that GH is useful for improving 
LBM, taking into account the catch-up in height, in PWS children. 
Trunk fat percentage decreased during GH treatment and increased in the control 
group, indicating that GH decreases trunk fat percentage. However, trunkal fat 
percentage includes both subcutaneous trunk fat and visceral fat. It remains to be 
established whether GH treatment is benefi cial for decreasing visceral fat in PWS 
children. 
It has previously been suggested that a normalisation of small hands and feet 
during GH treatment, would suggest that those features are the result of GH defi ciency 
rather than directly caused by the genetic defect [21]. Our results, however, show 
that the size of the feet, arm span and sitting height do not normalise during GH 
treatment, indicating that GH defi ciency cannot fully explain these features. We did 
not measure hand length, because in our experience, a reliable assessment of hand 
length is diffi cult in PWS subjects. Although we cannot exclude that further catch-up 
takes place after the fi rst 2 years of GH, it seems that increased growth stabilizes 
after the fi rst year.
During GH, median IGF-I levels rapidly increased to levels above the upper limit 
of normal, whereas IGFBP-3 increased more gradually to levels completely within the 
normal range. IGFBP-3 is the major carrier protein of IGF-I and binds 70-95% of IGF-I as 
a binary complex or as a ternary complex together with the acid labile subunit (ALS) 
[29]. Only a minor fraction of IGF-I circulates in its free form, which is considered the 
biologically active form [30]. An increase of the IGF-I/IGFBP-3 ratio therefore suggests 
a large increase in free IGF-I. IGF-I levels in the supraphysiological range are in line 
with those reported by others in pre-pubertal PWS children and infants/toddlers [7, 
22,31]. In one of our patients, the GH dose had to be decreased in order to keep 
IGF-I levels within reasonable limits. It is not known why PWS patients seem more 
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responsive in terms of IGF-I than GH defi cient children [32]. In our study, samples were 
collected and stored, as all assessments were performed afterwards. We therefore 
did not adjust GH dose in most children. Nevertheless, we do now recommend to 
monitor IGF-I levels regularly, to prevent extremely high levels of IGF-I. Based on our 
data, one might consider treating PWS subjects with a lower GH dose. However, it has 
been shown previously that in order to optimally benefi t the metabolic effects of GH, 
PWS children should be treated with at least 1 mg/m2/day [33]. Future studies should 
evaluate the optimal GH dose in PWS children.
In conclusion, we found a normalisation of median SD scores of height, BMI, and 
head circumference, in pre-pubertal PWS children. Foot length, arm span, tibia length, 
sitting height and body fat percentage improved signifi cantly, but did not completely 
normalise. LBMage SDS improved to levels within the normal range, but LBMheight SDS 
did not change in the GH group. However, we found that LBMheight SDS decreased in 
controls, and therefore GH may still be considered benefi cial to optimize LBM in 
PWS. IGF-I levels increased rapidly to supraphysiological levels in most PWS children, 
indicating that PWS children are highly sensitive to GH and that monitoring of IGF-I is 
warranted to keep IGF-I levels within reasonable limits, arbitrarily below +3 SDS.
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3.1 Abstract
Background: Prader-Willi Syndrome (PWS) is a neurogenetic disorder characterised 
by muscular hypotonia, psychomotor delay, feeding diffi culties and failure to thrive 
in infancy. Growth hormone (GH) treatment will improve growth velocity and body 
composition. Research on the effects of GH on psychomotor development in infants 
with PWS is limited. 
Objective: To evaluate psychomotor development in PWS infants and toddlers during 
GH compared with randomised controls.
Design/Patients: 43 PWS infants were evaluated at baseline. Twenty-nine of them 
were randomised into a GH group (n=15) receiving 1 mg/m2/day GH treatment or a 
non-GH-treated control group (n=14). At baseline and after 12 months of follow-up, 
Bayley Scales of Infant Development (BSID II) were performed. Data were converted 
to percentage of expected development for age (%ed), and changes during follow-up 
were calculated.
Results: Infants in the GH group had a median age of 2.3 years (interquartile range 
(iqr) 1.7 to 3.0) and in the control group of 1.5 years (iqr 1.2 to 2.7) (p=0.17). Both 
mental and motor development signifi cantly improved during the fi rst year of study 
in the GH group vs. the control group. Median (iqr) change in mental development 
was +9.3% (-5.3 to 13.3) vs. -2.9% (-8.1 to 4.9), p<0.05, and in motor development was 
+11.2% (-4.9 to 22.5) vs. -18.5% (-27.9 to 1.8), p<0.05, respectively.
Conclusion: One year of GH treatment signifi cantly improved mental and motor 
development in PWS infants compared with randomised controls.
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3.2 Introduction
PWS is characterised by muscular hypotonia and failure to thrive in infancy, 
hypogonadism, psychomotor delay, cognitive defi cits, short stature, and obesity. 
Children with PWS have an abnormal body composition with a relatively high body fat 
percentage and a low lean body mass (LBM). Even in infants, who are still underweight, 
body fat percentage is high [1,2]. Accumulating evidence shows that hypothalamic 
dysfunction is responsible for many of the features in PWS, including hypogonadism, 
excessive appetite with decreased satiety, respiratory dysfunction, dysfunctional 
thermoregulation and growth hormone (GH) defi ciency [3,4].
The cause of PWS is a paternal deletion or a uniparental maternal disomy of 
chromosome 15q11-13, and in 1-5%, an imprinting center mutation, which causes genes 
in the paternally inherited chromosome 15q11-13 to be silenced [5,6].
Reports have demonstrated that GH treatment in older PWS children not only 
resulted in a remarkable growth response, but also in a dramatic improvement 
of body composition, with a decline in fat percentage and an increment in LBM, 
which resulted in an increased muscle strength and agility [7-10]. Preliminary studies 
suggested that GH might improve psychosocial development in PWS [11,12]. Due to the 
increased awareness of paediatricians and neonatologists of the clinical presentation 
of PWS in infancy combined with the availability of the methylation test for rapid 
and reliable diagnosis of PWS [13,14], diagnosis is now usually confi rmed in infancy. 
So far, there is only one controlled study on psychomotor development in PWS infants 
during GH treatment, demonstrating an improvement in body composition and motor 
development (mobility) [15] and an improvement of cognitive development [16].
The aim of our randomised, controlled GH-study was to evaluate in a group of 
PWS infants and toddlers whether start with GH treatment at a very early age could 
contribute to improvement of mental and motor development.
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3.3 Patients and Methods
Patients
The study group consisted of 32 Dutch and 11 Swedish PWS infants and toddlers. They 
fulfi lled the following inclusion criteria: (1) genetically confi rmed diagnosis of PWS; 
(2) age between 6 months and 3 years at start of the protocol. Patients with severe 
degree of scoliosis (> 20º) or extremely low dietary intake were excluded from the 
study. The caloric intake of all infants and toddlers was evaluated at start of study 
and recommendations were given based on their height and weight. Compliance to 
the diet was evaluated 3-monthly by the research nurse.
Baseline group
We included 43 infants and toddlers aged up to 3 years at start of study (24 boys). 
Twenty-one patients had a paternal deletion, 13 had a uniparental maternal disomy, 
one had an unbalanced translocation x 15, and in 8 patients, the diagnosis of PWS was 
confi rmed by a positive methylation test, but the underlying genetic defect was not 
yet specifi ed. After stratifi cation for age, children were randomised into a GH group 
receiving Genotropin® (somatropin) 1 mg/m2/day (Pfi zer), or into a non-GH-treated 
control group.
After 12 months of follow-up
For repeated measurement analysis only children were included with two Bayley 
Scales of Infant Development − II (BSID II) scores available. BSID II can only be used 
if “developmental age” is maximally 3.5 years. Overall, 29 infants and toddlers were 
eligible for repeated BSID II analysis. Of these, 15 were randomised into the GH group 
(7 boys) and 14 in the control group (8 boys). Fifteen patients had a paternal deletion, 9 
had a uniparental maternal disomy, 1 had an unbalanced translocation of chromosome 
15, and in 4 the diagnosis was confi rmed, but the underlying defect not yet specifi ed. 
Results of 14 patients were not analysed due to the following reasons: Five children 
did not reach one year of study yet, 1 was excluded from the study because he had 
thyroid hormone defi ciency, and 8 had already passed the upper limit of BSID II after 
1 year of follow-up (equally divided over the GH group and the control group).
The study protocol was approved by the Medical Ethics Committee of Erasmus 
Medical Center, Rotterdam, The Netherlands and the Medical Ethics Committee of 
Karolinska Institute, Stockholm, Sweden. Written informed consent was obtained from 
the parents.
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Methods
Anthropometric parameters
Height (supine height below the age of 2.5, thereafter standing height, measured 
with a Harpenden stadiometer), weight and head circumference were measured 
before start of study, and after 12 months. Median height, body mass index (BMI) and 
head circumference were expressed as standard deviation scores (SDS) for age and 
sex, according to Dutch references [17]. Growth Analyser Version 3.0 software was 
used to calculate BMI, and SD scores of height, BMI and head circumference (www.
growthanalyser.org).
Psychomotor Development
Psychomotor development was assessed at baseline and after 12 months with BSID-
II. BSID II results were compared to reference data derived from healthy infants and 
toddlers of comparable age [18,19]. BSID II yields 2 scores: mental developmental age 
(in months) and motor developmental age (in months). The mental scale consists of 
items in relation to visual and auditory information processing, language development, 
memory, eye-hand coordination, imitation and problem solving. The motor scale 
assesses gross and fi ne motor skills. The mental scale was performed in all children, 
and the motor scale was only performed in the Dutch children (of 32 Dutch infants, 
30 underwent motor evaluation). All psychomotor tests were conducted by a qualifi ed 
psychologist (M.W., B.B.).
Body composition
Body composition was assessed at baseline and after 12 months in the Dutch 
participants, using dual energy X-ray absorptiometry (DXA, type Lunar Prodigy, GE 
Healthcare). Total fat mass (in gram), fat (%), and lean body mass (LBM in gram) were 
measured at start of the study and after 12 months. Since reference values for DXA 
in this age-group are not yet available, we expressed LBM and body fat as percentage 
of total body mass. 
Insulin-like growth factor (IGF) I and IGF binding protein 3 (IGFBP-3)
In all children, IGF-I was measured. In Dutch children an immunometric technique 
on an Advantage Chemiluminescense System (Nicholls Institute Diagnostics, San 
Juan Capistrano, USA) was used. In Swedish infants a semi-illuminiscent technique 
on Immulite 1000 analyzer (Los Angeles, USA) was used. Intra- and inter-assay 
coeffi cient of variation (CV) for IGF-I are 4% and 6% respectively for the Advantage 
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chemiluminescence System, and 2.3-3.9% and 3.7-8.1% respectively for the Immulite 
1000 analyser. In Dutch infants, serum IGFBP-3 levels were measured using a specifi c 
RIA [20] in one laboratory. The intra-assay CV was 4% and the inter-assay CV was 6%. 
Because of age- and sex-dependency, IGF-I and IGFBP-3 levels were transformed into 
SDS [20, 21]. 
Data analysis
Statistical Package for Social Sciences (SPSS, Version 11) was used to perform 
statistical analysis. Data were expressed as median (interquartile range, iqr). Test 
results of psychomotor development were expressed as developmental age divided by 
chronological age, multiplied by 100 refl ecting percentage of expected development 
(%ed) for that age. Most of our data were not Gaussian distributed. We therefore used 
non-parametric statistics. To compare psychomotor development with normal (100 
%ed), binomial test was used. Differences between groups at baseline (2-tailed) were 
calculated with Mann Whitney U tests. Changes in motor and mental development 
are expressed as percentage of change over 12 months (development at 12 months 
minus development at start, divided by development at start, multiplied by 100). 
The use of change scores, rather than absolute measures enabled to adjust for age 
and development at start of study. For analysis of the data, we used analysis of 
covariates (ANCOVA) (1-tailed) with age and mental/motor development at start of 
study as covariates to test the change in mental and motor development between the 
GH group and the control group. Spearman non-parametric correlations were used 
to evaluate associations between mental and motor development within patients, 
and associations between psychomotor development and anthropometric parameters. 
We investigated if infants with less motor or mental abilities at start, would benefi t 
more from GH treatment. We divided all infants in 4 groups, based on dichotomised 
variables: (1). Initial mental and motor development, and (2). GH group vs. control 
group, in order to achieve an equal number of patients in each of the four groups.
3.4 Results
At baseline
At baseline, 43 infants (24 boys) were evaluated. Median (iqr) age was 2.0 years (1.3 
to 3.1): 2.3 years (1.6 to 3.0) and 1.6 years (1.2 to 2.9) (p=0.17) in the GH group and in 
the control group, respectively. Clinical characteristics are listed in Table I. Height, 
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BMI, head circumference, IGF-I and IGFBP-3, all expressed as SDS, were signifi cantly 
below 0 SDS. Results of mental and motor development are presented in Table 2 and 
Figure 1. At baseline, median mental developmental age was 1.5 years (1.2 to 2.1) and 
1.2 years (1.0 to 2.0) (p=0.08) and median motor developmental age was 1.2 years 
(0.8 to 1.8) and 0.9 years (0.8 to 1.8) (p=0.22) for the GH group and the control group, 
respectively. Mental development in the total group was 71.6% (66.3 to 80.0) of the 
expected mental development and motor development was 56.8% (51.6 − 64.7) of 
the expected motor development. Mental development was signifi cantly higher than 
motor development (p<0.001) and they were both signifi cantly lower in PWS than in 
healthy children (100%) (p<0.001). Mental and motor development were signifi cantly 
correlated (r=0.45, p<0.05). We found no signifi cant correlation between psychomotor 
development and the anthropometric parameters and no signifi cant association 
between age and development at start of study (mental development: r=-0.02, p= 
0.91, motor development: r=0.16, p=0.41).
After 12 months of follow-up 
Anthropometric parameters (Table 3)
At start of study, the GH group and the control group were not signifi cantly different 
with regard to height SDS (p=0.75), BMI SDS (p=0.51), and head circumference SDS 
(p=0.29). After 12 months of follow-up, height SDS had signifi cantly increased from 
-2.6 SDS (-3.3 to -1.8) to -1.6 (-2.1 to -0.8) (p<0.005) in the GH group and remained low 
in the control group. Notably, head circumference SDS signifi cantly increased from 
-1.0 (-1.7 to -0.3) to -0.2 (-1.2 to 0.6) (p<0.005) in the GH group, and remained low in 
the control group. 
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Table 1. Clinical characteristics at baseline (total group)
Median iqr
n  43
Sex (m/f)  24/19
Age (yr) 2.0 (1.3 to 3.0)
Height (SDS) -2.01 (-2.9 to -1.0)
BMI (kg/m2) 16.3 (15.1 to 18.4)
BMI (SDS) -0.1 (-1.2 to 1.6)
Head circ. (SDS) -1.01 (-1.7 to -0.3)
Body fat* (%) 27.8 (23.7 to 33.5)
LBM* (%) 70.9 (65.2 to 74.7)
IGF-I (μg/L) 28.5 (21.0 to 47.3)
IGF-I (SDS) -1.91 (-2.6 to -1.3)
IGFBP-3 (μg/L) 1.0 (0.7 to 1.2)
IGFBP-3 (SDS) -2.11 (-3.1 to -1.4)
IGF-I was available in 34, and IGFBP-3 in 23 patients.
1 p<0.001, compared to 0 SDS. 
*Only available in Dutch patient group (n=32).
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Figure 1. Mental and motor development at baseline (total group). Open squares represent 
mental development and solid squares represent motor development. Reference line 
represents normal motor and mental development (100%).
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Table 2. Psychomotor development at baseline (total group)
Median iqr
n 43
Chronological age (yrs) 2.0 (1.3 to 3.0)
Mental developmental age (yrs) 1.3 (1.1 to 2.1)
Mental development (%ed) 71.6 (66.3 to 80.0)
Motor developmental age* (yrs) 1.0 (0.8 to 1.8)
Motor development* (%ed) 56.8 (51.6 to 64.7)
*Only available in Dutch patient group (n=30). 
Motor development (%ed) is signifi cantly lower than mental development (%ed) (p<0.001). Motor and mental 
development are both signifi cantly lower than in healthy children (100%ed) (p<0.001) and both signifi cantly 
correlated (r=0.45, p<0.05).
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Psychomotor development 
We found a signifi cant improvement during 1 year of follow-up in mental development 
for the GH group +9.3% (-5.3 to 13.3) compared with the control group, -2.9% (-8.1 to
4.9) (p =0.04). Also motor development improved signifi cantly in the GH group, +11.2% 
(-4.9 to 22.5), compared with the control group, -18.5% (-27.9 to 1.8) (p=0.04). For 
both motor and mental development in the GH group and control group, there was 
a large individual variation in change during follow-up (Figure 2). When infants were 
subdivided depending on their initial developmental age, the improvement in motor 
development was only signifi cant in infants with lower initial motor development (i.e. 
motor developmental age below 0.85 years) (Figure 3). We did not fi nd such differences 
for mental development. There was a weak correlation between the change in mental 
development and change in head circumference, but this did not reach signifi cance 
(r=0.31, p=0.11). The change in motor development did not signifi cantly correlate with 
the change in LBM % (r=0.27, p=0.31).
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Figure 2. Changes in mental and motor development during 12 months of study. The 
lower boundary of the boxplot is the 25th percentile, and the higher boundary is the 
75th percentile. The line in the box represents the median. Lines are drawn from the 
smallest to the largest observed value that is not an outlier. Horizontal line represents 
no change compared to normal children (change of 0%). A positive value represents a 
catch-up, compared to normal children, whereas a negative value represents less progress 
compared to normal children.
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Figure 3. Motor development for children with lower and higher developmental age at 
start of study. Horizontal line represents no change compared to normal children (change 
of 0%). A positive value represents a catch-up, compared to normal children, whereas a 
negative value represents less progress compared to normal children.
Body composition
LBM and body fat (both expressed as percentage of total body mass) are listed in Table 
3. Body composition was similar in both groups at start of study, and body composition 
did not signifi cantly change during follow-up in both groups. 
IGF-I and IGFBP-3 (Table 3)
The median (iqr) IGF-I SDS at start of study was -2.1 (-2.7 to -1.7) for the GH group and 
-2.0 (-2.6 to -0.3) for the control group. Median IGFBP-3 SDS was -2.8 (-3.5 to -2.4) and 
-1.8 (-3.4 to -0.9) respectively, which was not signifi cantly different. After 12 months 
compared with baseline, median IGF-I in the GH group had signifi cantly increased 
to 1.7 SDS (0.1 to 2.5) (p<0.005) with IGFBP-3 levels of 0.4 (-0.3 to 1.1) (p<0.05), 
whereas in the control group, IGF-I and IGFBP-3 levels remained low. This resulted in 
a signifi cantly higher IGF-I, and IGFBP-3 levels in the GH group, compared with the 
randomised controls after 1 year of study (p<0.001 and p<0.05, respectively).
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Safety aspects
GH was well tolerated. Compared with randomised controls, GH did not induce 
disadvantageous effects on carbohydrate metabolism, sleep-related breathing 
disorders, and thyroid hormone levels. The results of these safety aspects have been 
published separately [22-24]. 
3.5 Discussion
We assessed psychomotor development in relation to anthropometry in 43 infants 
with genetically confi rmed diagnosis of Prader-Willi Syndrome. Both mental and motor 
development were impaired in the PWS infants, compared to the normal population. 
We did not fi nd associations between psychomotor development, and anthropometric 
parameters. In the randomised GH study, we found a signifi cant improvement of 
both mental and motor development in the GH group compared with the control 
group. Infants with lower developmental age had the greatest improvement in 
motor development, suggesting that GH treatment might be considered at an early 
developmental age to optimize the GH effect on motor development.
Mental development improved after 1 year in the GH group compared with the 
control group. This is in line with previous data, in 7 GH-treated PWS infants compared 
with 5 randomised controls, showing an improvement of cognitive development and 
language development, combined with an improvement of head circumference [16]. 
We could not fi nd a signifi cant association between mental development and head 
circumference, neither at baseline nor after 1 year of follow-up (data not shown), 
but there was a weak correlation between the change in mental development and 
head circumference after 1 year of follow-up (r=0.31, p=0.11), which did not reach 
statistical signifi cance. Our sample size might have been too small to identify such 
an association. The increased head circumference might refl ect involvement of the 
central nervous system in the cognitive effects of GH treatment. 
Head circumference SDS was in our study in the low-normal range, which was 
relatively high compared to height SDS at start of the study. In syndromal short 
stature, height and head circumference are usually equally affected. Our data 
are however consistent with previous studies in which also relatively larger head 
circumferences were reported for PWS infants [16,25]. After one year of follow-up, 
we found a normalisation of head circumference, and a signifi cant increase of height 
SDS in the GH group, but not in the control group. The increase in height was similar 
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to the response reported by others in infants and toddlers with PWS and idiopathic 
GH defi ciency [26,27].
In the general population, there is evidence that intelligence tends to be higher 
in subjects whose head circumference is higher, and brain growth during infancy and 
early childhood seems to be more important than during foetal life in determining 
cognitive function [28]. Long-term data are needed in order to evaluate the effects of 
improved growth of head circumference in early infancy on cognition in PWS children 
and adults.
In our study, IGF-I levels rapidly increased during GH treatment from below the 
normal range to the high-normal range. These levels were similar to those found by 
others [15]. IGF-I receptors have been localized in several areas in the human brain, 
indicating that IGF-I may have a neuroregulatory role in the central nervous system 
[29]. Theoretically, IGF-I may directly infl uence the central nervous system or GH 
might induce local IGF-I expression in brain tissue, thereby improving psychomotor 
development.
Another possible explanation for the improvement of mental development during 
GH, might be that due to the improved motor development, children are able to sit, 
stand and walk independently, which enables them to explore and interact with the 
environment, resulting in a subsequent improvement of mental development. 
We found a signifi cant improvement of motor development in the GH group compared 
with the control group, particularly in children with initially lower developmental age. 
This might be explained by the effects of GH treatment on LBM. Differently from what 
observed in literature [15,26], body composition did not signifi cantly change in GH-
treated patients. Consequently, it is unlikely that signifi cant improvement of motor 
development in the GH group might be attributed to the effects of GH treatment 
on LBM. In addition, we did not fi nd associations between the change in LBM and 
change in motor development. This might be explained by the lack of sex- and age 
adjusted SD scores, because reliable reference data for DXA (by Lunar Prodigy) in 
infants and toddlers do not exist. Only one controlled study is available concerning 
motor development in PWS infants during GH treatment [15]. This study showed an 
improvement of mobility (defi ned as the ability to move the body from one position 
to another), but not stability in PWS infants. 
A limitation of our study is that motor development in these developmentally 
delayed infants with PWS, was below the reference data for normal children. We, 
therefore, were not able to express data as SDS for age. We addressed this issue 
by using the % of expected development, i.e. the ratio between developmental 
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age and chronological age. In addition, we could not use changes in SD scores to 
evaluate changes in mental and motor development in the GH group vs. the control 
group. Although there were at start no statistically signifi cant differences in age and 
mental or motor development between the GH group and the control group, baseline 
differences between groups might be of clinical relevance. For that reason we used 
relative changes and we also adjusted for age and development at start of study by 
using analysis of covariates.
In conclusion, we found after 1 year of GH treatment a signifi cant improvement 
in both mental and motor development in PWS infants and toddlers compared with 
randomised controls. Head circumference increased from low-normal to normal during 
GH treatment. Children with an initially lower motor developmental age, did improve 
more than children with a higher motor developmental age at start, which suggests that 
early start with GH might be benefi cial. Long-term studies are warranted to evaluate 
the effects of very early start with GH on cognition in childhood and adulthood. 
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4.1 Abstract
Background: Recently, several cases of sudden death in growth hormone (GH)-
treated and non-GH-treated, mainly young Prader-Willi Syndrome (PWS) patients, 
were reported. GH treatment in PWS results in a remarkable growth response, and an 
improvement of body composition and muscle strength. Data concerning effects on 
respiratory parameters, are however limited. 
Objective: To evaluate effects of GH on respiratory parameters in pre-pubertal PWS 
children.
Design/Patients: Polysomnography (PSG) was performed before GH in 53 children and 
repeated after 6 months of GH treatment 1 mg/m2/day in 35 of them.
Patients: 53 pre-pubertal PWS children (30 boys), with median (interquartile range, 
iqr) age of 5.4 (2.1 to 7.2) years and body mass index (BMI) of +1.0 standard deviation 
score (-0.1 to 1.7). 
Results: Median (interquartile range) Apnea Hypopnea Index (AHI) was 5.1/h (2.8 to 
8.7) (normal 0–1/h). Of these, 2.8/h (1.5 to 5.4) were central apneas and the rest 
mainly hypopneas. Duration of apneas was 15.0 sec (13.0 to 28.0). AHI did not correlate 
with age and BMI, but central apneas decreased with age (r=-0.34, p=0.01). During 
6 months of GH treatment, AHI did not signifi cantly change, from 4.8 (2.6 to 7.9) at 
baseline to 4.0 (2.7 to 6.2; p=0.36). One patient died unexpectedly during mild upper 
respiratory tract infection (URTI), although he had a nearly normal PSG. 
Conclusions: PWS children have a high AHI, mainly due to central apneas. Six 
months of GH does not aggravate the sleep-related breathing disorders in young PWS 
children. Our study also shows that monitoring during URTI in PWS children should be 
considered.
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4.2 Introduction
 
Prader-Willi Syndrome (PWS) is characterised by muscular hypotonia, hypogonadism, 
psychomotor delay, obesity that may become extreme after the age of 2-4 years, and 
short stature. Sleeping disorders and respiratory disorders such as hypoventilation, 
decreased pulmonary function, obstructive and central sleep apnea and abnormal 
ventilatory and arousal response during hypercapnia may also occur [1-5]. Hypothalamic 
dysfunction is thought to be responsible for many features of PWS [6].
The underlying cause of PWS is a paternal deletion or a uniparental maternal 
disomy of 15q11-13. In 1-5%, PWS is the result of an imprinting-center mutation, which 
causes genes in the paternally inherited chromosome 15q11-13 to be silenced [7, 8].
Several reports have demonstrated that GH treatment results in a remarkable 
growth response, but also in an impressive improvement of body composition, with 
decline in fat-percentage and increment in lean body mass, muscle strength and 
agility [9-11]. Preliminary studies suggested that GH might improve psychosocial 
development in PWS [12]. Data on effects of GH on respiratory parameters in young, 
pre-pubertal PWS children are however very limited. Haqq et al found after 6 months 
of GH a slight reduction in sleep apnea incidence in 12 PWS children, aged 4.5 to 14.5 
years [13]. Lindgren et al found improved CO2-responsiveness in 9 children with PWS 
after 6-9 months of GH compared with baseline [14]. Recently, several reports have 
been published on sudden death in children with PWS during GH treatment [15,16]. 
Unexpected death, however, has also been described in non-GH-treated children with 
PWS [17,18]. In fact, Whittington et al reported an overall death rate of 3% per year 
for PWS patients in one UK Health Region [19].
In our study we evaluated the occurrence of sleep-related breathing disorders 
(SRBD) in 53 young, pre-pubertal children with PWS and the effects of 6 months of GH 
treatment in 35 of them.
4.3 Patients and Methods
Patients
In April 2002, a multicenter, randomised, controlled, prospective GH trial in PWS 
children was started investigating the effects of GH treatment versus no GH on growth, 
body composition, activity level and psychosocial development. Participants fulfi lled 
the following inclusion criteria: (1) genetically confi rmed diagnosis of PWS by positive 
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methylation test; (2) age between 6 months and 16 years; (3) bone age less than 14 
years (girls) or 16 years (boys); (4) in children over 3 years: height standard deviation 
score (SDS) for age below zero (5) in children over 3 years: if height is > 0 SDS, weight-
for-height SDS must be over +2 SDS, according to Dutch standards [20,21]. Patients 
with non-cooperative behaviour or patients receiving medication to reduce fat were 
excluded. All patients over 3 years started a diet and exercise program 3 months prior 
to start of the study. Children were enrolled in the study irrespective of their GH 
status. Patients received Genotropin® (somatropin) in a dose of 1 mg/m2/day (Pfi zer). 
The fi rst 4 weeks of treatment, they received only 0.5 mg/m2/day in order to prevent 
fl uid retention.
In April 2003, we started a polysomnography (PSG) study in addition to the 
original protocol. For the PSG study we used the following inclusion criteria: (1) pre-
pubertal at baseline and at repeated PSG (2) no upper respiratory tract infection 
(URTI) during PSG (3) no previous GH treatment. On November 11, 2005, 83 patients 
had been included in the original study. Twenty-fi ve were excluded from the PSG 
study, because they received GH treatment, before start of the PSG study. For one 
patient, parents refused PSG, 3 were pubertal at repeated PSG and one was excluded 
because of treatment with nasal continuous positive airway pressure. As a result, 53 
patients were eligible for analysis of baseline PSG. Thirty-nine children had a PSG 
repeated after 6 months of GH treatment. Fourteen patients were followed in the 
control group of the original study. Their PSG will be repeated at 6 months after start 
of GH treatment. As all patients were stratifi ed for age and BMI before randomisation 
in the original study, these patients were not different from those who had repeated 
PSG. Of the 39 patients with repeated PSG, 4 had URTI during second PSG and were 
therefore excluded from group analysis.
The study protocol was approved of the Medical Ethical Committee of Erasmus 
Medical Center, Rotterdam, Netherlands. Informed consent was obtained from the 
parents.
Methods
Anthropometry
Supine length was recorded below the age of 2.5 years, and thereafter standing height, 
measured with a Harpenden stadiometer. Weight was assessed on an accurate scale, 
and body mass index (BMI) (kg/m2) was calculated. Height and BMI were converted 
into SDS according to Dutch references for age [20,21]. Calculations were performed 
with Growth Analyser Version 3.0 (www.growthanalyser.org).
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Polysomnography
PSG was performed before and after 6.6 (6.1-7.3) months of GH treatment. All PSGs 
were performed in one specialized sleep center (A.W., sleep specialist). Children 
were admitted to the sleep center at 5.00 p.m., accompanied by one parent. They 
underwent complete overnight PSG. Recordings included electroencephalogram, 
electro-oculogram, one channel derivation of electrocardiogram, and surface 
electromyography of the submental muscle and both anterior tibial muscles. Nasal-
oral airfl ow was monitored by nasal pressure prongs fi xed in the nose, respiratory 
effort by thoraco-abdominal strain gauges and oxygen saturation (SaO2) by pulse 
oximetry. All PSG studies were evaluated independently by two persons, both 
certifi ed in PSG analysis. In case of major discrepancies between both assessments 
a third expert opinion was asked. The polygraphic records were scored according to 
standard criteria of Rechtschaffen and Kales [22]. A period of apnea or hypopnea 
was defi ned as more than 90% (apnea) or 50% (hypopnea) reduction of airfl ow for 3 
breaths or longer. For hypopneas, the additional criterion was a reduction of SaO2 of 
4% or more. Periods of apnea and hypopnea were counted over the period of sleep 
during the night and calculated as mean per hour of sleep (apnea hypopnea index, 
AHI). An AHI above 1/hour is considered pathological [23]. Apneas were considered 
obstructive when absence of airfl ow occurred without a decrease in respiratory effort 
and central, when thoracic movements were absent. Abnormal SaO2 was defi ned as 
SaO2 below 92% or more than 4% below baseline values during 3 breaths or longer. 
Otorhinolaryngologic examination consisted of 3-monthly tonsillar inspection according 
to Brodsky staging system [24]. Snoring was recorded in a structured interview with 
parents. When snoring or obstructive sleep apnea syndrome (OSAS) was diagnosed, 
fi beroptic endoscopy was performed by an ear-nose-throat (ENT) surgeon. If adenoid 
or tonsillar hypertrophy was found, adenotonsillectomy was performed.
Data analysis
Statistical analysis was performed by the Statistical Package for Social Sciences (SPSS 
Version 11). Most of the data obtained in our patients were not Gaussian distributed. We 
therefore expressed our data as median and interquartile range (iqr). Nonparametric 
tests (Wilcoxon signed ranks test) were used to compare results before and after 
start of GH. Correlations were calculated using Spearman correlation coeffi cients. 
Chi Square test was used to evaluate whether OSAS is more common in children with 
BMI over +2 SDS compared to normal weight children. Associations between snoring, 
tonsillar size and AHI were calculated with Kruskal-Wallis tests. P-value <0.05 was 
considered statistically signifi cant. 
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4.4 Results
Clinical characteristics at baseline
Fifty-three pre-pubertal PWS children (30 boys) participated in the PSG study. The 
median (iqr) age was 5.4 years (2.1 to 7.2) and the median (iqr) BMI was 1.0 SDS 
(-0.1 to 1.7). Sixteen patients had paternal deletion, 21 had maternal disomy, 4 had 
an imprinting center mutation. In 12 patients diagnosis was confi rmed by a positive 
methylation test for PWS, but was not yet further specifi ed.
Thirty-nine patients (23 boys) started GH at a dose of 1 mg/m2/day. The fi rst 
month of GH, they received only 0.5 mg/m2/day, to avoid fl uid retention. 
Respiratory parameters at baseline
At baseline, the median (iqr) AHI was 5.1/h (2.8 to 8.7). Of these, 2.8/h (1.5 to 5.4) 
were identifi ed as central apneas, 0.0/h (0.0 to 0.3) as obstructive apneas and 0.9/h 
(0.0 to 2.7) as hypopneas. The longest median (iqr) duration was 15.0 sec (13.0 to 
28.0). In all children, the AHI exceeded the normal range of 0-1/hr, indicating that 
SRBD do frequently occur, even in normal-weight pre-pubertal children with PWS. In 
the total patient group, no correlation was found between BMI SDS and AHI. Forty-
fi ve of our 53 patients were not obese. Of them, only 9% had OSAS (4/45), defi ned as 
obstructive apnea index over 1/h. In contrast, in our 8 patients who were obese (i.e. 
BMI over +2 SDS) 50% had OSAS (4/8) (prevalence of OSAS in normal weight versus 
obese patients, p=0.01). We found a negative correlation between both age and BMI 
and the number of central apneas (r=-0.34, p=0.01 and r=-0.33, p=0.017 respectively). 
There was no signifi cant difference in AHI with regard to sex or genetic defect. Tonsil 
size as assessed by Brodsky staging system, was not associated with the AHI (data not 
shown).
Respiratory parameters after 6 months of GH
Thirty-fi ve pre-pubertal children had PSG repeated after 6 months of GH treatment. 
(Table 2) This group of 35 children had a median (iqr) age of 6.0 years (2.4 to 8.6), and 
median (iqr) BMI of 0.8 SDS (-0.1 to 1.5) before GH. At baseline, median (iqr) AHI in 
this group was 4.8/h (2.6 to 7.9), of which 2.9/h (1.5 to 5.2) were indicated as central 
and 0.0/h (0.0 to 0.3) as obstructive. After 6 months of GH (1 mg/m2/day), a non-
signifi cant decline in the AHI was found to 4.0/h (2.7 to 6.2). This decline was mainly 
due to a reduction in central apneas to 2.2/h (0.8 to 4.1). In 5, adenoidectomy and/or 
tonsillectomy was performed because adenoidal and/or tonsil hypertrophy developed 
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during the follow-up period. There was no association between changes in AHI and 
changes in number of awakenings or REM sleep-percentage (data not shown). 
Table 1: Clinical parameters of baseline group
Median iqr
N 53
Sex (m/f) 30 / 23
Age (yrs) 5.4 2.1 to 7.2
BMI (kg/m2) 17.7 15.9 to 19.4
BMI (SDS) 1.0 -0.1 to 1.7
Apnea hypopnea index 5.1 2.8 to 8.7
Central apnea index 2.8 1.5 to 5.4
Obstructive apnea index 0.0 0.0 to 0.4
Hypopnea index 0.9 0.0 to 2.7
Duration longest apnea (sec) 15.0 13.0 to 28.0
Genetic defect
Paternal deletion (n) 16
Maternal disomy (n) 21
Imprinting center mutation (n)  4
Unknown (n) 12
Breathing disorders during illness
Four patients were excluded from analysis because of URTI. The results of their PSGs 
during health and illness are listed in table 3. In one of them, PSG was repeated after 
recovery and adenoidectomy. In this particular patient, the AHI before GH treatment 
was 7.9/h (100% central), during illness after 6 months of GH treatment, the AHI had 
impressively increased to 38.6/h (1.2 central apneas/h, 12.4 obstructive apneas/h, 
and 25.1 hypopneas/h), whereas after recovery and adenoidectomy, AHI was 3.4/h 
(100% central). 
One patient in our study died unexpectedly. This 3-year old boy had GH treatment 
for 13 months. He responded very well in terms of growth and body composition. In 
this particular patient, PSG was performed before (AHI 1.7/h, 100% central) and after 
6 months of GH (AHI 1.4/h, 67% central, 33% hypopnea). Six weeks before his death, 
BMI was 1.6 SDS and tonsils were assessed as Brodsky I-II. He had mild URTI and was 
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clinically evaluated by his paediatrician the day prior to his death. At that time he 
had URTI, but was in good condition, running around and not generally ill. During the 
night, he suddenly deteriorated and was found dead in the morning. Autopsy did not 
reveal the cause of death.
Table 2: Clinical and respiratory parameters of GH-treated group 
Before start of GH After 6 mo of GH
Median iqr Median iqr p-value
N 35
Sex (m/f) 20/15
Age (yrs) 6.0 2.3 to 8.6 6.8 3.1 to 9.9
BMI (kg/m2) 17.1 15.9 to 19.2 17.6 15.7 to 18.9 0.38
BMI (SDS) 0.8 -0.1 to 1.5 0.8 -0.1 to 1.2 0.19
Apnea hypopnea index 4.8 2.6 to 7.9 4.0 2.7 to 6.2 0.36
Central apnea index 2.9 1.5 to 5.2 2.2 0.8 to 4.1 0.15
Obstructive apnea index 0.0 0.0 to 0.3 0.0 0.0 to 0.2 0.73
Hypopnea index 0.7 0.0 to 1.9 1.0 0.7 to 2.0 0.26
Longest apnea (sec) 15.0 13.0 to 28.0 17.0 14.0 to 23.3 0.92
Table 3: Respiratory parameters during health and URTI (n=4)
Health URTI p-value
Median iqr Median iqr
Apnea hypopnea index 5.7 3.1 to 9.5 36.5 18.1 to 39.5 0.07
Central apnea index 2.7 1.8 to 6.6 6.4 1.9 to 6.6 0.27
Obstructive apnea index 0.0 0.0 to 2.5 8.9 2.4 to 21.0 0.07
Hypopnea index 1.1 0.0 to 3.6 7.2 3.6 to 20.3 0.14
Longest apnea (sec) 24.5 18.5 to 33.5 35.5 27.3 to 49.8 0.27
Respiratory parameters as measured by PSG in health and during an episode of upper respiratory tract 
infection (URTI). 
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Figure 1: Apnea Hypopnea Index of 53 PWS children before start of GH. Line represents 
the upper limit of normal i.e. Apnea Hypopnea Index = 1 / h
4.5 Discussion
We found an increased AHI in 53 young, pre-pubertal children with genetically confi rmed 
diagnosis of PWS. The high AHI was mainly due to central apneas and hypopneas. In 
the total group of mainly non-obese PWS children, obstructive apneas were rare. 
In contrast, obstructive apneas were found in 4 of the 8 overweight patients. After 
6 months of GH treatment a non-signifi cant decrease of AHI was found, mainly due 
to a decrease in central apneas. No signifi cant change in obstructive apneas was 
found during GH. Illness or adenoid/tonsil hypertrophy, however did result into a 
marked increase in sleep-related breathing disorders, and particularly obstructive 
sleep apnea. Our study also shows that a relatively normal PSG does not exclude the 
possibility of unexpected death during mild URTI.
The increased number of central apneas, in our young PWS children suggests a 
central origin of SRBD. A hypothalamic origin of SRBD in PWS was already postulated 
20 years ago [25]. A decreased number of oxytocin neurons in the hypothalamic 
paraventricular nucleus was reported, which might also be involved in reduced neural 
modulation of breathing [26,27]. Recently, Ren et al [28] proposed that necdin (neurally 
differentiated embryonal carcinoma-cell derived factor) defi ciency may contribute to 
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the observed respiratory abnormalities in individuals with PWS as the Necdin gene is 
one of the protein-coding genes that are defi cient in PWS [29]. Defi ciency of Necdin 
in mice results in neonatal hypoventilation, which is usually fatal [30].
We found a negative association of both age and BMI, with number of central 
apneas. Because in PWS children, age and BMI are highly correlated, we cannot 
distinguish whether this is an effect of age or BMI. From a pathophysiological point 
of view, we consider it more likely to be an effect of age. In fact, our data are in line 
with a previous report, indicating that central apneas are more common in younger, 
healthy children, although within the normal range [31]. The mechanism is unclear, 
and might be related to a relatively more immature respiratory control in younger 
children. However, we cannot exclude that underweight in young PWS infants might 
contribute to as well.
OSAS was uncommon in normal-weight PWS patients. However, 4 of the 8 (50%) 
overweight (defi ned as BMI over +2 SDS) patients had signs of OSAS. Increased BMI has 
been associated with decreased SaO2 and higher AHI in older PWS children and adults 
[32]. Harris et al reported an improvement of OSAS and hypoventilation after weight-
loss in children and adults with PWS [33]. Tonsillar hypertrophy may also play a role 
in OSAS. Children with PWS might have a smaller naso- and oropharynx, which could 
contribute to obstruction [3]. Recently an improvement in AHI and oxygen saturation 
was reported after adenotonsillectomy in 5 PWS children with OSAS [34].
After 6 months of GH treatment, a non-signifi cant decline in AHI was found 
compared with baseline, mainly due to a lower number of central apneas. Thus, our 
study indicates that GH had no adverse effects on the respiration of PWS children. 
Several publications reported sudden death in infants and children with PWS during 
GH treatment [15,16,35]. Several ones suggested a causal relationship between GH 
and sudden death in PWS. 
Until now only limited data were available on the effects of GH on PSG. Miller et 
al recently reported an improvement of AHI after 6 weeks of GH in most of her PWS 
patients. She performed PSG in children and adults of which 12 were children under 
the age of 12 years. A subset of patients, however, had an increased AHI after 6 weeks 
of GH. Most of these patients had URTI during the second evaluation [36]. Haqq et 
al reported in a cross-over study a decrease in AHI after 6 months of GH in 12 PWS 
children, aged 4.5 to 14.5 years, although not statistically signifi cant [13]. Myers et al 
demonstrated that inspiratory and expiratory muscle strength improved in 20 children 
with PWS, aged 4 to 16 years after 12 months of GH compared with 10 controls [11]. 
Lindgren et al found improved CO2-responsiveness in 9 children with PWS after 6-9 
99
C
ha
pt
er
 4
 |
 S
le
ep
-r
el
at
ed
 b
re
at
hi
ng
 d
is
or
de
rs
 i
n 
PW
S 
an
d 
ef
fe
ct
s 
of
 G
H
 t
re
at
m
en
t
months of GH compared to baseline [14]. A number of hormones, including GH and 
IGF-I, are involved in the physiologic regulation of breathing [37]. IGF-I receptors 
are located around the central chemoreceptors in the brainstem, and also in the 
cerebellum where the inputs from chemoreceptors are integrated [38]. GH may 
therefore theoretically improve breathing via a direct mechanism. 
In our study we found only a small number of obstructive apneas both before 
and during GH treatment. There was no increase in obstructive apneas during 
GH treatment. Five children had adenotonsillectomy before the second PSG was 
performed, because of adenoid and/or tonsillar hypertrophy. Unfortunately this might 
confound our results, but for obvious safety reasons we could not avoid this. The AHI 
of these patients during both PSGs was not different compared with the rest of the 
study group. We found no signifi cant association between tonsil size or snoring and 
the AHI. Sleep apnea, both obstructive and central, occurs more frequently in adults 
with GH excess (acromegaly) [39] and is associated with thickening of the pharyngeal 
wall in the acromegalic patients [40]. We cannot rule out that GH might have resulted 
in some adenoidhypertrophy, as we only performed fi beroptic endoscopy when 
indicated by snoring or OSAS during PSG. It has been suggested that GH treatment 
might increase tonsil size, however, to our knowledge, no controlled, prospective 
study has been performed. 
One of our patients died unexpectedly during an episode of URTI. One of the most 
alarming fi ndings is that this patient had near-normal sleep-related breathing during 
PSG, both before and during GH treatment. This points out that a near-normal PSG in 
a healthy PWS child does not guarantee he/she won’t die during mild URTI. It might 
be related to a rise of apneas (both central and obstructive) during illness as shown in 
4 of our patients who had a PSG during an episode of mild URTI. Unexpected deaths 
have been described in PWS children both without and during GH and have been 
attributed to several possible causes, such as respiratory dysfunction, cardiomyopathy, 
temperature instability and adrenal insuffi ciency or combinations of these. 
We recommend monitoring of SRBD by PSG and regular ENT-evaluation in all PWS 
children, both before and during GH treatment. If adenoidhypertrophy or tonsillar 
hypertrophy occurs, adenotonsillectomy should be considered. It is important to 
mention that a relatively normal PSG does not exclude the possibility of unexpected 
death during mild URTI. Based on our results cardiorespiratory monitoring during 
URTI in children with PWS before and during GH treatment should be considered. 
Future studies are required for evaluating SRBD in PWS during URTI in order to give 
recommendations with regard to monitoring during URTI.
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In conclusion, our study shows that many pre-pubertal children with PWS have 
sleep-related breathing disorders, mainly due to central apneas. BMI or age cannot 
explain the variability in the severity of the SRBD, although OSAS was more prevalent 
in children with obesity than in normal weight children. After 6 months of GH, a non-
signifi cant decrease in AHI was found. Thus our data are reassuring with respect to 
the effects of GH on SRBD. Our study also shows that a normal PSG does not exclude 
the possibility of unexpected death during mild upper respiratory tract infections. 
During URTI, AHI may rise and obstructive apneas may occur. 
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5.1 Abstract
Background: Prader-Willi Syndrome (PWS) is a neurogenetic disorder with hypotonia, 
psychomotor delay, obesity, short stature, and sleep-related breathing disorders. 
Objective: To evaluate the association between psychomotor development and sleep-
related breathing disorders in PWS infants. 
Design and Patients: Bayley Scales of Infant Development were performed in 22 
PWS infants, with a median (interquartile range, iqr) age of 1.8 (1.1 to 3.4) years, 
and a body mass index (BMI) standard deviation score (SDS) of -0.5 (-1.3 to 1.6). We 
evaluated psychomotor development in relation to results of polysomnography. 
Results: Median (iqr) mental and motor development was 73.1% (64.3 to 79.6) and 
55.2% (46.5 to 63.1) of normal children, respectively. All infants had sleep-related 
breathing disorders, mostly of central origin. The apnea hypopnea index was not 
associated with psychomotor development. Only 4 infants had obstructive sleep apnea 
syndrome (OSAS). They had a signifi cantly delayed mental development of 65.5% (60.0 
to 70.3) of normal. They had a median BMI SDS of 1.4 (0.1 to 1.6), which tended to be 
higher than in those without OSAS. 
Conclusions: Our data indicate that psychomotor development in PWS infants is not 
related to central sleep-related breathing disorders, but infants with OSAS have more 
severely delayed mental development, suggesting that PWS infants should be screened 
for OSAS.
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5.2 Introduction
Prader-Willi Syndrome (PWS) is characterised by a number of signs and symptoms, 
including muscular hypotonia, hypogonadism, psychomotor delay, obesity that may 
become extreme after the age of 2-4 years, and short stature. Children with PWS 
have an abnormal body composition with a relatively high body fat percentage and 
a low lean body mass. Even in infants, who are underweight, body fat percentage is 
high [1,2]. Sleep-related breathing disorders (SRBD) may also occur [3]. The underlying 
cause of the syndrome is a paternal deletion or a uniparental maternal disomy of 
chromosome 15q11-13 [4]. In 1-5%, PWS is the result of an imprinting-center mutation 
[5], which causes genes in the 15q11-13 region of the paternally inherited chromosome 
to be silenced. Nowadays PWS is mostly diagnosed in infancy [6,7]. This results in 
optimal management opportunities with regard to diet, exercise and education. As a 
result, most young PWS patients are currently not severely obese.
In healthy children, associations between sleep-disordered breathing and cognition, 
school performance and psychiatric and behavioural co-morbidities are well-known 
[8,9]. In healthy infants, inverse associations between the snoring-related arousal 
index and standardised mental development assessment scores have been reported 
[10]. In this study we examined if there was an association between psychomotor 
development, and sleep-related breathing disorders in infants with PWS. 
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5.3 Patients and Methods
Patients
All infants, included in the current analysis, participated in a randomised, controlled, 
growth hormone (GH) trial in children with genetically confi rmed diagnosis of PWS. This 
trial investigated the effects of GH treatment versus no GH on growth, body composition, 
activity level and psychosocial development. In April 2003, a polysomnography (PSG) 
study was started in addition to the original protocol, in order to evaluate the effects 
of GH on sleep-related breathing disorders. The inclusion criteria for infants in the 
PSG study were: 1) no upper respiratory tract infection during PSG, and 2) no previous 
GH treatment. We used standardised tests to assess psychomotor development. Data 
were related with results of PSG. Tests were performed prior to start of GH treatment. 
Twenty-two infants with PWS were eligible for the present analysis.
The study protocol was approved by the Medical Ethical Committees of Erasmus 
Medical Center, Rotterdam, The Netherlands, and the other participating centers. 
Written informed consent was obtained from the parents.
Methods
Anthropometry
Below the age of 2.5 years, supine length was measured, and thereafter standing 
height. Height was measured with a Harpenden stadiometer. Weight was assessed on 
an accurate scale, and body mass index (BMI) (kg/m2) was calculated. Height and BMI 
were converted into standard deviation scores (SDS) [11,12] using Growth Analyser 
Version 3.0 (www.growthanalyser.org).
Psychomotor Development
Psychomotor development was assessed at baseline and after 12 months by the Bayley 
Scales of Infant Development  II, Dutch version (BSID II) [13]. BSID II yields 2 scores: 
mental developmental age (in months) and motor developmental age (in months). 
The mental scale consists of items in relation to visual and auditory information 
processing, language development, memory, eye-hand coordination, imitation and 
problem solving. The motor scale assesses fi ne and gross motor skills. All psychomotor 
tests were conducted by a psychologist. Reference data of healthy Dutch children 
were used to compare the results of our patients [13].
109
C
ha
pt
er
 5
 |
 P
sy
ch
om
ot
or
 d
ev
el
op
m
en
t 
an
d 
as
so
ci
at
io
ns
 w
it
h 
O
SA
S 
in
 P
W
S
Polysomnography
Patients were admitted to the sleep center at 5.00 p.m., accompanied by one parent. 
They underwent a complete overnight PSG. Recordings included electroencephalogram, 
electro-oculogram, one channel derivation of electrocardiogram, and surface 
electromyography of the submental muscle and both anterior tibial muscles. Nasal-
oral airfl ow was monitored by nasal pressure prongs fi xed in the nose, respiratory 
effort by thoraco-abdominal strain gauges and oxygen saturation (SaO2) by pulse 
oximetry. All PSG studies were evaluated independently by two persons, both certifi ed 
in PSG analysis. In case of major discrepancies between the two assessments, a third 
expert opinion was asked. The polygraphic records were scored according to standard 
criteria of Rechtschaffen and Kales [14]. A period of apnea or hypopnea was defi ned as 
more than 90% (apnea) or 50% (hypopnea) reduction of airfl ow for at least 3 breaths. 
For hypopneas, the additional criterion was a reduction of oxygen saturation of at 
least 4%. Periods of apnea and hypopnea were counted over the period of sleep 
during the night and calculated as mean per hour of sleep (apnea hypopnea index, 
AHI). An AHI of more than 1 per hour is considered pathological (15). Apneas were 
considered “obstructive” when absence of airfl ow occurred without a decrease in 
respiratory effort and “central”, when thoracic movements were absent. Patients 
with an obstructive sleep apnea index of more than 1/hour were considered to have 
obstructive sleep apnea syndrome (OSAS). Abnormal SaO2 was defi ned as a SaO2 below 
92% or a decrease in SaO2 of more than 4% compared with baseline values. 
Data analysis
Data were expressed as median (interquartile range, iqr). We could not use standardised 
scores for psychomotor development, because PWS infants scored generally below 
the lowest range, in particular for the subscale of motor development. We therefore 
expressed these results as developmental age divided by chronological age, multiplied 
by 100, which refl ects the percentage of expected development for that age. 
Differences between infants with and without OSAS were tested using independent 
sample t-tests. Multiple regression analysis was used to calculate the associations 
between anthropometric parameters and psychomotor development. One-way ANOVA 
was used to test differences in respiratory parameters and psychomotor development 
between children with paternal deletion and those with uniparental maternal disomy. 
In order to calculate the magnitude of the difference in development between infants 
with or without OSAS, a Cohen’s d was calculated, using the following formula [16]:
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 (χ OSAS=0 - χ OSAS=1)
 
sd2 *(n-1)OSAS=0 + sd
2 *(n-1)OSAS=1
(n-1)OSAS=0 + (n-1)OSAS=1
Cohen’s d of 0.20 was considered a minor, 0.50 a medium, and 0.80 a major 
difference. Statistical analysis was performed by the Statistical Package for Social 
Sciences (SPSS Version 11).
5.4 Results
General Clinical Characteristics
Complete BSID II tests and complete polysomnographies (PSGs) were performed in 
22 infants (15 boys) with PWS, who had a median (iqr) age of 1.8 (1.1 to 3.4) years 
(Table 1). Most infants were not obese, the median BMI of the total group being -0.5 
SDS (-1.3 to +1.6). Two of 22 infants (9%) had a BMI above +2 SDS. All infants had a 
genetically confi rmed diagnosis of PWS. Nine patients had a paternal deletion, 10 had 
a uniparental maternal disomy. In 3 patients PWS was confi rmed by methylation test, 
but the underlying genetic defect was not yet specifi ed.
Psychomotor development and sleep-related breathing disorders (SRBD) 
Median mental development in the total group was 73.1% of expected mental 
development for age and motor development was 55.2% of expected motor 
development. Both were signifi cantly below normal (Table 1). All infants had sleep-
related breathing disorders (SRBD). Median (iqr) AHI was 6.1 (4.2 to 13.3) /h. Most 
apneas were identifi ed as central apneas. Multiple regression analysis showed no 
association between mental or motor development and the severity of sleep-related 
breathing disorders. We did not fi nd any difference between children with paternal 
deletion and maternal disomy with respect to psychomotor development or respiratory 
parameters.
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Table 1: Clinical characteristics, psychomotor development and respiratory parameters in 
infants with PWS
Median iqr
n 22
Sex (m/f) 15/7
Age (yrs) 1.8 1.1 to 3.4
BMI (kg/m2) 16.1 14.7 to 18.1
BMI (SDS) -0.5 -1.3 to 1.6
Mental developmental ratio (%) 73.1 64.3 to 79.6
Motor developmental ratio (%) 55.2 46.5 to 63.1
Apnea hypopnea index 6.1 4.2 to 13.3
Central Apnea Index 5.2 2.6 to 7.9
Obstructive apnea index 0.0 0.0 to 0.8
Hypopnea index 0.4 0.0 to 2.7
Duration longest apnea (sec) 14.0 12.8 to 20.3
Age mentioned in Table corresponds with age at time of PSG. Median age during evaluation for psychomotor 
development was 1.6 (1.2 to 3.3) years.
Respiratory parameters are listed as indices (apneas/hour).
Table 2: Mental and motor development in infants with and without OSAS
OSAS No OSAS
Median iqr Median iqr
N 4 18
Age (yrs) 2.6 1.3 to 3.5 1.6 1.2 to 2.7
Sex 4 boys 11 boys/ 7 girls
BMI (kg/m2) 17.0 16.5 to 19.7 15.9 14.6 to 18.1
BMI (SDS) 1.4 0.1 to 1.6 0.6 -1.0 to 1.2
Mental development (%) 65.5* 60.0 to 70.3 74.9 64.8 to 81.3
Motor development (%) 50.1 45.2 to 61.8 56.2 47.9 to 63.3
Mental and motor development in % is calculated by dividing developmental age, assessed by BSID II by 
chronological age and multiplying by 100, which represents the percentage of expected development for 
age. Mental development is signifi cantly decreased in infants with OSAS compared to infants without OSAS. 
OSAS is defi ned as obstructive sleep apnea index over 1/h. * p<0.05
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Infants with obstructive sleep apnea syndrome (OSAS) 
Four infants had obstructive sleep apnea syndrome (OSAS), defi ned as an obstructive 
sleep apnea index of more than 1/hour. Motor development was not different between 
infants with and without OSAS. Mental development was however decreased in infants 
with OSAS (median (iqr) 65.5% (60.0 to 70.3) of normal) compared to those without 
OSAS; 74.9% (64.8 to 81.3) (p=0.03) (Figure 1, Table 2). The magnitude of the difference 
was 0.74 (Cohen’s d), indicating a substantial difference. Infants with OSAS tended to 
be older and tended to have a higher BMI (median 1.4 SDS) than infants without OSAS 
(median BMI 0.6 SDS), although this did not reach statistical signifi cance. Only one of 
the infants with OSAS was considered overweight, defi ned as a BMI above +2 SDS.
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Figure 1. Mental development in infants with or without obstructive sleep apnea syndrome. 
The Y axis represents mental development expressed as %  of expected development for 
age in children with (n=4) and without (n=18) OSAS. Mental development is signifi cantly 
lower in infants with OSAS compared to those without. (*p-value: 0.03, independent t-test 
for observations with unequal variances). Magnitude of the difference (Cohen’s d) is 0.74, 
indicating a medium to large difference.
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5.5 Discussion
In PWS infants, mental and motor development were both delayed compared to normal 
development for age. Sleep-related breathing disorders were common, in particular 
central sleep apnea. No associations between psychomotor development and any of 
the respiratory abnormalities were found. In the 4 infants with OSAS, we found a 
signifi cantly lower mental development compared to infants without OSAS. Infants 
with OSAS tended to be older and tended to have a higher BMI than the remaining 
18 children without OSAS. There was no signifi cant difference in motor development 
between both groups. 
Data concerning associations between psychomotor development and sleep-
related breathing disorders in PWS infants are limited. In healthy infants, it was shown 
that the snoring-related arousal index was associated with the mental developmental 
index, measured by BSID II [10]. These data suggested that even mild symptoms of 
sleep-disordered breathing were associated with lower mental development scores in 
healthy children. In a study by Greenfeld et al, 5 of 29 normal children with OSAS, due 
to adenotonsillar hypertrophy, had a developmental delay, as subjectively reported 
by parents. After adenotonsillectomy, the developmental delay resolved in 3 of them 
[17]. 
To our knowledge, so far only one author has reported associations between 
neurobehavioural abnormalities and sleep-related breathing disorders in patients 
with PWS. In 13 patients (3 infants), aged 1.5 to 28 years, OSAS was prevalent and 
associated with a higher BMI, and some behavioural abnormalities. Unfortunately, 
they did not present data on the psychomotor development of the 3 infants [18].
In children, enlargement of adenoid or tonsils, in association with increased upper 
airway collapsibility, is by far the most common cause of OSAS [19]. In addition, obesity 
may cause obstructive sleep-related breathing disorders, as has also been found in 
adults [20]. In children and adults with PWS, both obesity and a small nasopharynx 
are thought to cause OSAS [3]. 
We used BMI SDS to defi ne obesity in PWS infants. However, BMI underestimates 
the actual degree of obesity in individual with PWS, because of their abnormal body 
composition. As age-related reference data for body fat percentage, measured by 
dual energy X-ray absorptiometry (DXA) were not available for infants, we did not 
report DXA scans in the PWS infants.
Our results indicate that OSAS should be treated, by adenoidectomy and/
or tonsillectomy when adenoid and/or tonsils are enlarged. In order to optimize 
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mental development in PWS infants, it is also important to introduce weight control, 
particularly when obesity is already present. If weight control or adenotonsillectomy 
does not relieve symptoms of OSAS, the use of nasal continuous positive airway 
pressure might be considered [21]. 
The mechanism underlying the negative association between OSAS and mental 
development is unknown. Beebe and Gozal proposed a model [8], explaining the 
relation between OSAS, and lower cognition and neurobehavioural abnormalities. 
According to this model, OSAS-related sleep disruption and intermittent hypoxia and 
hypercapnia may impair the restorative features of sleep and the cellular or chemical 
homeostasis in the brain, resulting in a prefrontal cortical dysfunction. The latter 
would lead to a dysfunction of the cognitive executive system, which is responsible for 
developing a future-oriented, organized and fl exible approach to problem situations. 
This would result into adverse daytime effects, such as behavioural problems, in 
particular related to Attention Defi cit/Hyperactivity Disorder, and diffi culties with 
problem solving [22,23]. 
In our study, the infants with OSAS tended to be older and had a higher BMI 
than infants without OSAS. It cannot be excluded that the higher BMI in infants with 
OSAS also impaired their motor development. Motor development tended to be more 
impaired in infants with OSAS, although this did not reach statistical signifi cance. 
Remarkable is that the central apneas during sleep in infants with PWS are by 
far more common than obstructive sleep apneas. However, we found no associations 
between mental or motor development and central respiratory events during sleep. 
These results indicate that, although central respiratory abnormalities are more 
common in PWS, the obstructive events have more severe implications with regard 
to mental development in infants. Central apneas might refl ect the hypothalamic 
dysfunction in PWS [24]. In addition, it has previously been reported that the Neurally 
differentiated embryonal carcinoma-cell derived factor (Necdin) gene, one of the 
protein-coding genes that are defi cient in PWS, might be involved in the central SRBD 
in PWS [25].
To our knowledge, this is the fi rst study in infants with PWS evaluating the association 
between psychomotor development and sleep-related breathing disorders. Our results 
indicate that in PWS infants, as recently suggested for the normal population, mental 
development might be delayed in the presence of obstructive sleep apnea, suggesting 
that early treatment of OSAS in infancy should be considered. 
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6.1 Abstract
Background: Prader-Willi Syndrome (PWS) is a neurogenetic disorder characterised by 
hypotonia, hypogonadism, obesity and short stature. Neurobehavioural abnormalities, 
cognitive impairment and sleep-related breathing disorders (SRBD) are common. In the 
general population consistent relations have been found between neurobehavioural 
and cognitive abnormalities and SRBD. 
Objective: To investigate cognition and behaviour and their associations with sleep-
disordered breathing in pre-pubertal PWS children.
Design/patients: For this study, 31 pre-pubertal PWS children, aged 4.0 to 13.2 years, 
were evaluated (5 with paternal deletion, 14 with maternal disomy, 4 with an imprinting 
center mutation, and in 8 the defect was not specifi ed). Cognition was assessed 
by Wechsler Intelligence Scale subtests appropriate for age, and neurobehavioural 
abnormalities with parent-questionnaires. Polysomnography (PSG) was performed. 
Cognition, behaviour and associations with SRBD were evaluated.
Results: All cognitive subtests were signifi cantly below 0 SDS, with the lowest median 
(interquartile range, iqr) scores for one of the performance subtests (Block design) 
of -2.7 SDS (-3.0 to -0.3). In 60% of children, verbal subtests were less affected than 
performance subtests. Parents reported problem behaviour on subscales related to 
“emotions/behaviour not adapted to the social situation” and “insensitivity to social 
information”. All children had a sleep-related breathing disorder, with a median Apnea 
Hypopnea Index of 4.1/hour (2.6 to 7.9). One of the performance subtestscores was 
signifi cantly higher in children with better sleep effi ciency, and daytime sleepiness was 
associated with more autistic-like social impairment. In contrast to our expectations, 
behavioural abnormalities (particularly social relating behaviour) were worse in 
children with better sleep-related breathing. 
Conclusion: In pre-pubertal PWS children, cognition is greatly impaired. Neuro-
behavioural abnormalities are common, particularly autistic-like social impairment. 
Sleep effi ciency index was associated with better performance on the Picture 
Arrangements/Completion subtests, and neurobehavioural abnormalities were 
associated with daytime sleepiness. In contrast, we could not confi rm a positive 
association of neurobehavioural abnormalities with sleep-related breathing disorders 
in PWS.
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6.2 Introduction
Prader-Willi Syndrome (PWS) is characterised by a number of signs and symptoms, 
including muscular hypotonia, hypogonadism, psychomotor delay, short stature, and 
obesity that may become extreme after the age of 2-4 years. Psychomotor delay, 
neurobehavioural abnormalities and cognitive impairment are common [1,2]. Sleep-
related breathing disorders (SRBD) have also been reported [3-5]. The underlying 
cause of the syndrome is a paternal deletion or a uniparental maternal disomy (UPD)
of 15q11-13 [6]. In 1-5%, PWS is the result of an imprinting-center mutation [7], which 
causes genes in the paternally inherited chromosome 15q11-13 to be silenced. Genetic 
subtypes have been associated with different behavioural and cognitive phenotypes 
[2,8].
In healthy children, increasing attention has been drawn to the association between 
SRBD and neurobehavioural abnormalities, in particular symptoms of Attention-
Defi cit/Hyperactivity Disorder (ADHD). Associations between SRBD and cognition, 
school performance and psychiatric and behavioural co-morbidities are consistently 
reported, and seem to be at least partial reversible [9-11].
In subjects with PWS, there is a lack of data evaluating these associations. Only 
one report was recently published, describing, in 13 PWS subjects aged 1.5 to 28 years, 
that SRBD, in particular obstructive sleep apnea syndrome (OSAS), was associated with 
higher body mass index (BMI), daytime inactivity, sleepiness, autistic-related behaviour, 
and impulsivity. In this group, 7 of 11 subjects had a BMI >2 standard deviation score 
(SDS). Nowadays rapid diagnostic testing for PWS is available, leading to early diagnosis 
in infancy, and optimal management with regard to diet, exercise and education. 
As a result, the majority of young PWS children are nowadays not severely obese 
during childhood. In this study we examined cognition by age-appropriate Wechsler 
subscales, and neurobehavioural abnormalities by parent questionnaires. In addition, 
we investigated if there was an association between cognition or neurobehavioural 
abnormalities and SRBD in a homogeneous group of 31 not severely overweight, young, 
pre-pubertal PWS children.
122
C
ha
pt
er
 6
 |
 C
og
ni
ti
on
, 
be
ha
vi
ou
r 
an
d 
sl
ee
p-
re
la
te
d 
br
ea
th
in
g 
in
 P
W
S
6.3 Patients and Methods
Patients
In April 2002, a randomised, multicenter, controlled growth hormone (GH) trial in 
children with genetically confi rmed diagnosis of PWS was started, investigating the 
effects of GH treatment versus no GH on growth, body composition, activity level 
and psychosocial development. Children were referred to us by their paediatricians. 
In April 2003, we started a polysomnography (PSG) study in addition to the original 
protocol. Inclusion criteria for the PSG study were: (1) pre-pubertal at PSG, and (2) 
no upper respiratory tract infection (URTI). For the current analysis, 31 pre-pubertal 
children were included. All children were healthy at the time of these studies. Two of 
them received thyroxin replacement therapy to correct low levels of free T4. All were 
evaluated before enrolling in GH therapy.
The study protocol was approved of the Medical Ethical Committee of Erasmus 
Medical Center, Rotterdam, The Netherlands. Written informed consent was obtained 
from the parents, and from children over 12 years.
Methods
Anthropometry
Height was assessed by a Harpenden stadiometer and weight was assessed on an 
accurate scale. BMI (kg/m2) was calculated. Height and BMI were converted into SDS, 
according to Dutch references for age [12]. Growth Analyser Version 3.0 software was 
used to calculate BMI, height and BMI SDS (www.growthanalyser.org).
Intelligence
To assess intelligence, a short form of four subtests: Vocabulary, Similarities (verbal 
IQ subtests) and Block design, Picture arrangement (performance IQ subtests) of the 
Wechsler Intelligence Scale for Children-Revised, Dutch version (WISC-R), was used in 
children over 7 years of age or when appropriate [13]. A short form of four subtests: 
Vocabulary, Similarities (verbal IQ subtests) and Block design, Picture completion 
(performance IQ subtests) of the Wechsler Preschool and Primary Scale of Intelligence 
– Revised, Dutch version (WPPSI-R), was used for children with age below 7 years or 
when appropriate [14,15]. All cognitive tests were conducted by a psychologist (M.W.), 
experienced also in testing PWS children. All children had a PSG prior to start of GH 
treatment. All cognitive tests were performed, prior to start of GH, and not more 
than 6 months before or after PSG. WPPSI was assessed in 17 children and WISC in 
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10 children. Median age at WPPSI assessment was 6.5 years (5.8 to 6.8) and median 
age at completion of WISC was 9.6 years (8.5 to 11.9). Four children were too young 
to be tested with Wechsler scales. These children were excluded from the present 
analysis.
Behaviour
Developmental Behaviour Checklist
The Developmental Behaviour Checklist (DBC) is a 96-items checklist for all levels 
of mental disabilities, completed by parents or caregivers to assess emotional or 
behavioural problems over the last six months in children aged 4 to 18 years. We used 
the revised scale structure as developed by Dekker et al, containing 5 interpretable and 
relevant subscales: Disruptive/Antisocial, Self-Absorbed, Communication Disturbance, 
Anxiety and Social Relating. A total problem behaviour score was calculated by 
combining all subscale scores. For the DBC, we used reference data for Dutch children 
with mental disability, who have an IQ between 59 and 70. We considered this 
reference population to resemble most of our PWS children [16]. 
VISK
VISK is a Dutch Questionnaire to evaluate social behaviour in children, completed 
by parents or caregivers. This questionnaire contains 49 items, and 6 subscales: 
emotions/behaviour not adapted to the social situation, withdrawal, dysorientation 
with respect to place, time, persons and activity, insensitivity to social information, 
stereotypic behaviour, and resistance to change. This test is validated, standardised 
and widely used in The Netherlands. Dutch reference data are available for children 
with different psychiatric disorders and mental disability. We used Dutch reference 
data for children with mental disability [17]. We expressed data in SD scores. Both 
questionnaires were fi lled out, prior to start of GH, and not more than 6 months 
before or after PSG.
Polysomnography 
Children were admitted to the sleep center at 5.00 p.m., accompanied by one 
parent. Children underwent complete overnight polysomnography (PSG). Recordings 
included electroencephalogram, electro-oculogram, one channel derivation of 
electrocardiogram, and surface electromyography of the submental muscle and both 
anterior tibial muscles. Nasal-oral airfl ow was monitored by nasal pressure prongs 
fi xed in the nose, respiratory effort by thoraco-abdominal strain gauges and oxygen 
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saturation (SaO2) by pulse oximetry. All PSG studies were evaluated independently by 
two persons, both certifi ed in PSG analysis. In case of major discrepancies between 
both assessments a third expert opinion was available, but this was never required. 
The polygraphic records were scored according to standard criteria of Rechtschaffen 
and Kales [18]. A period of apnea or hypopnea was defi ned as more than 90% (apnea) 
or 50-80% (hypopnea) reduction of airfl ow for 3 breaths or longer. For hypopneas, 
the additional criterion was a reduction of SaO2 of 4% or more. Periods of apnea and 
hypopnea were counted over the period of sleep during the night and calculated 
as mean per hour of sleep, apnea hypopnea index (AHI). An AHI above 1/hour is 
considered pathological [19]. Apneas were considered obstructive when absence of 
airfl ow occurred without a decrease in respiratory effort and central, when thoracic 
movements were absent. Abnormal SaO2 was defi ned as SaO2 below 92% or more than 
4% below baseline values. 
Sleep effi ciency and daytime sleepiness
Sleep effi ciency index (SEI) was calculated as total sleep time/time in bed, as 
measured during PSG. To assess daytime sleepiness, 2 questions of the Developmental 
Behaviour Checklist were used, as proposed by O’Donoghue et al [20]: question 48 
(“moves slowly, underactive, does little”), was used to score inactivity and question 
69 (“sleeps too much”) to obtain a measure for excessive daytime sleepiness.
Data analysis
Data were expressed as median, and interquartile range (iqr). To compare results of 
subtests of Wechsler scales (WPPSI-R and WISC-R), values were expressed as SDS. In 
order to evaluate the difference between performance and verbal components, we 
used a plot of the difference between verbal and performance tests within a child 
against the mean of both subtests according to the method of Bland and Altman. If 
the difference between verbal and performance subtests was between -2*standard 
error and +2*standard error, they were considered equally impaired [21,22]. Multiple 
regression was used to adjust raw data, after adjustment for age, sex and different 
tests (WISC-R or WPPSI-R). All statistical testing was fi xed at 0.05 level (2-sided). 
Binomial tests were used to compare SDscores for cognitive and behavioural tests with 
reference data. Statistical analysis was performed by the Statistical Package for Social 
Sciences (SPSS, Version 11).
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6.4 Results
General Clinical Characteristics
Clinical characteristics are shown in Table 1. Diagnosis of PWS was confi rmed by 
positive methylation tests in all children. Five children had a paternal deletion, 14 had 
uniparental maternal disomy, and 4 had an imprinting center mutation. In 8 children 
the underlying defect was not yet specifi ed. Five of 31 children were considered to be 
overweight, defi ned as BMI over +2 SDS.
Table 1. Baseline clinical characteristics
Median iqr
N 31
Sex (m/f) 14/17
Age (yrs) 6.4 6.0 to 9.1
Height (SDS) -2.4 -3.2 to -1.7
BMI (kg/m2) 18.2 17.0 to 19.7
BMI (SDS) 1.2 0.6 to 1.7
Apnea hypopnea index 4.1 2.6 to 7.9
Central apnea index 2.2 1.3 to 3.0
Obstructive apnea index 0.0 0.0 to 0.5
Hypopnea index 1.1 0.1 to 2.9
Duration longest apnea (sec) 17.0 13.0 to 29.0
Cognition
Data of four subtests of WPPSI and WISC, expressed as SDS compared to normal 
reference population, are listed in Table 2 and Figure 1a. The median scores on subtests 
were -1.7 SDS (-2.0 to -0.3) for Vocabulary, -1.7 SDS (-2.7 to -0.3) for Similarities, -2.7 
SDS (-3.0 to -1.7) for Block Design, and -1.7 SDS (-2.8 to -0.2) for Picture Completion 
and Picture Arrangement on WPPSI and WISC, respectively. The median of all subtest-
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scores was signifi cantly below the mean of the normal reference population (p<0.001, 
p<0.005 p<0.001, p<0.001). For individual children (Figure 1b), we found that the 
psychological profi le did not show a consistent impairment on all subtests. A subgroup 
of children (60% of children) had higher verbal than performance scores, and the 
opposite was true for other children (24% of children). Only a minority of children had 
a verbal and performance score within the same range (16% of children). 
Table 2. Cognition and behaviour in pre-pubertal children with PWS
Median iqr
Cognitive subtests (SDS)
Vocabulary -1.73 -2.0 to -0.3
Similarities -1.72 -2.7 to -0.3
Block design -2.73 -3.0 to -1.7
Picture completion/Picture arrangement -1.73 -2.8 to -0.2
Developmental behaviour checklist (SDS)
Disruptive/Antisocial -0.5 -0.8 to 0.1
Self-absorbed -0.7 -0.9 to 0.2
Communication disturbance -0.3 -0.6 to 0.4
Anxiety  -0.52 -0.9 to -0.2
Social relating 0.6 -0.5 to 1.0
Total score -0.7 -0.9 to 0.3
VISK (SDS)
Not adapted  0.51 -0.1 to 1.1
Withdrawal -0.3 -0.8 to 0.1
Dysorientation -0.1 -0.4 to 0.1
Insensitive to social information  0.61 -0.2 to 0.8
Stereotypic behaviour -0.3 -0.6 to 0.7
Resistance to change -0.2 -0.8 to 0.4
Total score -0.3 -0.8 to 0.4
Subtestscores of cognition were compared to healthy references. Scores of subtests of DBC and VISK were 
expressed as SD scores compared to children with mental delay. Higher SD scores indicate higher level of 
problematic behaviour. 
1 p<0.05, 2 p<0.005, 3 p<0.001.
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Figure 1a. Subtestscores expressed as SD scores for four subtests of WPPSI and WISC. Line 
represents 0 SDS (=normal subtestscore)
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Figure 1b. Disbalance between verbal and performance intelligence profi le in PWS 
children. Verbal and performance subtests of WPPSI and WISC-R are expressed as SD scores 
compared to a Dutch healthy reference population. If the ratio is higher than 2*SE, verbal 
subtests are higher than performance subtests and if it is less than -2*SE, performance 
tests are higher than verbal tests.
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Behaviour
In Table 2, subtest-scores of both behaviour questionnaires are presented. In these 
tests, a higher SD score indicates more severe problem behaviour. Compared to these 
reference data, our PWS children had less anxiety-related problems on DBC (p<0.005), 
and more behavioural problems on 2 of the subscales of VISK, indicating “emotions/
behaviour not adapted to the social situation” (p<0.05), and “insensitivity to social 
information” (p<0.05). 
Sleepiness
Inactivity was reported “never” by 8/24 parents, “sometimes” by 10/24 parents 
and “often” by 6/24 parents. Sleepiness was reported “never” by 19/24 parents, 
“sometimes” by 4/24 parents, and “often” by 1/24 parents. The median (iqr) sleep 
effi ciency index (SEI) during PSG for all children was 79% (75 to 86). 
Associations of cognition and behaviour with sleep-related breathing
All children had sleep-related breathing disorder, defi ned as an AHI over 1/hour (Table 
1). Median (iqr) AHI of the total group was 4.1 (2.6 to 7.9). Most apneas were of central 
origin, with a median central apnea index of 2.1 (1.3 to 23.0). Obstructive apneas were 
uncommon, with median obstructive apnea index of 0.0 (0.0 to 0.5). Median duration 
of longest apnea was 17 sec (13.0 to 29.0). We found no difference in SRBD between 
children with paternal deletion, maternal disomy or imprinting center mutation. 
In Table 3, associations between cognition and SRBD, after adjustment for sex, age, 
and different tests are summarized. Sleep effi ciency index (SEI), measured during PSG, 
was signifi cantly associated with one of the performance subtests: Picture Completion 
(of WPPSI-R) and Picture Arrangement (of WISC-R) (β=0.78, p<0.001). None of the 
respiratory parameters did signifi cantly explain the verbal or other performance 
subtests of the Wechsler scales.
Associations between behaviour and sleep-related breathing disorders are listed 
in Table 4. Sleepiness, was consistently associated with problem behaviour, related 
with subtests of the DBC on ‘communication disturbance’ (β=0.41, p<0.05), ‘anxiety’ 
(β= 0.49, p<0.05), and ‘social relating’ (β=0.45, p<0.05), and total problem behaviour 
score (β=0.48, p<0.05). In VISK, two subscales were signifi cantly related to sleepiness, 
i.e. ‘stereotypic behaviour’ (β=0.53, p<0.05), and ‘anxiety to change’ (β=0.53, 
p<0.05). Surprisingly, PSG measures, in particular AHI, were negatively associated 
with most subscales of behavioural questionnaires, reaching statistical signifi cance 
in “total problem behaviour score” (β=-0.41, p=0.05), and “social relating score” 
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(β=-0.47, p<0.05), indicating that children with higher apnea hypopnea index, had 
less problem behaviour. In addition, duration of longest apnea explained variability 
in problem behaviour negatively, indicating that if apneas had a longer duration, 
problem behaviour was less severe, reaching statistical signifi cance for subscale of 
‘communication disturbance’ (β=-0.45, p<0.05).
Figure 2. Bars represent the problem behaviour score for children with PWS, compared to 
reference data from children with mental delay. Data are expressed as SD scores. 
* Represents problem behaviour with a median signifi cantly above or below the reference 
population.
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Figure 2a.  Figure 2b.
Developmental Behaviour Checklist Questionnaire for social behaviour in children 
(DBC) (VISK)
1. Disruptive / Antisocial 1. Not Adapted
2. Self-absorbed 2. Withdrawal
3. Communication Disturbance 3. Dysorientation
4. Anxiety 4. Insensitive to social situations
5. Social Relating 5. Stereotyping Behaviour
6. Total score 6. Resistance to change
  7. Total social problem behaviour
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6.5 Discussion
This study shows that pre-pubertal not overweight PWS children, have impaired 
cognitive abilities with an unequal distribution. Sixty percent of the children had 
better scores on verbal than on performance subtests. In addition PWS children 
had neurobehavioural abnormalities, particularly autism-related social behaviour, 
and sleep-related breathing disorders which were mainly of central origin. Sleep 
effi ciency index was associated with better performance on the subscales of Picture 
Completion/Arrangement, and neurobehavioural abnormalities were associated with 
daytime sleepiness. In contrast, we could not fi nd associations between cognition or 
neurobehavioural abnormalities and SRBD, as previously described for the general 
population. Surprisingly, a negative association was found between social relating 
problem behaviour and total problem behaviour and apnea hypopnea index, indicating 
that children with more apneas had less behavioural problems. 
Our results indicate overall cognitive impairment, although not equally divided 
between verbal and performance subtests. Sixty percent of children did better on 
verbal than on performance subtests. In our study group, UPD was relatively common, 
which might explain this fi nding, because a signifi cantly higher verbal IQ in PWS 
subjects with UPD compared to deletions has been reported [2]. Our sample does 
not refl ect the general population of PWS subjects, with respect to the distribution 
of the underlying genetic defect. However, an increase in UPD, relative to paternal 
deletion has been reported recently in young PWS children, and has been attributed 
to increasing maternal age at conception [23]. Better sleep effi ciency was associated 
with a better performance on “picture completion/picture arrangement” subscales, 
which might be related to executive functioning, as has been proposed by Beebe 
and Gozal [9]. According to this model, sleep disruption, together with intermittent 
hypoxia and hypercapnia, elicited by SRBD, induce disruption of the restorative 
features of sleep and of cellular and chemical homeostasis which in turn results in 
frontal cortical dysfunction. Dysfunction of the frontal cortex is considered to impair 
the cognitive executive functioning (indicating the ability to develop an approach to 
problem situations), which may contribute to the association of performance cognitive 
subtests and sleep effi ciency. 
As PWS subjects might have an increased need for nocturnal sleep [24], management 
strategies to reduce behavioural problems at bedtime may be indicated to improve 
sleep effi ciency [3]. Future research is needed to evaluate whether improvement of 
sleep effi ciency also results in improvement of performance intelligence. We did not 
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fi nd an association between cognitive parameters and BMI (data not shown) or SRBD, 
but this might be due to the fact that obstructive sleep apnea and overweight were 
rather uncommon in our study-group.
 We found in our PWS children, compared to reference data for children with 
mental disability, less anxiety-related problem behaviour and more behavioural 
problems particularly more “emotions/behaviour not adapted to the social situation” 
and “insensitivity to social information”, which refl ect more autistic-like social 
impairment. Autistic like social behaviour is more common in UPD [25], and the high 
prevalence of these abnormalities in our study group may be due to the high prevalence 
of UPD in this group. It is remarkable that, compared to a reference population 
with mental disability, disruptive/antisocial behaviour (including “impulsiveness” 
and “temper tantrums”) was not commonly reported. Notably, children with more 
severe behavioural abnormalities had less severe SRBD. In addition, if apneas had a 
longer duration, problem behaviour in particular on the subscale “communication 
disturbance’, tended to be less severe. 
These fi ndings in PWS children are diffi cult to understand or explain, and not 
in line with the general pediatric population, in which associations between SRBD 
(mostly obstructive apnea) measured with PSG and problem behaviour, particularly 
ADHD, are reported [26]. 
We cannot explain the inverse relationship between SRBD and behavioural 
abnormalities. It might be that parents of relatively well functioning PWS children, 
reported more problem behaviour, because their child attend normal school and they 
compared their child to healthy peers, whereas children with more severe mental 
disabilities were compared to other children with mental disability, which may 
have resulted in underestimation of problem behaviour in more severely affected 
children. 
Another explanation for the absence of a positive association between SRBD and 
behavioural abnormalities, might be that in children with PWS, neurobehavioural 
abnormalities, cognitive impairment and SRBD may have different genetic causes. 
SRBD are proposed to be caused by absence of the Necdin gene in PWS, via abnormal 
neuronal activity within the respiratory rythm-generating center, the pre-Bötzinger 
complex, as was shown by Ren et al in Necdin-defi cient mice [27]. One of the proposed 
genes involved in behavioural abnormalities, particularly autistic-like behaviour is the 
ubiquitin protein ligase gene, UBE3A [8]. UBE3A is maternally expressed in a few 
specifi c areas, including the hippocampus and the cerebellar Purkinje cells [28], which 
both have been implicated in the neuropathology of autism [8]. UBE3A is located on 
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chromosome 15 and paternally imprinted. In subjects with a UPD of chromosome 15, 
UBE3A is over-expressed. In particular, increased autistic-like social impairments are 
consistently more common in UPD cases compared to children with deletions [8]. Also 
in our study-group, autistic-like social impairment was the most common reported 
behavioural abnormality and the majority of our PWS children had UPD, which does 
not refl ect the general population of PWS subjects. In addition, our sample size was 
not large enough to study differences in behavioural phenotypes between the genetic 
subtypes. 
Our results are in contrast with the only previous report in PWS subjects, aged 1.5 
to 28 years, including 6 children below the age of 12. In this report autistic behaviour 
was associated with low sleep effi ciency and oxygen desaturations and impulsivity with 
SRBD. One possible explanation for the difference with our results might be that in 
these subjects, obesity was more common, which might have caused obstructive sleep 
apnea, with drops in oxygen saturation, resulting in neurobehavioural abnormalities 
as found in children with OSAS in the general population. 
In conclusion, this is the fi rst study evaluating cognition, behaviour and their 
associations with sleep-related breathing disorders in a large, homogeneous group 
of pre-pubertal PWS children. Our results show that PWS children have impaired 
cognitive abilities, not equally divided between verbal and performance subtests. 
Their problem behaviour is particularly related to autistic-like social impairment, 
i.e. “emotions/behaviour not adapted to the social situation” and “insensitivity to 
social information”. Sleep effi ciency index was associated with better performance 
on the “Picture completion/arrangement” subtests, whereas neurobehavioural 
abnormalities were associated with daytime sleepiness. Future studies are required 
to evaluate whether improvement of nocturnal sleep and daytime sleepiness may 
improve cognitive and behavioural functioning.
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Thyroid hormone levels in 
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7.1 Abstract
Background: Prader-Willi Syndrome (PWS) is a neurogenetic disorder characterised by 
muscular hypotonia, psychomotor delay, obesity, and short stature. Several endocrine 
abnormalities have been described, including growth hormone (GH) defi ciency, and 
hypogonadotropic hypogonadism. Published data on thyroid hormone levels in PWS 
children are very limited.
Objective: To evaluate thyroid function in children with PWS, before and during GH 
treatment.
Design/Patients: At baseline, serum levels of T4, free T4 (fT4), T3, reverse T3 (rT3) 
and TSH were assessed in 75 PWS children. After one year, assessments were repeated 
in 57 of them. These children participated in a randomised study with two groups: GH 
group (n=34) treated with 1 mg GH/m2/day and control group (n=23) as controls. 
Results: Median age (interquartile range, iqr) of the total group at baseline was 4.7 
years (2.7 to 7.6). Median (iqr) TSH level was -0.1 SDS (-0.5 to 0.5), T4 level, -0.6 SDS 
(-1.7 to 0.0), and fT4 level, -0.8 SDS (-1.3 to -0.3), the latter two being signifi cantly 
lower than 0 SDS. T3 level, 0.3 SDS (-0.3 to 0.9), was signifi cantly higher than 0 SDS. 
After one year of GH treatment, fT4 decreased signifi cantly from -0.8 SDS (-1.5 to -0.2) 
to -1.4 SDS (-1.6 to -0.7), compared with no change in untreated PWS children. T3 did 
however not change, 0.3 SDS (-0.1 to 0.8). 
Conclusions: We found normal fT4 levels in most PWS children. During GH treatment, 
fT4 decreased signifi cantly to low-normal levels. TSH levels remained completely 
normal. T3 levels were relatively high or normal, both before and during GH treatment, 
indicating that PWS children have increased T4 to T3 conversion.
141
C
ha
pt
er
 7
 |
 T
hy
ro
id
 h
or
m
on
e 
le
ve
ls
 i
n 
PW
S 
an
d 
ef
fe
ct
s 
of
 G
H
 t
re
at
m
en
t
7.2 Introduction
Prader-Willi Syndrome (PWS) is a genetic disorder, in the majority of subjects caused 
by either a microdeletion on the paternally derived chromosome 15q11-13 or a 
uniparental maternal disomy affecting the same region [1]. In approximately 1-5%, 
PWS is the result of an imprinting center mutation [2], which results in silencing of 
genes that are normally active only in the paternally inherited chromosome 15q11-
13.
PWS is characterised by a number of signs and symptoms, including muscular 
hypotonia, psychomotor delay, short stature and obesity, which may become extreme 
after the age of 2-4 years. Temperature instability and sleep-related breathing disorders 
contribute to the clinical characteristics of the PWS. Most of the characteristic features 
of PWS are thought to be the result of hypothalamic dysfunction [3].
Several endocrine abnormalities have been described, including growth hormone 
(GH) defi ciency and hypogonadotropic hypogonadism [4]. Studies concerning thyroid 
hormone levels in PWS children are very limited. Congenital hypothyroidism has been 
reported in one girl with PWS [5]. 
In general, it has been suggested that GH therapy of non-PWS GH-defi cient patients 
could unmask an underlying TSH defi ciency, leading to defi ciencies in T4 and T3 [6, 
7]. In addition, GH might increase peripheral conversion of T4 to T3 [8-10]. Myers et al 
found that 3/35 (9%) of PWS children required thyroxin replacement while on GH [11]. 
This was also reported in other studies [12,13]. 
Prior to the study we hypothesized that a certain percentage of PWS children would 
have hypothyroidism (approximately 20%) of central origin and that GH treatment 
could unmask an underlying TSH defi ciency. For that reason, one of our objectives 
was to evaluate thyroid hormone levels at baseline and during GH treatment. We 
assessed levels of T4, free T4 (fT4), T3, reverse T3 (rT3) and TSH and their relations, 
in a group of PWS children in a randomised GH trial, at start and after 1 year.
7.3 Patients and Methods
Patients
Seventy-nine children were enrolled in a large randomised controlled trial to 
investigate the effects of GH treatment on growth, body composition, activity level 
and psychosocial development. Participants fulfi lled the following inclusion criteria: 
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(1) genetically confi rmed diagnosis of PWS; (2) age between 6 months and 16 years; (3) 
bone age less than 14 years (girls) or 16 years (boys). Patients with non-cooperative 
behaviour or patients receiving medication to reduce fat were excluded. There was 
no familiarity for thyroid disease, and all children were naïve to GH treatment at the 
start of study. They were included irrespective of their growth hormone status. Caloric 
intake and activity level of all participants were standardised, and recommendations 
were given. Compliance to diet and exercise was evaluated by the research nurse, 
in close collaboration with the dietician and, if indicated, the physiotherapist. After 
stratifi cation for age and body mass index (BMI), children with an age below 12 years 
(girls) or 14 years (boys) were randomised, into either the GH treatment group or the 
control group. Children with an age over 12 years (girls) or 14 years (boys) were all 
treated with GH. 
Seventy-fi ve children were eligible for baseline analysis. Fifty-seven were 
analysed after 1 year of study, divided into two groups: GH group (n=34) receiving 
Genotropin® (somatropin) GH 1 mg/m2/day s.c. (Pfi zer)(during the fi rst 4 weeks 
children received 0.5 mg/m2/day, to avoid fl uid retention) and control group (n=23) as 
controls. Eighteen patients did not yet reach 1 year of study or we could not obtain 
a blood sample due to diffi cult venapuncture. In 4 children, thyroxin treatment was 
started to correct low levels of fT4, prior to study. They are described separately.
The study protocol was approved by the Medical Ethics Committee of Erasmus 
Medical Center, Rotterdam, The Netherlands. Written informed consent was obtained 
from the parents and children over 12 years of age.
Methods 
Collection of blood
Blood samples were collected in the morning, after overnight fasting for assessment 
of T4, fT4, T3, rT3, and TSH. After centrifugation samples were immediately frozen 
at -20° until assayed.
Assays
Thyroid hormone levels 
Plasma levels of rT3 were measured by established radioimmunoassay procedures, 
as previously described [14,15]. Serum TSH, fT4, T4 and T3 levels were measured by 
Vitros Eci technology (Ortho-Clinical Diagnostics, Amersham, UK). The within-assay 
coeffi cient of variation (CV) of Vitros was 3-7% and the between-assay CV 5-10%. 
Thyroid hormone standard deviation scores (SDSs) were calculated with data from 
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a control group comprising 500 healthy Dutch children (age 1.4-18 years) from the 
Rotterdam region, The Netherlands, participating in a study to assess reference 
values. They agreed to a blood test to assess biochemical parameters. The Medical 
Ethics Committee of the Erasmus Medical Center Rotterdam approved this study, and 
written informed consent was obtained from the parents or guardians. 
IGF-I and IGFBP-3 levels
IGF-I was measured using an immunometric technique on an Advantage 
Chemiluminescense System (Nicholls Institute Diagnostics, San Juan Capistrano, USA). 
Serum IGFBP-3 levels were measured using a specifi c RIA [16] in one laboratory. 
The intra-assay CV was 4% and the inter-assay CV was 6%. Because of age- and sex-
dependency, IGF-I and IGFBP-3 levels were transformed into SDS [16].
Anthropometry
At baseline and after 1 year, standing height (or supine length, when appropriate) was 
measured with a Harpenden stadiometer. Weight was assessed on an accurate scale, 
BMI was calculated, and head circumference was measured. Height, BMI, and head 
circumference were expressed as SD scores adjusting for sex and age according to Dutch 
reference data for children [17,18]. BMI, height SDS, BMI SDS, and head circumference 
SDS were calculated with Growthanalyser, Version 3.0. (www.growthanalyser.org).
Statistical analysis
Statistical analysis was performed by the Statistical Package for Social Sciences 
(SPSS Version 11.0, Chicago, IL). Most of our data were not Gaussian distributed. 
After log- or square root transformation of skewed data, data were still not normally 
distributed. We therefore expressed data as median (interquartile range, iqr) and 
we used non-parametric tests if indicated. Differences between groups at baseline 
and between changes over time were evaluated using independent sample t-test for 
anthropometric data, and Mann Whitney U tests on standardised thyroid hormone 
levels. Changes within subjects were calculated with paired t-test or Wilcoxon signed 
rank test, respectively. Posthoc Bonferroni correction was used to adjust for multiple 
testing. To compare the data, expressed as SDS, with those of healthy references (0 
SDS), we used binomial test to exclude the infl uence of outliers. Correlations were 
calculated using Spearman’s correlation coeffi cient. One-way ANOVA was used to 
analyse variation in thyroid hormone levels for different genetic defects. P-value 
<0.05 was considered as statistically signifi cant. 
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7.4 Results
Clinical characteristics at baseline
Baseline clinical characteristics are summarized in Table 1. The baseline group had a 
median (iqr) age of 4.7 years (2.7 to 7.6). Median height SDS and head circumference SDS 
were signifi cantly lower in the patients than in the normal population. BMI was higher 
in our patients than in the normal population. Twenty-one percent of our patients 
were considered overweight, defi ned as BMI > +2 SDS. Five of 79 (6%) children were 
underweight defi ned as BMI < -2 SDS. All children had genetically confi rmed diagnosis 
of PWS by positive methylation test. Twenty-six children had a paternal deletion, 24 
had a uniparental maternal disomy and 7 had an imprinting center mutation. In one 
patient, the absence of 15q11-13 was caused by a Robertsonian translocation. In the 
remaining 17 patients the underlying genetic defect was not yet specifi ed. 
Thyroid hormone levels at baseline
Baseline thyroid hormone levels are listed in Table 1. Free T4 was -0.8 SDS (-1.3 
to -0.3), which was signifi cantly lower than 0 SDS. Only one patient of 75 (1.4%) 
had a fT4 level below –2 SDS. In addition, 4 patients were described separately 
because they received thyroxin treatment to correct low fT4 levels, prior to 
study. As a result 5/79 (6.3%) had fT4 levels below -2 SDS, thus most children 
had fT4 levels well within the normal range. Interestingly, median T3 levels 
were signifi cantly higher than 0 SDS. None of our 75 patients had a T3 level 
below -2 SDS, and 5.5% had a T3 above +2 SDS. Median rT3 and TSH levels were 
-0.3 SDS (-0.9 to 0.4) and -0.1 SDS (-0.5 to 0.5), which was not signifi cantly lower than 
0 SDS. We did not fi nd any difference in thyroid hormone levels between the different 
genetic defects, or between boys and girls (data not shown). 
Children with low fT4 levels
Four patients were excluded from group analysis, because they received thyroxin 
replacement therapy, prior to start of GH study. At start of replacement therapy 
they had a mean age of 3.5 years, and a mean BMI of +1.0 SDS. Free T4 levels, prior 
to start of thyroxin replacement, were low (ranging from 7.2 to 8.4 pmol/l, normal 
range: 11-25 pmol/l). TSH levels were completely normal, ranging from 1.52 to 3.48 
mU/l. In 2 of them, T3 levels were available, which were within the normal range in 
both patients (2.1 and 2.2 nmol/l, normal range: 1.43-2.51 nmol/l). One patient of the 
baseline group (n=75) had a fT4 level below –2 SDS, but T3 level (-0.38 SDS) and TSH 
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level (-0.32 SDS) were completely normal. Thus, 5/79 (6.3%) patients had a fT4 below 
-2 SDS at baseline, without abnormalities in TSH and T3 levels.
Table I: Clinical characteristics and thyroid hormone levels before GH treatment
Median iqr p-value 
n 75
Sex (m/f) 39/36
Age (yrs) 4.7 (2.7 to 7.6)
Height (SDS) -2.2 (-3.0 to -1.2) <0.001
Head circ (SDS) -0.8 (-1.6 to -0.3) <0.001
BMI (kg/m2) 17.7 (15.9 to 20.3)
(SDS) 1.1 (-0.2 to 1.9) <0.001
IGF-I (ng/ml) 53.0 (34.0 to 87.0)
(SDS) -2.0 (-2.7 to -1.3) <0.001
IGBFBP-3 (ng/ml) 1.2 (0.8 to 1.4)
(SDS) -2.2 (-3.1 to -1.6) <0.001
T4 (nmol/L) 98.0 (85.3 to 112.8)
(SDS) -0.6 (-1.7 to 0.0) <0.001
fT4 (pmol/L) 16.2 (14.3 to 17.8)
(SDS) -0.8 (-1.3 to -0.3) <0.001
T3 (nmol/L) 2.6 (2.3 to 3.0)
(SDS) 0.3 (-0.3 to 0.9) 0.02
rT3 (nmol/L) 0.3 (0.3 to 0.4)
(SDS) -0.3 (-0.9 to 0.4) 0.10
TSH (mU/L) 2.0 (1.6 to 2.7)
(SDS) -0.1 (-0.5 to 0.5) 0.64
Baseline levels of height, BMI and head circumference (n=75), TSH (n=75), T3, fT4 (n=73), T4 (n=72) and rT3 
(n=64), IGF-I (n=53), IGFBP-3 (n=52).
p-value represents p-value compared to normal (0 SDS). 
Correlations at baseline
T4 SDS and rT3 SDS were positively correlated with age (r=0.68; p<0.001 and r=0.67; 
p<0.001, respectively) and with BMI SDS (r=0.40; p<0.005 and r=0.44; p<0.001, 
respectively). As age and BMI SDS were highly correlated, the associations were no 
146
C
ha
pt
er
 7
 |
 T
hy
ro
id
 h
or
m
on
e 
le
ve
ls
 i
n 
PW
S 
an
d 
ef
fe
ct
s 
of
 G
H
 t
re
at
m
en
t
longer signifi cant after correction for BMI or age respectively. Free T4 SDS did neither 
correlate with age nor with BMI SDS. Free T4 levels were not associated with IGF-I levels 
(r=0.04, p=0.77). We did not fi nd associations between thyroid hormone levels and 
height SDS. Interestingly, T3 SDS did signifi cantly correlate with head circumference 
SDS (r=0.35; p<0.005).
Effects of GH treatment
Table 2 shows the clinical parameters of children, before and after 1 year of follow-
up. Although children in the GH group were older (p=0.02), height, BMI and head 
circumference, expressed as SD scores, were similar in both groups at baseline. During 
GH treatment, height SDS increased signifi cantly from -2.1 (-2.9 to -1.3) to -1.1 (-1.5 
to -0.5) (p<0.005). In controls, height SDS remained unchanged. BMI SDS decreased in 
GH-treated children from 1.2 SDS (0.0 to 2.3) to 0.8 SDS (-0.4 to 1.7) (p<0.05 compared 
with change in controls). Head circumference had signifi cantly increased in GH-treated 
children, compared with no change in controls.
Table 2: Clinical parameters before and during 1 year follow-up
GH group Control group
Baseline 12 months Baseline 12 months
n 34 34 23 23
Sex (m/f) 17/17 17/17 13/10 13/10
Age (yrs) 6.31 (3.4 to11.5) 7.3 (4.4 to 12.4) 3.61 (1.6 to 5.2) 4.5 (2.6 to 6.1)
Height (SDS) -2.1 (-2.9 to -1.3) -1.124 (-1.5 to -0.5) -2.2 (-3.3 to -1.4) -2.34 (-3.5 to -1.8)
BMI (kg/m2) 17.8 (16.0 to 24.0) 17.7 (15.7 to 22.5) 17.2 (15.9 to19.5) 17.9 (16.4 to 19.8)
BMI (SDS) 1.2 (0.0 to 2.3) 0.83 (-0.4 to 1.7) 1.1 (-0.7 to 1.6) 1.33 (0.1 to 1.6)
Head circ (SDS) -0.8 (-1.5 to -0.2) -0.123 (-1.1 to 0.4) -1.1 (-1.7 to –0.4) -0.83 (-1.2 to -0.1)
IGF-I (SDS) -2.1 (-2.8 to -1.3) 2.224 (1.4 to 2.8) -1.6 (-2.6 to -0.8) -2.64 (-3.9 to -0.9)
IGFBP-3 (SDS) -2.3 (-3.1 to -1.9) 0.324 (-0.6 to 0.7) -2.2 (-3.1 to -1.5) -2.44 (-3.6 to -1.8)
Data are expressed as median (interquartile range) 
1 p<0.05 Signifi cantly different GH group vs. control group at baseline, after correction for multiple 
testing
2 p<0.005 Signifi cantly different 12 months vs. baseline, after correction for multiple testing
3 p<0.05 4 p <0.005 Change during follow-up GH group vs. control group, after correction for multiple 
testing
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Table 3: Thyroid hormone levels at start and after 12 months of follow-up
GH group Control group
Baseline 12 months Baseline 12 months
T4 (nmol/l) 96.5 (84.5 to 110.3) 93.5 (82.8 to 102.3) 101.0 (87.0 to 118.0) 102.0 (93.0 to 107.0)
(SDS) -0.4 (-1.3 to 0.1) -0.6 (-1.5 to 0.3) -0.6 (-2.1 to 0.1) -0.9 (-1.8 to 0.0)
fT4 (pmol/l) 16.0 (14.5 to 17.7) 14.1 (13.4 to 16.4) 16.7 (14.6 to 17.8) 15.9 (14.0 to 17.9)
(SDS) -0.8 (-1.3 to -0.4) -1.41 (-1.6 to -0.7) -0.6 (-1.2 to -0.3) -0.9 (-1.4 to -0.3)
T3 (nmol/l) 2.6 (2.4 to 3.0) 2.6 (2.4 to 2.9) 2.6 (2.3 to 3.1) 2.6 (2.3 to 2.8)
(SDS) 0.4 (-0.2 to 1.1) 0.3 (-0.1 to 0.8) 0.5 (-0.4 to 1.1) 0.1 (-0.4 to 0.5)
rT3(nmol/l) 0.33 (0.28 to 0.37) 0.25 (0.22 to 0.33) 0.36 (0.31 to 0.41) 0.30 (0.26 to 0.34)
(SDS) 0.0 (-0.9 to 0.6) -0.71 (-1.5 to -0.2) -0.3 (-0.8 to 0.4) -0.7 (-1.1 to -0.1)
TSH (mU/l) 1.8 (1.6 to 3.4) 1.8 (1.3 to 2.3) 2.3 (1.8 to 3.0) 2.2 (1.5 to 3.1)
(SDS) -0.3 (-0.4 to 0.9) -0.3 (-0.9 to 0.2) 0.1 (-0.3 to 0.6) 0.1 (-0.6 to 0.7)
In GH group, rT3 was available in 32 patients at start and after 12 months of follow-up. In control group, 
fT4, T4, T3 and rT3 were available in 21 children at start of the study. After 12 months of follow-up fT4 and 
T3 were available in 22 children and rT3 in 19.
Data are expressed as median (interquartile range). At baseline there were no signifi cant differences 
between both groups.
1 p<0.05 Signifi cantly different 12 months vs. baseline, after correction for multiple testing
No signifi cant change during follow-up GH group vs. control group.
Thyroid hormone levels before and after one year of study are listed in Table 3 
and Figure 1. At start of study, thyroid hormone levels were similar in both groups. 
After 1 year, fT4 levels had signifi cantly decreased in the GH group compared with 
baseline, from -0.8 SDS (-1.3 to -0.4) to -1.4 (-1.6 to -0.7) (p<0.05), and had not changed 
in controls. In 3/34 GH-treated patients (8.8%) but also in 1/23 control patients (4.5%), 
fT4 levels were below –2 SDS after 1 year of follow-up. All these patients had, however, 
T3 levels well within the normal range (range -0.15 to 0.73 SDS). T3 SDS levels did 
not signifi cantly change during 1 year of follow-up in both groups. Reverse T3 SDS 
decreased signifi cantly in GH-treated children (p<0.05), but not in controls. We found 
no change in TSH during follow-up. TSH remained well within the normal range. The 
change in fT4 over 1 year was not signifi cantly correlated with the change in IGF-I (r=-
0.21, p=0.29 in the GH group; r=-0.10, p=0.76 in the control group).
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TSH
3
2
1
0
-1
-2
-3
N= 34 34 23 23
TSH (SDS) at start
TSH (SDS) after 12 m
20
GH Group Control Group
Figure 1 a-e: Figures represent levels of T4, fT4, T3, rT3 and TSH for GH-treated children 
with Prader-Willi Syndrome and for randomised controls, at start of the study and after 12 
months. Lines represent zero SDS. Boxplots represent median and interquartile range.
7.5 Discussion
Our study shows that most PWS children have fT4 levels within the normal range, 
although signifi cantly lower than 0 SDS. Five of 79 children had fT4 levels below -2 
SDS. We found, however, normal T3 levels in all patients, with a median T3 even 
above the median of the reference population. Sex, height SDS and underlying genetic 
defect did not explain variations in serum thyroid hormone levels at baseline. T3 SDS 
correlated positively with head circumference, and T4 and rT3 levels with age and 
BMI SDS. Thyroid hormone levels did not correlate with IGF-I. After 1 year of study, 
fT4 levels had signifi cantly decreased in GH-treated children from -0.8 SDS (-1.3 to 
-0.4) to -1.4 SDS (-1.6 to -0.7) but remained unchanged in controls. In 3/34 GH-treated 
patients (8.8%), fT4 levels decreased below the -2 SDS, but also in one of the control 
patients (4.5%). In contrast, T3 levels remained normal in all GH-treated children and 
controls. 
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Our fi nding that the baseline median fT4 level was signifi cantly below 0 SDS might 
be consistent with the fact that most endocrine abnormalities in PWS are thought to 
be the result of hypothalamic dysfunction [3]. In line with this, Bray et al [19], showed 
that 5 obese, adult PWS patients, had a TRH-stimulated TSH response of about 2 SD 
higher than obese controls, however within the normal range. These fi ndings indicate 
an alteration in the hypothalamic-pituitary control system for thyroid hormones in 
PWS. 
We did not measure auto-antibodies to thyroglobulin or thyroid peroxidase. 
Because PWS is primarily a hypothalamic disorder, we expected low fT4 levels as a 
result of low hypothalamic stimulation. Indeed, we did fi nd low-normal fT4 levels, in 
combination with completely normal TSH levels. We had no reason to suspect auto-
immune abnormalities in the PWS children.
Increased peripheral conversion from fT4 to T3 might compensate for the relatively 
lower fT4 levels in most PWS patients. Recent in vitro studies showed that cells, 
transfected with deiodinase type 1 and type 2 expressing plasmids, and incubated 
with low fT4 concentrations had relatively more deiodinase type 2 activity compared 
to deiodinase type 1 activity, resulting in an increased fraction of T4 converted to T3 
by deiodinase type 2 [20]. Furthermore, in the cortex of rats with low fT4 levels, T4 
deiodination increases and D2 mRNA levels elevate, indicating that D2 in the central 
nervous system is also controlled by T4 status [21]. In addition, leptin was recently 
suggested to be a potential mediator in the conversion from T4 to T3 via increased 
deiodinase type 2 mRNA expression, which was shown after intracerebroventricular 
administration of leptin in rats [22]. Leptin is produced by adipocytes and correlates 
well with body fat percentage [23]. It has been shown that children with PWS have a 
relatively high body fat percentage, even when they are not obese [24,25]. They have 
high leptin levels, which are highly correlated with the increased body fat percentage 
[26]. Thus, the relatively lower fT4 levels, in combination with normal T3 levels, as 
shown in most PWS children, might be the result of an increased peripheral conversion 
by deiodinase type 2, as a result of a combination of high leptin levels and low fT4 
levels. 
Reports on serum thyroid hormone levels in PWS are very limited, and to our 
knowledge, T3 levels have not yet been reported in children with PWS [27]. In our 
study, 4 children were excluded from group analysis, because they received thyroxin 
treatment, based on low fT4 levels, prior to the study. One child in our study had a 
baseline fT4 level below -2 SDS, and 3 GH-treated patients and one control patient 
after one year of study, but all these children had normal T3 and TSH levels.
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Although low fT4 levels are considered an important measure in the diagnosis of 
hypothyroidism, the combination of relatively low fT4 levels within the normal range, 
with normal or slightly elevated T3 levels and completely normal TSH levels in PWS 
children might not warrant start of thyroxin treatment. 
We found a signifi cant positive correlation between T3 and head circumference. 
Thyroid hormone plays an essential role in early prenatal brain development [28]. 
Higher total T4 and fT4 levels were associated with better overall performance on 
cognitive functioning in healthy, euthyroid men [29]. Brain growth during infancy and 
early childhood is suggested to be an important determinant of cognitive function 
[30]. The association between T3 and head circumference, as we found in our patients 
has, however, never been reported. Future studies are required, to evaluate if there is 
an association between head circumference, intelligence and thyroid hormone levels, 
particularly T3, in PWS. 
We found no signifi cant correlation between fT4 and T3 and BMI. Several studies 
reported an elevation of serum T4, T3 and TSH levels in obese versus non-obese 
healthy children and a decrease of T3 and T4 levels after weight reduction [31-36]. It 
might be that we found no correlation because most of our patients were not severely 
obese.
Concerning the effects of GH treatment, we found a decrease in median fT4 in 
GH-treated children, although levels remained well within the normal range for most 
children. There was no change in the randomised controls. However, T3 levels in 
our patients were completely normal, both before and during GH treatment. It has 
previously been reported that fT4 and TSH levels decrease during GH treatment in GH 
defi cient children and adults [7-10,37-40]. Also in PWS children, thyroxin replacement 
therapy during GH therapy has been reported [11,12]. Several mechanisms have been 
proposed. Lippe et al demonstrated an inhibition of the TSH response to TRH during 
GH treatment and postulated that this might be mediated by somatostatin secretion 
in response to pulse doses of GH [7]. Others found a decrease of fT4 without changes 
in TSH, indicating an increased peripheral conversion from fT4 to T3 [10,37]. This 
effect might be mediated by either GH itself or via IGF-I, or both [10,40]. Jorgensen et 
al showed in GH defi cient adults treated with GH a signifi cant blunting of serum TSH 
levels and a stimulated peripheral conversion from T4 to T3 [9,38,39]. In our study, 
we found no change in TSH SDS, whereas the median T3 level was above 0 SDS after 
1 year of GH, which might indicate an increased peripheral conversion by outer ring 
deiodination [41]. The response to GH treatment in terms of growth in our patients was 
impressive, as in patients with isolated idiopathic GH defi ciency, who had during GH 
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a decrease in fT4 within the normal range [8]. Such a decrease during GH treatment, 
with normal T3 and TSH levels, might therefore not warrant substitution therapy.
Reverse T3 levels were normal before start of GH treatment, but decreased in GH-
treated, and not in non-GH-treated PWS patients after one year of follow-up. Portes 
et al [10] have observed a similar decrease of rT3, in association with an increase of 
T3 levels and unchanged TSH values, during long-term GH therapy in non-PWS GH 
defi cient children, but its signifi cance remains to be established. 
In conclusion, we found normal fT4 levels in most children with PWS. Five of 
79 children had fT4 levels below -2 SDS. After 1 year of GH treatment, fT4 levels 
decreased signifi cantly, but remained normal in most children. In contrast, baseline 
levels of T3 were normal or relatively high in all PWS children and remained so during 
GH treatment, indicating that in PWS children, peripheral conversion from T4 to T3 
increases when fT4 levels become lower. To improve our knowledge, we recommend 
regular monitoring of fT4, T3 and TSH levels in PWS children, particularly during GH 
treatment.
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Adiponectin levels in 
pre-pubertal children with 
Prader-Willi Syndrome before and 
during growth hormone therapy
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8.1 Abstract
Background: Children with Prader-Willi Syndrome (PWS) may have obesity and an 
abnormal body composition with a high body fat percentage, even if they have a 
normal body weight. Adiponectin has been inversely related to obesity and insulin 
resistance.
Objective: To evaluate in pre-pubertal PWS children (1) adiponectin levels, body 
composition, carbohydrate metabolism, and triglyceride levels, (2) associations 
between adiponectin and body composition, carbohydrate metabolism and 
triglycerides, and (3) effects of growth hormone (GH) treatment on these outcome 
measures.
Design/Patients: 20 pre-pubertal PWS children were randomised into a GH treatment 
group (n=10, 1 mg/m2/day) and a non-GH-treated control group (n=10).
At baseline, after 1 and 2 years of GH treatment, fasting levels of adiponectin, glucose, 
insulin, and triglycerides were assessed. Body composition and fat distribution were 
measured by Dual Energy X-ray Absorptiometry. 
Results: PWS children had signifi cantly higher median (interquartile range) adiponectin 
levels; 17.1 mg/l (13.9 to 23.2), than healthy sex- and age-matched controls; 11.8 mg/l 
(9.7 to 12.5) (p<0.005). Body fat percentage was signifi cantly higher than 0 SDS; 1.8 
SDS (1.5 to 2.1) (p<0.001). Adiponectin levels were inversely related to triglyceride 
levels (r=-0.52, p=0.03). There was a tendency to an inverse relation with body 
fat percentage and BMI, but no correlation with fasting insulin or glucose levels, 
the insulin/glucose ratio or HOMA-index. During GH treatment, adiponectin levels 
increased signifi cantly and did not change in randomised controls.
Conclusion: Adiponectin levels were increased, and inversely associated with 
triglyceride levels, in pre-pubertal, not overweight PWS children, although they had a 
relatively high body fat percentage. During GH treatment, adiponectin levels further 
increased, whereas no change was found in the controls, which is reassuring with 
respect to the development of insulin resistance during GH treatment.
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8.2 Introduction
Prader-Willi Syndrome (PWS) is a genetic disorder, in the majority of subjects caused 
by either a microdeletion on the paternally derived chromosome 15q11-13 or a 
uniparental maternal disomy affecting the same region. In approximately 1-5%, PWS 
is the result of an imprinting center mutation, which results in silencing of genes 
that are normally active only in the paternally inherited chromosome 15q11-13 [1, 
2]. PWS is characterised by a number of signs and symptoms, including hypotonia, 
psychomotor delay, short stature and obesity. 
Children with PWS have an abnormal body composition, even when they have 
a normal body weight, with a relatively high body fat percentage and a low lean 
body mass (LBM) [3,4]. As a group, euglycemic PWS individuals have lower fasting 
insulin, and higher insulin sensitivity than a weight comparable group [5-9]. Suggested 
mechanisms for the higher insulin sensitivity are GH defi ciency [10] and an abnormal 
body fat distribution compared to simple obesity, as described in PWS female adults 
[11]. In these PWS women, insulin sensitivity was higher and hepatic insulin extraction 
was increased compared to women with simple obesity. Nevertheless, a subgroup of 
PWS individuals does develop insulin resistance and the absolute prevalence of NIDDM 
in PWS subjects over the age of 20 years is high [12]. A familial component in insulin 
resistance, as in non-PWS subjects, might also contribute in PWS subjects [12]. 
Adiponectin is an anti-infl ammatory adipocytokine that has been inversely related 
to adiposity and insulin resistance [13-16], and is thought to be protective with regard 
to diabetes mellitus and cardiovascular disease [17]. Adiponectin levels increase during 
weight-loss [18]. Adiponectin levels in obese adults with PWS are high, compared to 
simple obesity [19-22] and low [19, 22] or similar [21] compared to lean adult controls. 
So far, no published data concerning adiponectin levels in pre-pubertal, not severely 
overweight PWS children compared to normal-weight healthy controls are available.
Because body fat, more than body mass index per se is reported to be inversely 
related to adiponectin [23], we hypothesized that adiponectin levels would be low 
in PWS children compared to healthy sex- and age matched children, due to their 
expected relatively high body fat percentage, although the counteraction of their low 
insulin levels might result in normal adiponectin levels. GH treatment might have a 
dual effect on adiponectin levels. GH is known to decrease body fat percentage which 
would increase adiponectin levels. On the other hand, GH treatment has also been 
associated with lower insulin sensitivity [24]. We hypothesized that the effects of GH 
on insulin sensitivity would be superior, and therefore that adiponectin levels would 
decrease.
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The aim of the present study was to evaluate (1) serum adiponectin levels, 
measures of body composition and body fat distribution, carbohydrate metabolism 
and triglyceride levels, (2) the associations between these parameters and (3) the 
effects of GH treatment on these parameters, compared with randomised controls in 
pre-pubertal, generally not overweight PWS children.
8.3 Patients and Methods
Patients
Twenty PWS children were evaluated for the present study. These children were all 
enrolled in a randomised controlled trial to investigate the effects of GH treatment 
on growth, body composition, activity level and psychosocial development. They 
fulfi lled the following inclusion criteria: (1) genetically confi rmed diagnosis of PWS; 
(2) age between 4 and 9 years at start of study; (3) pre-pubertal, defi ned as Tanner 
breast stage 1 for girls, and testicular volume less than 4 ml for boys [25], both 
before and during the study. Most children were regularly seen by a dietician and a 
physiotherapist. The caloric intake and activity level of all children were standardised 
at 3 months prior to study, and recommendations were given. Compliance to diet and 
exercise was evaluated by the research nurse, in close collaboration with the dietician 
and, if indicated, the physiotherapist. All children were naïve to GH treatment at start 
of study. They were included irrespective of their GH status. After stratifi cation for 
age and BMI (<2 standard deviation score (SDS) vs. >2 SDS), children were randomised, 
into either the GH group or the control group. For 2 years, children of the GH group 
(n=10) were treated with Genotropin® (somatropin) /1 mg/m2/d s.c. (Pfi zer) (during 
the fi rst 4 weeks they received 0.5 mg/m2/day, to avoid fl uid retention) and children 
of the control group (n=10) were not treated with GH. After 2 years, the control group 
also started GH treatment. At start of study, reimbursement for GH treatment in 
Dutch PWS children had not yet been approved. As there was a lack of controlled data 
with respect to GH treatment in PWS, a controlled study was considered ethical by 
the Dutch Advisory Board on GH in children and the Medical Ethics Committee, and 
the study protocol was approved by the Medical Ethics Committee of Erasmus Medical 
Center, Rotterdam, The Netherlands. Written informed consent was obtained from 
the parents.
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Methods
Anthropometry
At baseline and after 1 and 2 years of GH treatment or follow-up in the control group, 
standing height (or supine length, when appropriate) and weight were measured and 
BMI was calculated. Height and BMI were expressed as SD scores, adjusting for age and 
sex, according to Dutch reference data for children [26,27]. We defi ned overweight 
as a BMI >+2 SDS. BMI, height SDS, and BMI SDS were calculated with Growthanalyser, 
Version 3.0. (www.growthanalyser.org)
Body composition
Dual Energy X-ray Absorptiometry (DXA, type Lunar Prodigy, GE Healthcare) was 
performed in all children and total fat mass, fat percentage, LBM and fat of the trunk 
region were measured. The trunk region consisted of chest, abdomen and pelvis. The 
trunk fat to total fat ratio was considered as estimate for fat distribution. Fat mass, 
fat percentage and LBM were transformed into SD scores adjusting for sex and age, 
using Dutch reference values for children [28].
Collection of blood
Blood samples were collected in the morning after a 12h overnight fast, immediately 
centrifuged and stored at -20° until assayed. 
Assays
Each assay was performed in the same laboratory. Serum glucose and triglyceride 
levels were assessed on Abbott Architect Clinical Chemistry Analyzer (Abbott 
Laboratories, Irving, TX, USA). The intra- and interassay coeffi cient of variation 
(CV) were respectively 0.7% and 0.8% for glucose and 0.5% and 0.6% for triglycerides. 
Serum insulin levels were measured by IRMA (Medgenix, Biosource Europe). Fasting 
normal range was <15 mU/l (manufacturer’s information). The intra-assay CV was 2 
to 4.7% and the inter-assay CV was 4.2 to 11.3%. The minimal detectable dose (MDD) 
was 1 mU/l, and no cross-reactivity with pro-insulin was observed. Assessment of 
insulin resistance was calculated using the homeostasis model assessment (HOMA) as 
previously described [29,30]. Serum adiponectin levels were assessed in duplicate by 
an enzyme-linked immunosorbent assay (ELISA; R&D Systems Inc. Minneapolis. USA). 
The intra-assay CV was <7 %, and the inter-assay CV was <7 %. The MDD was 0.246 
ng/ml, and no signifi cant cross-reactivity or interference was observed. Adiponectin 
control values were obtained from 40 healthy pre-pubertal children with normal height 
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and BMI (23 boys, 17 girls), aged 5.0 – 10.2 years, attending the outpatient clinic for 
a minor surgical procedure. Children suffering from any systemic illness, syndrome 
or dysmorphic feature were excluded. Normal height and BMI were defi ned as height 
and BMI between -2 SDS and +2 SDS, according to Dutch standards. The reference 
study was approved by the Medical Ethics Committee of Erasmus Medical Center, 
Rotterdam, The Netherlands and written informed consent was obtained from the 
parents. Serum insulin like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) 
were measured using a specifi c RIA in one laboratory [31]. The intra-assay CV was 4% 
and the inter-assay CV was 6%. The MDD for IGF-I was 6.0 ng/mL and for IGFBP-3 0.002 
mg/L, and no signifi cant cross-reactivity or interference was observed. For IGF-I and 
IGFBP-3, sex- and age-matched references were available obtained from a healthy 
Dutch population. This reference study was approved by the Medical Ethics Committee 
of Wilhelmina’s Children’s Hospital Utrecht, The Netherlands and written informed 
consent was obtained from the parents. Because of the age- and sex dependency IGF-I 
and IGFBP-3 levels were transformed into SD scores. 
Statistics
Statistical analysis was performed by the Statistical Package for Social Sciences 
(SPSS), Version 11.0. Most of our data were not Gaussian distributed. We therefore 
expressed data as median (interquartile range, iqr) and we used non-parametric tests. 
Differences compared with baseline within groups were calculated using Wilcoxon 
signed rank test. Differences in changes compared with baseline between the GH 
group and the control group were calculated with Mann Whitney U tests. Afterwards, 
we used Bonferroni’s correction for multiple testing for both inter- and intra-individual 
testing. Correlations were calculated by partial correlation coeffi cient, adjusting for 
age and sex. We compared the adiponectin levels of PWS children with reference data 
of healthy sex- and age matched controls (n = 40) with Wilcoxon signed rank test. 
8.4 Results
Clinical characteristics
Clinical characteristics of the study group are listed in Table 1. All children had a 
genetically confi rmed diagnosis of PWS. Six children had a paternal deletion, 5 had 
a uniparental maternal disomy, 2 had an imprinting center mutation, and in 7, PWS 
was confi rmed by a positive methylation test, but the underlying genetic defect was 
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yet unknown. There was no signifi cant difference between age, height or BMI of both 
groups at start of the study. The median (iqr) BMI at start of study was 0.8 SDS 
(0.1 to 1.2) in the GH group and 1.1 SDS (0.6 to 1.5) in the control group. Only two 
children were considered overweight, at start of the study, defi ned as BMI>+2 SDS (1 
patient in the GH group and 1 in the control group). Median (iqr) height SDS increased 
signifi cantly during the fi rst and the second year of GH treatment from -2.2 (-3.1 to 
-1.8) to -1.3 (-1.7 to -0.8) (p<0.05) to -0.6 (-0.9 to -0.3) (p<0.05), but remained low 
in control group; from -2.8 (-3.4 to 7.8) to -2.8 (-3.5 to -2.0) to -3.0 (-3.5 to -1.8). BMI 
tended to decrease in the GH group during the fi rst year, resulting in a signifi cantly 
greater decrease in BMI SDS compared with baseline in the GH group than in the 
control group after 1 year of study (p<0.05). 
Table 1: General clinical characteristics in GH Group and Control Group
GH Group Control Group
Baseline 1 year 2 years Baseline 1 year 2 years
N (m/f) 10 (5/5) 10 (3/7)
Age (yrs) 6.2
(5.1 to 7.1)
7.2
(6.1 to 8.1)
8.2
(7.2 to 9.1)
5.8
(4.9 to 7.8)
6.8
(5.9 to 8.8)
7.8
(6.9 to 9.8)
Height (SDS) -2.2
(-3.1 to -1.8)
-1.31.3
(-1.7 to -0.8)
-0.61
(-0.9 to -0.3)
-2.8
(-3.4 to -2.0)
-2.8
(-3.5 to -2.0)
-3.0
(-3.5 to -1.8)
BMI (kg/m2) 16.9
(15.8 to 17.7)
16.12
(15.2 to 17.6)
16.3
(15.8 to 19.0)
17.3
(16.4 to 19.3)
18.5
(17.6 to 19.3)
18.5
(17.5 to 20.6)
BMI (SDS) 0.8
(0.1 to 1.2)
0.22
(-0.2 to 0.8)
0.4
(-0.3 to 1.1)
1.1
(0.6 to 1.5)
1.3
(1.0 to 1.6)
1.2
(0.9 to 1.5)
Data are expressed as median (interquartile range)
1p<0.05, Compared with baseline *)
2p<0.05, 3p<0.01 Change compared with baseline in GH group vs control group *)
*) Corrected for multiple testing
Adiponectin
Adiponectin levels are presented in Figure 1 and Table 2. At baseline, adiponectin 
levels were signifi cantly higher in the total group of PWS children; 17.1 mg/l (13.9-23.2), 
compared to healthy age- and sex matched controls; 11.8 mg/l (9.7-12.5) (p<0.005). 
During GH treatment, median (iqr) adiponectin signifi cantly increased from 15.9 mg/I 
(13.3 to 23.9) to 24.7 mg/I (15.0 to 25.9) (p<0.05) to 24.6 mg/I (15.4 to 28.2) (p<0.05) 
after 1 and 2 years, respectively. In the control group, adiponectin levels did not 
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change signifi cantly during the study; from 17.1 mg/I (13.1 to 23.1) to 13.4 mg/I (11.6 
to 21.4) to 15.8 mg/I (12.5 to 19.2). During 2 years, the increase in adiponectin was 
signifi cantly greater in the GH group than in the control group (p<0.05). 
Body composition
Body composition of the study groups is presented in Table 3. Median LBM increased 
signifi cantly, during 2 years of GH treatment compared with baseline from -2.2 SDS 
(-2.7 to -2.0) to -1.6 SDS (-1.9 to -1.4) (p<0.05) to -1.2 SDS (-1.7 to -1.1) (p<0.05). In the 
control group, LBM decreased compared with baseline from -2.3 SDS (-2.8 to -1.8) 
to -2.5 SDS (-3.0 to -1.8) to -2.8 SDS (-3.3 to -1.9), (p<0.05 after 2 years). Body fat 
percentage decreased during the fi rst year of GH treatment from 1.7 SDS (1.6 to 2.0) 
to 1.4 SDS (0.9 to 1.7) (p<0.05) and increased during the second year to 1.7 SDS (0.9 to 
1.9). In contrast, in the control group, body fat percentage increased signifi cantly over 
time from 1.8 SDS (1.5 to 2.4) to 2.1 SDS (1.8 to 2.2) to 2.1 SDS (1.9 to 2.4) (p<0.05 after 
2 years). Trunk fat/total fat ratio tended to decrease compared with baseline during 
the fi rst year of GH treatment (p = 0.06). After 24 months of GH treatment the trunk 
fat/ total fat ratio was not signifi cantly lower than at baseline (p=0.12).
Fasting insulin, glucose and triglyceride levels
Median fasting insulin and glucose levels, the insulin glucose ratio, and the HOMA-
index as a measure of insulin resistance (HOMA-IR) were within normal range for the 
total group (Table 2). The change after 1 and 2 years of study was not signifi cantly 
different between the GH group and the control group. In the GH group, fasting insulin 
levels and insulin/glucose ratio increased signifi cantly during the fi rst year (p<0.05), 
but returned to baseline during the second year. In contrast, in the control group, 
fasting insulin levels, insulin/glucose ratio, and HOMA-IR had signifi cantly increased 
after 2 years compared with baseline (p<0.05). All children of the GH group had insulin 
and glucose levels, insulin/glucose ratio, and HOMA-IR within the normal range during 
the entire study. In contrast, 3 children of the control group had fasting insulin levels 
above the upper limit of normal after 2 years of study (range 19 to 31 mU/l). Fasting 
triglycerides at start were above normal range in 3/20 (15%) children (2 children of 
the GH group and 1 of the control group). Of the 2 overweight PWS children at start 
of study, one had increased serum triglycerides. 
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IGF-I and IGFBP-3 levels
IGF-I and IGFBP-3 levels were low compared to normal in our PWS children. During 2 
years of GH treatment, IGF-I SDS increased signifi cantly from -1.7 (-2.2 to -1.2) to 2.3 
(1.6 to 3.0) (p<0.05) to 2.3 (2.1 to 2.9) (p<0.05) and IGFBP-3 SDS from -2.0 (-3.0 to -1.3) 
to 0.5 (-0.1 to 1.0) (p<0.05) to 0.6 (0.4 to 1.1) (p<0.05), but IGF-I and IGFBP-3 remained 
low in the control group.
Table 3: Body composition in GH Group and Control Group
Baseline 1 year 2 years
GH LBM (SDS) -2.2 (-2.7 to -2.0) -1.61 (-1.9 to -1.4) -1.21 (-1.7 to -1.1)
Group Fat mass (SDS) 0.8 (0.6 to 1.0) 0.5 (0.2 to 1.0) 0.9 (0.4 to 1.4)
% fat (SDS) 1.7 (1.6 to 2.0) 1.41 (0.9 to 1.7) 1.71 (0.9 to 1.9)
Trunk fat/total fat 0.44 (0.34 to 0.47) 0.40 (0.33 to 0.42) 0.41 (0.34 to 0.46)
Control LBM (SDS) -2.3 (-2.8 to -1.8) -2.5 (-3.0 to -1.8) -2.81 (-3.3 to -1.9)
Group Fat mass (SDS) 0.8 (0.6 to 1.2) 1.11 (0.9 to 1.2) 1.21 (0.9 to 1.4)
% fat (SDS) 1.8 (1.5 to 2.4) 2.1 (1.8 to 2.2) 2.11 (1.9 to 2.4)
Trunk fat/total fat 0.40 (0.35 to 0.46) 0.41 (0.40 to 0.44) 0.41 (0.38 to 0.45)
Data are expressed as median (interquartile range) 
1p<0.05, Compared with baseline, corrected for multiple testing
Table 4: Partial correlation coeffi cients (r) and p-values between serum adiponectin levels 
and the various parameters, adjusted for age and sex at baseline. 
Parameter r p-value
Triglycerides -0.52 0.03*
Body fat % (SDS) -0.46 0.07
BMI (SDS) -0.44 0.08
Trunk fat/Total fat -0.32 0.21
LBM (SDS) -0.20 0.45
Glucose 0.02 0.95
Insulin -0.07 0.78
Insulin glucose ratio -0.10 0.71
HOMA index -0.10 0.71
p-value <0.05 is considered statistically signifi cant. 
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Figure 1: Adiponectin levels in PWS children and controls. Boxplots represent adiponectin 
levels during study. The lower boundary is the 25th percentile, and the upper boundary 
the 75th percentile. The line in the box represents the median. Lines are drawn from the 
smallest to the largest observed value that is not an outlier. Open circles are outliers. 
1 p <0.05 adiponectin levels compared with baseline levels. 
Changes in adiponectin levels from baseline are signifi cantly greater in the GH group 
compared with the randomised PWS control group after 12 (p<0.001) and after 24 months 
(p<0.001). 
PWS children had signifi cantly higher adiponectin levels than healthy sex- and age matched 
controls (p<0.005). 
*Healthy sex-, and age-matched controls.
Associations between adiponectin and body composition, triglyceride 
levels, and carbohydrate metabolism
Results of correlations between serum adiponectin levels, body composition and 
body fat distribution, carbohydrate metabolism and circulating triglycerides, after 
adjustment for age and sex, are listed in Table 4. There was a signifi cant inverse 
relation between adiponectin and triglyceride levels (r=-0.52, p=0.03). Although there 
was a tendency towards inverse relationships between adiponectin and BMI and body 
fat percentage, these did not reach statistical signifi cance (p-value 0.08 and 0.07, 
respectively). Notably, no association was found between adiponectin levels and the 
168
C
ha
pt
er
 8
 |
 A
di
po
ne
ct
in
 l
ev
el
s 
in
 P
W
S 
an
d 
ef
fe
ct
s 
of
 G
H
 t
re
at
m
en
t
HOMA-IR or insulin/glucose ratio (r=-0.10, p=0.71). The increase in adiponectin levels 
after 2 years of follow-up, was strongly inversely correlated with the change in body 
fat percentage (r=-0.81, p<0.001), but there was no signifi cant association between 
the increase in adiponectin levels and the change in triglyceride levels.
8.5 Discussion
Our study demonstrates high serum adiponectin levels in young, pre-pubertal, generally 
not overweight children with Prader-Willi Syndrome, compared to healthy sex- and 
age-matched controls. Serum adiponectin levels related inversely with triglyceride 
levels. There was a tendency to an inverse relation between adiponectin and body fat 
percentage and BMI, but no signifi cant association between serum adiponectin levels 
and fasting insulin and glucose levels, insulin/glucose ratio, and HOMA-IR. During 
GH treatment, serum adiponectin levels increased signifi cantly, compared with no 
change in the control group. The increase in adiponectin levels was strongly, inversely 
correlated with the change in body fat percentage. Fasting insulin and glucose levels, 
as well as insulin/glucose ratio, increased signifi cantly during the fi rst year of GH 
treatment, but returned to baseline levels during the second year. In the control 
group, fasting insulin, insulin/glucose ratio and HOMA-IR signifi cantly increased over 2 
years compared with baseline. 
This is the fi rst report showing that young, pre-pubertal, not severely overweight 
PWS children have high serum adiponectin levels compared to healthy sex- and age-
matched controls. As the reported prevalence of NIDDM in individuals with PWS is high 
[12], and body fat percentage in PWS is relatively high, we expected relatively low 
adiponectin levels. In previous studies in obese adults with PWS, serum adiponectin 
levels were high compared to obese non-PWS controls [19-22], but compared to lean 
adult controls, adiponectin levels were low [19,22] or similar [21]. Previous studies 
showed that, in PWS children and adults, insulin sensitivity is high [6,10], which might 
be due to a relatively low amount of visceral fat compared to obese controls [11]. We 
postulate that, in addition to a relatively low amount of visceral fat, high adiponectin 
levels might contribute to the increased insulin sensitivity in PWS children. 
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We found no signifi cant association between adiponectin levels and BMI and body 
fat percentage, although there was a tendency towards an inverse relationship. In 
healthy subjects, a negative association has been described [13], but nowadays it is 
concluded that low adiponectin levels are more closely related to the degree of insulin 
resistance and hyperinsulinemia than to the degree of adipositas [16]. Also Hoybye et 
al reported the absence of a relationship between adiponectin and BMI in adult PWS 
patients [22]. Our study did not show an association between adiponectin levels and 
trunk/total fat mass as measured by DXA. This was in contrast to our expectations, 
because previous studies showed that adiponectin concentrations correlated stronger 
with central adiposity than with overall adiposity [32-34]. The trunk/total fat mass 
ratio is however not a validated procedure for measuring visceral adipose tissue, 
which might explain the absence of the relation. It might also be that, particularly in 
PWS subjects trunk/total fat is not a good measure for visceral fat. It has been shown 
in PWS women [11], that they had low visceral fat, as measured by MRI, whereas 
measures of waist diameter, waist-hip ratio, waist/height ratio, or trunk/limb skinfold 
were similar to obese controls. This is most likely due to the fact that in PWS subjects 
particularly the subcutaneous trunk fat, instead of the visceral fat is high. These data 
strongly ask for more accurate measurements by MRI of visceral fat vs. subcutaneous 
fat in PWS.
We found a signifi cant inverse association between serum adiponectin and 
triglyceride levels in young PWS children. This is in line with fi ndings in healthy obese 
and non-obese adolescents [35]. It might well be that adiponectin modulates insulin 
sensitivity by diminishing the accumulation of triglycerides in the skeletal muscle 
tissue, as was found in animal studies [36]. 
We did not fi nd a signifi cant correlation between baseline adiponectin levels and 
insulin/glucose ratio, or HOMA index, which is in contrast to previous fi ndings in obese 
adults with PWS [20]. This discrepancy might be explained by the fact that insulin 
resistance and overweight were not yet present in our young PWS children. In healthy 
children, adiponectin correlated with body weight, BMI, waist, fasting glucose and 30 
min insulin, but the correlations were positive in boys and negative in girls, indicating 
that plasma adiponectin is not a simple marker of central fat and insulin sensitivity in 
children [37]. In our study, we did not fi nd such sex differences (data not shown). 
During the fi rst year of GH treatment, adiponectin levels increased, and remained 
at the same level during the second year. Also body fat percentage, LBM and IGF-I 
levels changed, particularly during the fi rst year. Based on these fi ndings, the 
increase of adiponectin levels during GH treatment might refl ect the decline in body 
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fat percentage during GH treatment compared with the control group. The increase in 
LBM during GH treatment might also be related to the increased adiponectin levels. As 
skeletal muscle is the primary tissue of insulin-stimulated glucose uptake, disposal and 
storage [38], the increased LBM might contribute to the increased insulin sensitivity. 
Insulin levels were normal at start of the study. During the fi rst year of GH 
treatment, insulin and glucose levels did increase, but levels returned to baseline 
after 2 years. The high adiponectin levels in PWS children may contribute to the 
relatively low insulin levels, since adiponectin is suggested to be protective against 
insulin resistance and diabetes mellitus [14,15]. The high IGF-I levels after 2 years of 
treatment, indicate that children were compliant to GH treatment.
In conclusion, adiponectin levels are increased in young, pre-pubertal, not severely 
overweight PWS children. This is in line with the relatively high insulin sensitivity 
in PWS. Adiponectin levels are inversely related to serum triglyceride levels. There 
is a non-signifi cant tendency to an inverse relation with body fat percentage and 
BMI, and no relation with carbohydrate metabolism. GH treatment resulted into a 
signifi cant increase in serum adiponectin levels compared with the control group, 
which is particularly important, because adiponectin is considered protective for 
cardiovascular disease and insulin resistance. Our results are therefore reassuring 
with respect to the development of insulin resistance during GH treatment in PWS 
children.
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This thesis describes several aspects of a large cohort of generally non-severely 
obese children with genetically confi rmed diagnosis of Prader-Willi Syndrome (PWS). 
We evaluated several aspects of the clinical picture of PWS, such as anthropometry 
and body composition, sleep-related breathing, cognition, behaviour, psychomotor 
development, thyroid hormone levels, adiponectin levels, and the effects of growth 
hormone (GH) treatment on these aspects. In this chapter, results of this study 
are compared and discussed in view of current literature. Subsequently, clinical 
implications and directions for future research are given.
9.1  Growth and body composition and effects of growth hormone 
 treatment
We evaluated height, body composition, and body proportions in 89 pre-pubertal 
PWS children, prior to and during 2 years of the study. Children were treated with GH 
1 mg/m2/day or followed as randomised controls for 1 year (infants <3.5 years) or 2 
years (pre-pubertal children >3.5 years). Height, head circumference, length of foot 
and tibia, span width, and sitting height were all signifi cantly lower than 0 SDS prior 
to start of GH treatment. Body mass index (BMI) was higher than 0 SDS, and body 
composition was abnormal, with a high body fat percentage and low lean body mass 
(LBM), after correction for age and sex (LBMage) or for height and sex (LBMheight). 
We found a complete normalisation of median SD scores of height, BMI, and head 
circumference after 2 years of GH. Body fat percentage, length of foot, tibia, span 
width, and sitting height improved but did not completely normalise (Figure 1). LBMage 
improved in GH-treated patients, compared with randomised controls. LBMheight did not 
improve in GH-treated children, but did decrease in randomised controls, indicating 
that GH is benefi cial for LBM in PWS children.
This is the fi rst study, including a control group for 2 years. Previous studies were 
not controlled for more than one year [1-3]. Those studies reported mostly obese 
PWS children. Nowadays, rapid diagnostic testing is available, and diagnosis is usually 
confi rmed within the fi rst months of life, whereas extreme obesity can often be 
prevented by a strictly controlled diet. In our experience, most PWS patients are 
nowadays not severely overweight during childhood. 
To our opinion, the most important metabolic effect of GH is the improvement of 
LBM. Low LBM in children with PWS most likely refl ects low muscle mass. Low muscle 
mass may be responsible for the clinical hypotonia in young PWS infants and for exercise 
intolerance in PWS children and adults. Muscle mass is metabolically more active. 
Low muscle mass might therefore contribute to decreased energy expenditure that 
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has been reported in PWS [4,5]. It has been shown that LBM progressively decreases 
with age [6]. It is remarkable that previous controlled GH studies in PWS, described 
effects of GH on LBM in absolute increase [2,3]. LBM is sex- and age dependent, 
and should therefore be expressed compared to children with similar age and sex. 
However, expressing LBM in SDS adjusting for age and sex, does not take into account 
that LBM may be underestimated in children with short stature. Additionally, during 
GH, the increased growth velocity may result in an overestimation of the GH effect 
on LBM. This is of major importance because we are particularly interested in the 
additional effect of GH beyond the increased growth velocity. This was fi rst pointed 
out by Eiholzer et al [7]. These authors showed that LBM after correction for height 
(LBMheight), did not signifi cantly increase during GH, indicating that the increase in LBM 
is growth related, and that the initial defi cit of lean mass cannot be compensated for 
by GH therapy. However, this was a non-controlled study in 12 overweight patients. 
Our controlled study is the fi rst one to show that: (1) during longitudinal follow-
up, LBMheight progressively decreases in non-GH-treated PWS subjects; (2) there is 
no signifi cant effect of GH on LBMheight, during 2 years of follow-up compared with 
baseline, but there is a signifi cant difference in LBMheight compared with the untreated 
control group, because the latter decreased LBMheight over 2 years. Thus, our results 
therefore indicate that, even when taking into account the height dependency of 
LBM, GH treatment has a benefi cial effect on LBM.
We found a strong correlation between BMI and height SDS at baseline. This is in 
favour of the hypothesis that growth in PWS is the result of 2 opposite mechanisms: 
a lower growth velocity as a result of GH defi ciency, which is counteracted by an 
increased growth velocity, as found in children with simple obesity [8]. In non-
syndromal obesity, GH levels are usually decreased whereas other mechanisms are 
suggested to promote growth velocity, such as increased insulin levels, and decreased 
Insuline-like growth factor (IGF) binding protein (BP)-1 levels, resulting in an increase 
in free IGF-I, and consequently in its biological activity. A third proposed mechanism 
is via increased leptin levels [9]. In vitro studies, using mice mandibular condyle, 
demonstrated that leptin administration resulted in proliferation and differentiation 
of chondrocytes within the growth center. In addition, leptin administration resulted 
in increased expression of the IGF-I receptor in the growth center, suggesting that the 
effect of leptin may, at least partially be mediated via local IGF-I [10]. Because insulin 
levels in PWS children are decreased compared to normal children [11], and circulating 
IGF-I levels are low due to GH defi ciency [11], we postulate that the association 
between BMI and height SDS is mediated via leptin. It has been shown that leptin in 
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PWS, as in the normal population, is highly correlated with body fat percentage [12], 
and in children with PWS, body fat percentage is high [6]. 
IGF-I levels increased during GH treatment, from levels below the normal range 
to levels above normal range in most GH-treated PWS children, in some children to 
extreme levels of 5 SDS. This is in line with previously reported IGF-I levels in PWS 
children [2,13,14], indicating that they are highly sensitive to GH treatment in terms 
of IGF-I response. IGFBP-3 also increased, but to levels completely within the normal 
range, resulting in an increase in the IGF-I/IGFBP-3 ratio. This suggests that free 
IGF-I, which is believed to represent the biologically active IGF-I [15], had particularly 
increased during GH. According to the study protocol, IGF-I levels were assessed 
retrospectively in our study. Based on our fi ndings, however, we do recommend to 
monitor IGF-I levels in PWS children, and titrate the GH dose in order to maintain IGF-I 
levels below 3 SDS.
Figure 1: Boy with PWS, before and 1 year after start of GH treatment (with permission).
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GH treatment normalises height, BMI and head circumference —
GH treatment improves, but does not normalise body fat percentage and body  —
proportions
LBM — height did not signifi cantly improve during GH, but did decline in the control 
group, resulting in an improvement of LBM in GH-treated children compared 
with randomised controls
IGF-I levels increased to levels above normal range in most children, indicating  —
that PWS children are highly sensitive to GH
We recommend monitoring of IGF-I levels in order to titrate the GH dose and  —
maintain IGF-I levels below 3 SDS
9.2  Psychomotor development in PWS infants
In 1992, a diagnostic genetic test has been developed (PW71 methylation test), 
which provides the possibility of rapid diagnosis of PWS in newborns and infants with 
hypotonia [16]. This method has been validated for PWS infants and is nowadays the 
method of choice [17]. Together with the increased awareness of neonatologists 
and pediatricians with the clinical picture of PWS in infancy, the diagnosis is now 
usually confi rmed early in life. The question was therefore raised whether it might be 
benefi cial to start GH treatment in infancy. 
We performed a randomised, controlled GH trial in PWS infants evaluating 
the effects of both mental and motor development. This study was carried out in 
collaboration with the Swedish group (Dr. A.C. Lindgren, Dr. B. Böhm), to enlarge the 
sample size. We used the Bayley Scales of Infant Development, which is a widely used 
and well-validated method for evaluating psychomotor development. Reference data 
for healthy infants are available [18]. 
The PWS infants scored below the low-normal range, particularly for motor 
development. We therefore expressed mental and motor development as developmental 
age, and we calculated the percentage of expected development by dividing the 
developmental age by the chronological age. Our data show that mental development 
signifi cantly improved after 1 year of GH compared with randomised controls. This 
improvement was accompanied by a normalisation of head circumference in the GH 
group, and not in the control group. Our data did not reveal a signifi cant correlation 
between the change in head circumference and the change in mental development 
during follow-up, although there was a non-signifi cant tendency to a positive 
correlation. It might be that the sample size was not large enough to fi nd such an 
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association. Recently, it has been demonstrated in the general population, that brain 
growth during infancy and early childhood is more important than growth during 
foetal life in determining cognitive function [19]. This study in 221 healthy children 
demonstrated that full scale IQ at the age of 9 years increased by 1.98 points (95% 
confi dence interval, CI 0.34 to 3.62) for each SD increase in head circumference at 
the age of 9 months and with 2.87 points (95% CI 1.05 to 4.96) for each SD increase 
in head circumference at the age of 9 years, after adjustment for many confounding 
factors. In this perspective it might be that early normalisation of head circumference 
in our PWS infants may be related to the improvement of mental development in the 
GH-treated infants compared with randomised controls. 
Parallel to the increase in mental development, we found a rapid increase in IGF-I 
levels in our patients from levels below the normal range prior to start of GH to levels 
above the upper limit of normal during GH, comparable to levels reported by others 
[13]. As IGF-I receptors have been localized in several areas of the human brain, these 
may have a neuroregulatory role in the central nervous system [20]. Theoretically, 
GH treatment might thus affect mental development via IGF-I, either by a direct 
infl uence on the central nervous system or GH might induce local IGF-I expression in 
brain tissue. 
A third explanation might be that mental development improved as a consequence 
of the GH effects on motor development. Early acquisition of abilities such as sitting, 
standing and walking may independently improve mental development because the 
child is more capable of exploring and interacting with his environment. Our study 
indeed demonstrated that also motor development signifi cantly improved during GH 
treatment. If children were subdivided according to their motor abilities before start 
of study, the motor improvement of GH-treated children compared with controls was 
only signifi cant in children with less motor abilities at start of study. It has been 
suggested that the improvement of motor development is the result of the increased 
muscle mass during GH treatment, but we could not fi nd such an association. This 
might be due to a lack of age-, height- and sex adjusted reference data for DXA results 
in this age group. 
An increase in LBM in GH-treated PWS infants has been reported in 2 previous 
studies, one of which also adjusted for the GH-induced increase in height [13,21], but 
this study did not include a control group of similar age. Only one controlled study 
evaluated effects of GH on psychomotor development in PWS infants [13,22]. This 
study demonstrated an improvement of mobility (the ability to move the body from one 
position to another), but not stability during GH treatment compared with randomised 
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controls, only if GH was started before the age of 18 months (13). In addition, an 
improvement of cognition (as measured with tests) and language (as reported by 
parents) was found in 7 GH-treated PWS infants compared with 5 randomised controls 
[22].
Our data suggest that GH should be considered in an early developmental stage in 
order to optimize the effects of GH on motor development.
GH improves both mental and motor development in PWS infants, compared  —
with randomised controls 
If GH is started at an early developmental age, infants might benefi t with  —
respect to motor development
9.3  Sleep related breathing disorders in children with PWS
The prevalence of sleep-related breathing disorders in children and adults with PWS 
is diffi cult to establish based on the literature, due to different patient selection 
(including adults or children, with or without genetic confi rmation of PWS, with a 
different degree of obesity, or selection, based on symptoms indicating breathing 
abnormalities). In addition, many different methods for evaluating sleep-related 
breathing disorders have been used. Pulmonary function tests, ventilatory and 
arousal response tests during hypercapnic, hyperoxic and hypoxic challenges, 
and polysomnography (PSG), with many different defi nitions of apneas, or oxygen 
desaturation have been reported, which make comparison diffi cult. 
We evaluated the prevalence of sleep-related breathing disorders with PSG prior to 
start of GH treatment in 53 pre-pubertal children, who were not severely overweight. 
Only 8 children (15%) had a BMI over +2 SDS and could therefore be considered 
overweight. 
The most striking fi nding of our study was, that all children had increased central 
sleep apneas. These apneas were generally not accompanied by oxygen desaturation 
and the median duration of the longest measured apnea was 15.0 sec. Our fi nding 
is in line with recent fi ndings of others and suggests a primary disturbance of the 
central respiratory control mechanism [23-25]. A hypothalamic origin of sleep-related 
breathing disorders in PWS was already postulated 20 years ago [26]. A decreased 
number of oxytocin neurons, the putative satiety neurons in the hypothalamic 
paraventricular nucleus was reported and was suggested as the basis of the insatiable 
appetite and obesity in PWS patients [27]. Oxytocin neurons might also be involved 
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in neural modulation of breathing and might play a role in central sleep apnea in 
PWS [28]. Mack et al described the projections of oxytocin-containing neurons 
from the hypothalamic paraventricular nucleus to the phrenic nuclei and to the 
pre-Bötzingercomplex in the rostral ventrolateral medullary region in rats (Figure 
2), which is involved in respiratory rhythm generation [28]. Recently, Ren et al [29] 
proposed that necdin (neurally differentiated embryonal carcinoma-cell derived factor) 
defi ciency may contribute to the observed respiratory abnormalities in individuals 
with PWS. Necdin is one of the protein-coding genes which are lacking in PWS [30]. 
Defi ciency of necdin in mice results in neonatal hypoventilation, which is usually fatal 
[30]. Ren et al demonstrated that this effect can be explained by abnormal neuronal 
activity within the putative respiratory rhythm-generating center, the pre-Bötzinger 
complex. The authors suggested that the developing respiratory center is particularly 
sensitive to the loss of necdin activity and may refl ect abnormalities of respiratory 
rhythm-generating neurons. Interestingly, a previous study investigating Necdin 
defi cient mice, showed hypothalamic and behavioural alterations which resembled 
human Prader-Willi syndrome, including a decrease of oxytocin-producing neurons in 
the hypothalamus compared to wild type mice [31].
In contrast to our expectations, obstructive sleep apnea syndrome (OSAS) was 
relatively uncommon in our PWS patients and for the total group, no correlation 
between OSAS and BMI was found. However, 50% of the patients with BMI > 2 SDS 
had OSAS, whereas of the other patients only 8% had OSAS. It seems therefore that 
OSAS is related to obesity in PWS, as in the general population. Several mechanisms 
have been proposed for the association between OSAS and BMI. The increased fat 
deposition around the upper airway may compress the upper airway, which may 
contribute to increased pharyngeal collapsibility as has been shown in obese adults 
[32-34]. This is supported by the fi nding that after weight loss, pharyngeal adipose 
tissue volume decreased together with a reduction in apneas and hypopneas [33]. 
OSAS is also associated with increased efforts of accessory respiratory muscles, which 
are the result of an increased amplitude of out-of-phase respiratory movements of the 
thorax and the abdomen [34]. Furthermore, chest wall compliance may be decreased, 
due to increased weight load of the thorax, whereas the obese abdomen displaces 
the diaphragm, particularly in the supine position, resulting in a small lung volume. 
This may lead to narrowing of the upper airway, as the pharyngeal cross-sectional 
area has been described to directly parallel changes in lung volume in normal men 
[35]. In PWS, as in the general population, increased BMI has been associated with 
obstructive hypoventilation, decreased oxygen saturation (SaO2) and increased apnea 
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hypopnea index (AHI) [36]. Moreover, weight-loss in children and adults with PWS 
improved OSAS and hypoventilation [36]. 
Amplitudo
PVN
OXY-containing
neurons
RVLM
Pre-Botzinger
complex
Spinal Cord
C3-C5
Diaphragm
Ti/Te
Figure 2: Schematic representation of the neural pathways involved in the oxytocin-
related regulation of respiratory output. PVN=paraventricular nucleus, OXY=oxytocin, 
RVLM=rostral ventrolateral medulla, Ti=inspiratory time, Te=expiratory time. Adapted 
from [28].
In addition to the relation with BMI, other possible mechanisms for OSAS in PWS 
should be considered. In healthy children, adenotonsillar hypertrophy is the most 
common cause of OSAS [34,37]. Also in PWS children, with or without obesity, 
adenotonsillar hypertrophy may contribute to OSAS, and adenotonsillectomy has 
been shown to improve OSAS in both obese and non-obese PWS children [38]. In 
addition, PWS children may have a smaller naso- and hypopharynx. Richards et al 
demonstrated in PWS children, during radiological assessment performed in supine 
posture, a reduction in the cross-sectional area, compared to normal control subjects, 
at the oropharyngeal level in 9 out of 14 subjects and at the nasopharyngeal level in 
4 out of 14 subjects [39]. The relatively small naso- and oropharynx may contribute to 
the obstruction caused by adenotonsillar hypertrophy in PWS subjects. Sticky saliva 
and muscular hypotonia may contribute to OSAS as well. In addition, OSAS has been 
described in non-PWS patients with severe kyphoscoliosis [40]. In PWS, scoliosis is 
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common, and may be severe in some cases [41]. Scoliosis may therefore also add to 
OSAS, in a subgroup of PWS patients.
Pre-pubertal, non-severely overweight PWS children have sleep-related  —
breathing disorders, mainly of central origin  
Obstructive sleep apnea is rare, but is more common in children with  —
overweight
Does GH treatment induce or aggravate sleep-related breathing 
disorders?
Since October 2002, several reports of unexpected death in infants and children 
with PWS during GH treatment were published [42-45], most of them related to a 
complicated course of a relatively mild respiratory tract infection, sleep apnea, 
adenoid and/or tonsil hypertrophy, hypoventilation and aspiration, or related to 
obesity. At fi rst, a causal relationship between GH and unexpected death in PWS was 
suggested [42,43,46]. Two mechanisms were proposed by which GH could be related 
to unexpected death during the initial phase of therapy. The incidence of OSAS might 
increase as a result of hypertrophy of adenoid and/or tonsils mediated via increased 
serum IGF-I levels due to GH, as it had been reported that sleep apnea, both obstructive 
and central, occurred more frequently in adults with GH excess (acromegaly) [47]. 
One of the proposed mechanisms for OSAS in acromegaly was thickening of upper 
airway soft tissue bulk. A decrease of IGF-I in acromegalic patients was correlated 
with a decrease in soft tissue swelling of the tongue, as measured with MRI, and 
it was suggested that improvement of sleep apnea was mediated via a reduction 
of soft tissue bulk [48]. Although it was proposed that GH treatment resulted in an 
increase in tonsil size [49], to our knowledge, no controlled, prospective studies on 
this topic are available. The second explanation proposed an augmentation of volume 
load, because short-term GH therapy might cause sodium retention with secondary 
water retention due to prostaglandin-mediated activation of the renine-angiotensin-
aldosterone system, which resolves after continuation of GH, and via increased distal 
nephron sodium and water reabsorption [50]. This has been reported for GH-treated 
adults.
We therefore performed PSG prior to and after 6 months of GH treatment. Our 
data did not show any change in sleep-related breathing abnormalities compared with 
baseline. Importantly, no increment of obstructive apneas was found. 
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Our study is the largest controlled PSG study in PWS children, and our results are 
in line with other studies, evaluating the effects of GH on breathing disorders in PWS 
[3,51-53]. Lindgren et al found improved CO2-responsiveness, resting ventilation and 
airway occlusion pressure in 9 children with PWS, aged 7-14 years, after 6-9 months 
of GH compared with baseline [52]. Myers et al demonstrated that inspiratory and 
expiratory muscle strength improved in 20 children with PWS, aged 4 to 16 years, 
after 12 months of GH compared with 10 controls [3]. Haqq et al reported in a 
double-blind placebo-controlled cross-over study a decrease in AHI after 6 months 
of GH in 12 PWS children, aged 4.5 to 14.5 years, although the difference compared 
with controls was not statistically signifi cant. In addition, various components of 
pulmonary function improved [51]. Very recently, Miller et al reported the AHI on 
polysomnography after 6 weeks of GH treatment in a mixed group of 25 adults and 
children. They reported a decrease in most patients, a subset of patients, however, 
had an increased AHI with more obstructive events after 6 weeks of GH. Most of these 
patients had upper respiratory tract infections and adenoid/tonsil hypertrophy during 
the second evaluation [53]. The mechanism by which GH improved sleep apnea and 
CO2 responsiveness is yet unknown. A direct effect of GH or IGF-I, via GH and IGF-I 
receptors has been postulated. Improved weight control and increased respiratory 
muscle strength during GH treatment may also play a role. 
Notably, 5 patients had adenotonsillectomy between the fi rst and the second PSG. 
It cannot be excluded that this confounds our results, but for obvious safety reasons 
we could not avoid this.
GH treatment does not aggravate the pre-existing sleep-related breathing 
disorders in PWS children
Effects of illness on sleep-related breathing disorders
We did not aim to evaluate sleep-related breathing during illness, but we had the 
opportunity to measure 4 patients with PSG during an episode of URTI. We found 
a dramatic increase in total AHI in these patients, with a particular increase in 
obstructive apneas. Results of one of the patients are shown in Figure 3: A 3-year 
old girl was evaluated with PSG prior to start of GH treatment (AHI was 7.9/h, all 
central apneas). After 6 months of GH, she had an upper respiratory tract infection 
and adenoid hypertrophy, and AHI increased to 38.6/h, including many obstructive 
apneas/hypopneas. GH was continued, adenoidectomy was performed and PSG after 
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recovery showed an AHI of 3.4/h (all central apneas). Our results are in line with 
those of Miller et al [53]. In our study, one boy died unexpectedly. He was 3 years 
old and had GH treatment for 13 months. He responded very well in terms of growth 
and body composition. PSG was performed before and 6 months after start of GH. His 
PSGs were nearly normal (AHI 1.7/h and 1.4/h, respectively), and BMI and tonsil size 
were well within the normal limits. He had a mild URTI and was clinically evaluated 
by his pediatrician the day prior to his death. At that time he was in a good condition, 
running around and not generally ill. During the night, he suddenly deteriorated and 
was found dead in the morning. Autopsy did not reveal the cause of death. Thus, 
a relatively normal PSG does not exclude a complicated course of relatively mild 
respiratory tract infection, or even unexpected death.
The consequences of the respiratory muscle weakness itself could also be severe. 
When the maximum expiratory pressure is reduced to less than 40 cmH2O, as has 
been found in 7/35 PWS patients (including both adults and children), patients can no 
longer breathe deeply or cough effectively [54]. It was postulated that thoracic muscle 
weakness could result in a decreased ability to clear airway secretions, predisposing 
patients to pulmonary infections, and airway obstructions. Another contributing 
factor that warrant alertness in PWS is temperature instability in infants or altered 
temperature sensitivity in older children and adults, which is one of the supportive 
fi ndings for the clinical diagnosis of PWS [55]. Many patients will not present with 
fever during respiratory tract infection, which may result in an underestimation of 
disease severity.
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Figure 3: Sleep related breathing during illness and adenoid hypertrophy
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During illness the apnea hypopnea index increased dramatically and obstructive  —
sleep apnea may be present 
Normal PSG during health does not exclude sudden deterioration during mild  —
upper respiratory tract infection
9.4  Sleep-related breathing, psychomotor development, cognition, 
 and neurobehavioural abnormalities
In the general population, associations between sleep-related breathing disorders and 
cognition, school performance, and psychiatric and behavioural co-morbidities are 
consistently reported [56-58]. Also in individuals with PWS, OSAS is associated with 
some behavioural disturbances, such as autistic relating behaviour, and impulsiveness 
[59]. Beebe and Gozal proposed a model by which cognitive and neurobehavioural 
abnormalities in sleep-related breathing disorders are caused by sleep disruption, 
intermittent hypoxia and hypercapnia, leading to disruption of restorative features 
of sleep and cellular and chemical homeostasis which results in frontal cortical 
dysfunction. Dysfunction of the frontal cortex is considered to impair the cognitive 
executive functioning, which is the ability to develop an approach to problem 
situations, resulting in neurobehavioural abnormalities, such as over-activity and 
impulsivity [60] (Figure 4). 
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Sleep
Disruption
Intermittent hypoxia and 
hypercapnia
Disruption of restorative 
features of sleep
Disruption of cellular or 
chemical homeostasis
Prefrontal cortical dysfunction
Behavioural 
inhibition
Set
 
shifting
Self-regulation of 
affect and arousal
Working
memory
Analysis/
synthesis
Contextual 
memory
Dysfunction of cognitive executive system
Adverse daytime effects
Problems in mentally manipulating information
Poor planning and haphazard execution of plans
Disorganisation
Poor judgement/decision-making
Rigid thinking
Difficulty in maintaining attention and motivation
Emotional lability (‘mood swings’) 
Overactivity/impulsivity (especially in children)
Figure 4: Model proposed by Beebe and Gozal for the association between sleep-related 
breathing disorders and cognitive and behavioural problems. Adapted from [60] 
Are sleep-related breathing disorders related with mental or motor 
development in PWS infants and toddlers? 
A recent study in healthy infants indicated that higher snoring-related arousal indices, 
being a measure for mild obstruction during sleep, were associated with lower scores 
on tests for mental development [61]. 
We investigated if there was an association between sleep-related breathing, as 
measured with PSG, and the delay in psychomotor development, as measured with 
Bayley Scales of Infant Development in PWS infants and toddlers. 
For the total group, we did not fi nd an association between the total AHI and scores 
of mental or motor developmental tests. However, when we subdivided the group in 
infants with or without OSAS, we found that children with OSAS had signifi cantly lower 
mental development. The children with OSAS tended to be older, to have a higher 
BMI and to have a lower motor development, although those differences did not reach 
statistical signifi cance. 
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This is the fi rst study reporting an association between mental development and 
OSAS in young PWS children. Our results indicate that OSAS in young PWS children 
should be treated early, in order to prevent further delay in mental development. 
OSAS in young infants and toddlers is associated with lower mental  —
development 
Our results indicate that OSAS in PWS should be treated early in order to  —
prevent further delay in mental development
Are sleep-related breathing disorders related with cognitive defi cits and 
neurobehavioural abnormalities in pre-pubertal PWS children? 
We evaluated cognition using a short form of age-appropriate Wechsler intelligence 
scales, which is validated and widely used for assessment of intelligence in children. 
Neurobehavioural abnormalities were evaluated using two parent questionnaires for 
children with mental disabilities: Developmental Behaviour Checklist (DBC) and VISK 
(Vragenlijst voor Inventarisatie van Sociaal gedrag bij Kinderen). The latter is a widely 
used Dutch questionnaire to evaluate particularly social behaviour in children. Dutch 
reference data are available for children with several degrees of mental disabilities 
for both tests. We related the results on cognition and behaviour to the results of 
sleep-related breathing as measured with PSG before start of GH treatment.
Our study demonstrated that pre-pubertal PWS children have overall impaired 
cognitive abilities compared to healthy children. Interestingly, the impairment was 
not equally distributed between verbal and performance subtests. Sixty percent 
of children scored signifi cantly better on verbal subtests compared to performance 
subtests. Although we could not fi nd a relation with the genetic defects, it might be 
that the relatively high number of patients with uniparental maternal disomy (UPD) in 
our study group contributes to this fi nding, because previous studies have shown that 
verbal IQ is higher in PWS patients with UPD compared to those with deletions [62]. 
In addition, compared to children with similar mental abilities, PWS children have 
less anxiety-related behavioural problems and more autism-related social problem 
behaviour, particularly on the subscales “emotions and behaviour not adapted to 
the social situation” and “insensitive to social information”. Notably, compared to 
the mentally disabled reference population, disruptive/antisocial behaviour (including 
“impulsiveness” and “temper tantrums”) is not commonly reported. The relatively 
high incidence of autistic like social behaviour might also be due to the relatively high 
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incidence of UPD in this group. Previous studies showed that UPD is associated with 
autistic-like social behaviour [63]. 
We found a positive association between sleep effi ciency index, as measured with 
PSG, and one of the performance subtests (Picture arrangement/completion), after 
adjustment for age, sex and different type of test. One suggestion is that better 
sleep effi ciency, with less sleep disruption results in better executive functioning, 
according to the model proposed by Beebe and Gozal [60] (Figure 4). PWS patients 
may have an increased need for nocturnal sleep [64]. Sleep effi ciency might be 
improved by behavioural management strategies when PWS children are put to bed as 
has been suggested by Nixon et al [65]. Future studies are needed to evaluate whether 
improvement of sleep effi ciency might contribute to better cognitive functioning in 
PWS children. 
In our study, children with more severe sleep-related breathing abnormalities 
had less severe behavioural abnormalities. This is neither in line with the general 
population [66], nor with the only previous report in PWS [59]. In the latter study in a 
group of 13 PWS patients, aged between 1.5 and 28 years, including 6 children below 
the age of 12 years, autistic like behaviour was associated with low sleep effi ciency 
and oxygen desaturation and impulsivity with sleep-related breathing disorders. The 
difference between this study and our results might be related to patient selection. 
Our study group consisted of pre-pubertal non-severely obese PWS children, in which 
obesity-related OSAS is uncommon. 
In the model proposed by Beebe and Gozal [60] (Figure 4), sleep disruption and 
intermittent hypoxia and hypercapnia induce the cascade of frontal dysfunction. 
One explanation why we did not fi nd an association between sleep-related breathing 
disorders (SRBD) and behaviour is that children with PWS have a higher arousal treshold 
in response to hypercapnia [25]. 
We cannot explain why we found an inverse association between sleep-related 
breathing disorders and neurobehavioural abnormalities. It might be that parents of 
high functioning PWS children compared their children to healthy peers, whereas 
parents of lower functioning PWS children compared them to other children with 
similar mental disability. Most likely, sleep-related breathing and neurobehavioural 
abnormalities are not causally related in PWS, as both may have a different genetic 
cause. Sleep-related breathing disorders have been associated with Necdin defi ciency 
[29] and autistic like social behaviour has been associated with the UBE3A gene 
(Ubiquitin protein ligase gene 3A) [67,68]. UBE3A is maternally expressed in a few 
specifi c areas, which have been implicated in the neuropathology of autism, such as the 
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hippocampus and the cerebellar Purkinje cells [67]. UBE3A is located on chromosome 
15 in the PWS/Angelman Syndrome critical region, and paternally imprinted. In 
patients with maternal UPD, UBE3A is therefore over-expressed. In particular autistic 
like social impairment is more common in patient with UPD compared to patients with 
paternal deletion [68], which might be attributed to the overexpression of UBE3A. 
We therefore suggest that, in contrast to the general population, in PWS SRBD and 
cognitive/neurobehavioural defi cits are not causally related, but both the result of 
the genetic defect in PWS.
We found a positive relationship between sleep effi ciency and one of the  —
performance subtests, and between behavioural problems and daytime 
sleepiness, suggesting that improvement of nocturnal sleep and daytime 
sleepiness may improve cognition and behaviour in PWS children
We did not fi nd a positive association between sleep-related breathing disorders  —
and neurobehavioural abnormalities
9.5  Thyroid hormone levels
Hypothalamic dysfunction in PWS may result in several endocrine abnormalities 
including GH defi ciency, and hypogonadotropic hyopogonadism [69]. The thyroid 
hormone axis, however, was not yet extensively investigated in PWS children. 
Previous studies in small patient groups suggested normal thyroid hormone function 
or minor alterations in the hypothalamo-pituitary-thyroid axis in adults with PWS, 
mostly overweight and with a clinical diagnosis of PWS without genetic confi rmation 
[70,71]. During GH treatment in non-PWS GH defi cient patients, a decrease of fT4 
has been reported. This might be due to either unmasking of an underlying TSH 
defi ciency, or to increased peripheral conversion from fT4 to T3 [72-76]. Our study 
is the fi rst study to prospectively evaluate thyroid hormone function in a large group 
of relatively young, non-severely overweight PWS children. Four patients received 
thyroxin replacement therapy because of low fT4 levels prior to start of study. We 
found that fT4 was within the normal range in almost all patients, but signifi cantly 
below 0 SDS. Surprisingly, T3 levels were signifi cantly higher than 0 SDS, suggesting an 
increased peripheral conversion from T4 to T3. T3 is the more active thyroid hormone 
and increased conversion might compensate for the relatively lower fT4 levels in most 
PWS patients. 
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Recently, an in vitro model was developed in which human deiodinase type 1 
and deiodinase type 2 were transiently expressed to compare their different 
catalytic effi ciency for converting T4 to T3. These authors showed that at lower fT4 
concentrations, deiodinase type 2 was relatively more active than deiodinase type1, 
and that higher fT4 levels inhibited the activity of deiodinase type 2, but not type 1 
[77]. In the cortex of rats with low fT4 levels, T4 deiodination, and D2 mRNA levels 
increased. This indicates that also in the central nervous system, the expression of 
deiodinase type 2 is regulated by T4 status (78). In addition, leptin was recently 
suggested as a potential mediator in the conversion from T4 to T3 via increased 
deiodinase type 2 mRNA expression, which was shown after intracerebroventricular 
administration of leptin in rats [79]. Leptin is an adipocytokine which is highly 
correlated with body fat percentage [80]. Children with PWS have a relatively high 
body fat percentage, even when they are not obese [6,81]. They have high leptin 
levels, correlating with their body fat percentage [12]. Thus, we postulate that the 
relatively lower fT4 levels, in combination with normal T3 levels, as we found in most 
PWS children, might result from an increased peripheral conversion by deiodinase 
type 2, as a result of a combination of high leptin levels and low fT4 levels. 
Recently, Butler et al showed in 47, mostly adult PWS subjects, that 2.1% (= 1/47) 
had hypothyroidism (defi ned as low fT4, low T4 and normal TSH levels), which is similar 
to the expected frequency of 2% for the normal population. The authors therefore 
concluded that there is most likely no general hypothalamic pituitary dysfunction in 
PWS with respect to the thyroid axis [82]. The incidence of hypothyroidism in our 
study is higher (6.3% prior to start of study). This may be the result of the lower 
prevalence of overweight in our study, which included mostly non-obese patients. 
Obese patients as described by Butler may have upregulation of their thyroid hormone 
levels, probably refl ecting the reset of their central thyrostat at a higher level [83]. 
This might counteract mild hypothyroidism in obese PWS subjects. 
During GH treatment, fT4 decreased signifi cantly compared with baseline, although 
levels remained within the normal range in most children. T3 levels, however, 
remained completely normal, indicating an increased peripheral conversion from T4 
to T3. PWS children, who needed thyroid replacement therapy during GH therapy had 
been reported previously [2,3,84], and although thyroid hormone levels are within 
the normal range in most of our patients, and low fT4 levels are compensated by 
increased T3 levels, monitoring of thyroid hormone levels in PWS before and during 
GH should be recommended. It is not yet established whether the combination of low 
fT4 levels and completely normal T3 levels warrants start with thyroxin replacement 
therapy.
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Free T4 levels are relatively low in pre-pubertal children with PWS, although for  —
most children, within the normal range. Surprisingly, T3 levels are signifi cantly 
higher than 0 SDS, indicating a compensation of relatively low fT4 levels by 
increased peripheral conversion from T4 to T3 
During GH treatment, fT4 further decreased, but remained within the normal  —
range for most patients. It remains to be established whether low-normal 
levels of fT4 with completely normal, or even elevated levels of T3 warrants 
thyroxin replacement therapy
Monitoring of thyroid hormone levels before and during GH is indicated —
9.6  Adiponectin levels and cardiovascular risk factors
Adult patients with PWS have a high prevalence of diabetes mellitus type 2, associated 
with BMI, and with a median age of onset of 20 years [85]. However, as a group, 
euglycemic PWS patients (some studies including children) have lower fasting insulin 
levels and a relatively lower amount of visceral fat than weight comparable control 
subjects [70,86-90]. During GH treatment of non-PWS children, increased insulin 
resistance has been reported. Adiponectin is highly and specifi cally expressed 
in differentiated adipocytes and circulates at high levels in the bloodstream [91]. 
Adiponectin is an anti-infl ammatory adipocytokine, which is inversely related to 
adiposity, and to insulin resistance [92-95]. Adiponectin is considered protective 
against diabetes mellitus and insulin resistance [96]. At the time we started the GH 
study, it was not known whether adiponectin in PWS patients was low (due to their 
relatively high total body fat percentage) or high, because visceral fat is relatively low, 
and because insulin sensitivity is relatively high amongst euglycemic PWS children. 
It was also unclear whether insulin sensitivity would increase during GH treatment 
(due to the lipolytic effects of GH treatment) or decrease (due to increased insulin 
resistance during GH).
Our data showed that adiponectin levels were high in pre-pubertal non-severely 
overweight PWS children compared to normal weight healthy controls, prior to start 
of study. In addition, adiponectin levels were highly and inversely correlated with 
triglyceride levels. The latter is in line with fi ndings in healthy obese and non-obese 
adolescents [97]. Interestingly, in a mouse model with lipo-atrophy and complete 
absence of white adipose tissue and subsequently of adiponectin, circulating free 
fatty acids and triglycerides, as well as triglyceride levels in skeletal muscle and liver 
were elevated. Treatment of these mice with adiponectin increased the expression of 
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molecules involved in fatty acid transport and combustion in skeletal muscle, which 
resulted in a decreased triglyceride content in the muscle and lower serum free fatty 
acids and triglyceride levels [98]. It might well be that adiponectin modulates insulin 
sensitivity by diminishing the accumulation of triglyceride levels in the muscle and by 
decreasing serum free fatty acids and triglyceride levels. 
During follow-up, adiponectin levels increased in GH-treated children, compared 
with randomised PWS controls. This might be explained by altered body composition, 
during GH treatment. Body fat percentage decreased during GH treatment, and 
adiponectin is considered inversely associated with body fat [99]. LBM, on the other 
hand, increased and might independently contribute to higher insulin sensitivity, by 
increasing the insulin-dependent glucose uptake, storage and disposal in the skeletal 
muscle [100]. In addition, a recent in vitro study showed that GH increases adiponectin 
gene expression directly in a dose dependent matter through the JAK2-P38 MAP 
kinase pathway, suggesting a direct effect of GH on adiponectin expression [101]. 
Another report showed that GH is also the positive regulator of the newly identifi ed 
adiponectin receptors, suggesting that regulation of the adiponectin pathway might 
represent an important aspect of GH actions [102] (Figure 5). 
   Adiponectin gene 
expression 
Growth hormone Adiponectin levels
Body fat percentage
LBM
  JAK2P38 MAP
kinase pathway 
  insulin dependent glucose 
uptake, storage and disposal 
in skeletal muscle
Upregulation of adiponectin receptors
Figure 5: Hypothetical model summarizing possible mechanism for the increased serum 
adiponectin levels during GH treatment in PWS children
In contrast, in conditions with GH-excess, such as in acromegalic patients, serum 
adiponectin levels are reduced, and as such probably involved in the induction of 
insulin resistance, generated by these conditions [103]. The fi nding of increased 
adiponectin levels during GH treatment is particularly important, because adiponectin 
is considered protective against cardiovascular disease and insulin resistance. Our 
results are therefore reassuring with respect to the development of insulin-resistance 
during GH in PWS. 
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Adiponectin levels are increased in PWS children compared to healthy  —
controls
During GH treatment, adiponectin levels increased, indicating that GH  —
treatment does not induce insulin resistance in PWS children
9.7  Clinical implications and considerations for future research
GH is benefi cial for improving height, body composition, and body proportions in PWS 
children. In addition, both mental and motor development is better in GH treated 
children compared with their randomised controls. These data suggest that GH 
treatment should be considered in PWS children, from 6 months or older. It remains to 
be established whether early start with GH, infl uences cognition later in life.
According to the study protocol we evaluated IGF-I levels, after 1 year of GH 
treatment and we found that PWS children were highly sensitive to GH with respect 
to IGF-I response. Based on our data, we do recommend to monitor IGF-I levels, 
during GH treatment, particularly in PWS children, to keep circulating IGF-I within 
reasonable limits (below 3 SDS).
Our study did not fi nd a negative effect of GH on thyroid hormone levels or adiponectin 
levels. PWS children may have a higher risk of (subclinical) hypothyroidism. They are 
at risk of developing insulin resistance if they would become extremely overweight, 
which is intrinsic to PWS. Therefore monitoring of endocrine and metabolic aspects is 
of major clinical importance, before and during GH.
Our study shows that most children with PWS have sleep-related breathing disorders 
and that in young infants, OSAS is associated with lower mental development. This 
indicates that screening for sleep-related breathing disorders by PSG should be 
considered in all PWS children. If OSAS is present, particularly in young infants, 
this should be treated in order to prevent deterioration of mental development. If 
adenoid and/or tonsils are enlarged, adenoidectomy and/or tonsillectomy should be 
considered. It is also important to introduce weight control, particularly when obesity 
is already present in infancy. If OSAS is still present despite adequate weight control 
and adenotonsillectomy, the use of nasal continuous positive airway pressure might 
be considered [104].
With regard to safety monitoring, it is particularly important that future research 
will focus on sleep-related breathing during illness. There is need for guidelines for 
parents and pediatricians, what to do if a PWS child becomes ill with or without 
respiratory tract infections. The possible role for home monitoring of sleep-related 
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breathing (during illness) remains to be established. Meanwhile, parents should be 
strongly cautioned about the risk of sleep-related breathing disorders during times of 
upper respiratory tract infections.
No studies are available with respect to fi nal height in PWS children. GH is indicated, 
only for children with PWS, irrespective their endogeneous GH secretion. The aim is 
to improve growth velocity and body composition. When epiphysial fusion is complete 
and fi nal height is reached, GH treatment has to be discontinued. Preliminary studies 
have now showed that also PWS adults might benefi t from GH treatment [105-107], 
especially with regard to body composition, and psychosocial wellbeing. The optimal 
duration of treatment or dosage has, however, not yet been established. Further 
research should focus on the effects of GH treatment during the transition period 
from reaching fi nal height until approximately 24 years. The effects of GH on weight, 
body composition, psychosocial functioning, carbohydrate metabolism, circulating 
lipids, and respiratory function in young adults with PWS needs to be investigated.
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This doctoral thesis describes the results of the Dutch multicenter, randomised 
growth hormone (GH) trial in children with Prader-Willi syndrome (PWS). This study 
investigated several aspects of PWS, such as anthropometry, psychomotor development, 
cognition, behaviour, sleep-related breathing disorders (SRBD), thyroid hormone 
levels, and adiponectin levels and effects of GH on these outcome measures.
Chapter 1
This chapter provides an overview of the prevalence, etiology and clinical picture 
of the PWS, including several endocrinological aspects associated with PWS. It also 
provides a summary of previously reported data on the effects of GH treatment in 
PWS. At the end of this chapter, the aims and outlines of this thesis are presented as 
well as the study design, and in- and exclusion criteria of the study.
Chapter 2
Children with PWS have impaired growth, and an abnormal body composition, with 
a high body fat percentage and a low lean body mass (LBM). Previous one-year 
controlled studies demonstrated that GH treatment resulted in improved growth and 
body composition in PWS. These studies, however, described relatively small patient 
groups of -mostly overweight- PWS patients. We performed a randomised controlled 
GH trial in 91 pre-pubertal PWS children (42 infants, 49 children aged 3-14 years) to 
evaluate growth, body composition, and body proportions. Infants were randomly 
assigned to GH treatment (GH group; 1 mg/m2/day; n=20), or no treatment (control 
group; n=22) for 1 year. Children >3yrs, were randomly assigned to GH treatment (GH 
group; 1 mg/m2/day; n=27) or no treatment (control group; n=22) for 2 years. We 
performed anthropometric assessments yearly, and body composition (in children >4 
years) was measured by Dual Energy X-ray Absorptiometry (DXA). After 1 and 2 years 
of GH treatment, height, body mass index (BMI) and head circumference completely 
normalised. Body composition, after adjustment for age and sex, and body proportions 
improved, but did not completely normalise during GH. LBM, adjusted for height and 
sex, did not increase in the GH group, but decreased in the control group, resulting 
in a better outcome for GH-treated children. Serum insulin-like growth factor I (IGF-I) 
increased to supra-physiological levels in most children. In conclusion, 2 years of 
GH in PWS children normalises height, BMI and head circumference, and improves 
body composition, and body proportions. PWS children are highly sensitive to GH, 
suggesting that monitoring of serum IGF-I is indicated.
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Chapter 3
Previous GH studies in PWS have mainly focused on anthropometry and body 
composition. Data on the effects of GH on psychomotor development in infants with 
PWS are limited. Therefore we evaluated psychomotor development before and 
after 1 year of GH treatment in PWS children. Forty-three children were evaluated 
at baseline. Twenty-nine of them were randomised into the GH group (n=15) or to a 
non-GH-treated control group (n=14). At baseline and after 1 year of follow-up, we 
used Bayley Scales of Infant Development (BSID II) for assessment of psychomotor 
development. Data were converted to percentage of expected development for 
age (%ed), and changes during follow-up were calculated. Median age was 2.3 years 
(interquartile range (iqr) 1.7 to 3.0) for the GH group and 1.5 years (iqr 1.2 to 2.7) 
for the control group (p=0.17). Compared with randomised controls, both mental and 
motor development improved signifi cantly during the fi rst year of study in the GH 
group. Median (iqr) change in mental development was +9.3% (-5.3 to 13.3) vs. -2.9% 
(-8.1 to 4.9) (p<0.05), and change in motor development was +11.2% (-4.9 to 22.5) vs. 
-18.5% (-27.9 to 1.8) (p<0.05), for the GH group and the control group, respectively. 
Children with a lower motor developmental age at start of study, improved more 
during GH treatment, compared with randomised controls, than children with a higher 
motor developmental age at start. In conclusion, 1 year of GH treatment resulted 
in signifi cant improvement of both mental and motor development in PWS infants, 
compared with randomised controls. 
Chapter 4
Several cases of unexpected death have recently been reported in both GH-treated 
and non-GH-treated young children with PWS. These unexpected deaths were often 
related to a complicated course of upper respiratory tract infections (URTIs). Some 
clinicians suggested a causal relationship between GH treatment and unexpected 
death. Data concerning effects of GH on respiratory parameters are, however, limited. 
We therefore evaluated respiratory parameters in 53 pre-pubertal PWS children (30 
boys) before and during GH treatment. We performed complete polysomnography 
(PSG) before start with GH treatment and repeated PSG 6 months after start of GH 
treatment in 35 of them. Median (iqr) age at baseline was 5.4 (2.1 to 7.2) years and 
BMI was +1.0 standard deviation score (SDS) (-0.1 to 1.7). Apnea Hypopnea Index (AHI) 
was 5.1/h (2.8 to 8.7) (normal range 0 -1/h). Of these, 2.8/h (1.5 to 5.4) were central 
apneas and the rest mainly hypopneas. Median duration of longest apneas was 15.0 sec 
(13.0 to 28.0). AHI did not correlate with age and BMI, but central apneas decreased 
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with age (r=-0.34, p=0.01). During 6 months of GH treatment, AHI did not signifi cantly 
change, from 4.8 (2.6 to 7.9) at baseline to 4.0 (2.7 to 6.2) (p=0.36). One patient died 
unexpectedly during a relatively mild URTI although he had a nearly normal PSG 
both prior to and during GH treatment. In conclusion, PWS children have a high AHI, 
mainly due to central apneas. Six months of GH does not aggravate the SRBD in young 
PWS children, but a (nearly) normal PSG, does not exclude a complicated course of a 
relatively mild URTI. Based on our data, monitoring of sleep-related breathing during 
URTI in PWS children should be considered.
Chapter 5 
Recently, it has been reported that snoring related arousal indices are inversely 
associated with mental development in healthy infants. We therefore evaluated the 
association between psychomotor development and SRBD in PWS infants. We performed 
BSID II in 22 PWS infants. They had a median (iqr) age of 1.8 (1.1 to 3.4) years, and a 
BMI SDS of -0.5 (-1.3 to 1.6). We evaluated psychomotor development in relation to 
the results of PSG. Median (iqr) mental and motor development in this group of infants 
was 73.1% (64.3 to 79.6) and 55.2% (46.5 to 63.1) of normal children, respectively. All 
infants had SRBD, mostly of central origin. Only 4 infants had obstructive sleep apnea 
syndrome (OSAS). We did not fi nd any association between the AHI and psychomotor 
development for the total group. However, the children with OSAS had a signifi cantly 
delayed mental development of 65.5% (60.0 to 70.3) of normal, compared to those 
without OSAS. Children with OSAS had a median BMI SDS of 1.4 (0.1 to 1.6), which 
tended to be higher than in those without OSAS. Our data indicate that psychomotor 
development in PWS infants is not related to central SRBD. However, infants with 
OSAS have more severely delayed mental development, suggesting that PWS infants 
should be screened for OSAS.
Chapter 6
Neurobehavioural abnormalities, cognitive impairment and SRBD are all common 
features of PWS. In the general population consistent relations have been found 
between neurobehavioural abnormalities and cognitive defi cits, and SRBD. We 
therefore evaluated cognition, behaviour and their associations with sleep-disordered 
breathing in pre-pubertal PWS children. We evaluated 31 pre-pubertal PWS children, 
aged 4.0 to 13.2 years. We assessed cognition by age appropriate Wechsler Intelligence 
Scale subtests, and neurobehavioural abnormalities with parent-questionnaires. We 
evaluated the results of cognition, behaviour and their associations with SRBD, as 
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measured with PSG. All cognitive subtests were signifi cantly below 0 SDS, with the 
lowest median (iqr) scores for one of the performance subtests (Block design) of -2.7 
SDS (-3.0 to -0.3). Notably, we did not fi nd a consistent impairment of all cognitive 
subtests. In 60% of children, verbal subtests were less affected than performance 
subtests. Problem behaviour was scored mainly on subscales related to “emotions/
behaviour not adapted to the social situation” and “insensitivity to social information”. 
These fi ndings might be explained by the relatively high prevalence of uniparental 
maternal disomy in our patient group. All children had SRBD, with a median (iqr) 
AHI of 4.1/hour (2.6 to 7.9). One of the performance subtest-scores was signifi cantly 
higher in children with better sleep effi ciency, as measured with PSG. Autistic-like 
social impairment was associated with daytime sleepiness, as reported by parents. 
In contrast to our expectations, children with better sleep-related breathing had 
more behavioural abnormalities (particularly social relating behaviour). In conclusion, 
cognition is impaired in pre-pubertal PWS children. Neurobehavioural abnormalities 
are common, particularly autistic-like social impairment. Sleep effi ciency index was 
associated with better performance on the Picture Arrangement/Completion subtests, 
and daytime sleepiness was associated with autistic like social impairment. In contrast, 
we could not confi rm a positive association of neurobehavioural abnormalities with 
SRBD in PWS.
Chapter 7
Several endocrine abnormalities have been described in PWS, such as GH defi ciency, 
and hypogonadotropic hypogonadism. However, data on thyroid hormone levels in PWS 
children are very limited. GH treatment has been suggested to unmask an underlying 
TSH defi ciency and to increase peripheral conversion from T4 to T3. We therefore 
evaluated thyroid function in children with PWS, before and during GH treatment, 
compared with randomised controls. Serum levels of T4, free T4 (fT4), T3, reverse 
T3 (rT3) and TSH were measured in 75 PWS children. After one year, assessments 
were repeated in 57 of them. Thirty-four of them were treated with GH and 23 were 
followed as randomised controls. Median (iqr) age of the total group at baseline was 
4.7 years (2.7 to 7.6). Median (iqr) TSH level was -0.1 SDS (-0.5 to 0.5), T4 level, -0.6 
SDS (-1.7 to 0.0), and fT4 level, -0.8 SDS (-1.3 to -0.3), the latter two being signifi cantly 
lower than 0 SDS. T3 level, 0.3 SDS (-0.3 to 0.9), was signifi cantly higher than 0 SDS. 
After one year of GH treatment, fT4 decreased signifi cantly from -0.8 SDS (-1.5 to -0.2) 
to -1.4 SDS (-1.6 to -0.7), compared with no change in untreated PWS children. T3 did, 
however, not change. In conclusion, we found fT4 levels within the normal range in 
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most PWS children at start of study. During GH treatment, fT4 decreased signifi cantly 
to low-normal levels, but TSH levels remained completely normal. T3 levels were 
relatively high or normal, both before and during GH treatment, indicating that PWS 
children have increased T4 to T3 conversion. We recommend monitoring of thyroid 
hormone levels in PWS children, particularly during GH treatment.
Chapter 8
Obesity and an abnormal body composition with relatively low LBM and high body fat 
percentage, all common factors in PWS, may predispose to the development of insulin 
resistance and of cardiovascular diseases. Adiponectin is an adipocytokine, which is 
considered protective with regard to diabetes mellitus and cardiovascular disease. 
We evaluated in pre-pubertal PWS children (1) adiponectin levels, body composition, 
carbohydrate metabolism, and triglyceride levels, (2) associations between adiponectin 
and body composition, carbohydrate metabolism and triglycerides, and (3) effects of 
GH treatment on these outcome measures. Twenty PWS children were randomised 
into a GH treatment group (n=10) and a non-GH treated control-group (n=10). We 
measured fasting levels of adiponectin, glucose, insulin, and triglycerides at start, 
after 1 and after 2 years. We measured body composition and fat distribution by DXA. 
At baseline, median (iqr) adiponectin levels, 17.1 mg/l (13.9 to 23.2) were signifi cantly 
higher in PWS children than in healthy sex- and age-matched controls, 11.8 mg/l (9.7 
to 12.5) (p<0.005). Body fat percentage was signifi cantly higher than 0 SDS, 1.8 SDS 
(1.5 to 2.1) (p<0.001). Adiponectin levels were inversely associated with triglyceride 
levels (r=-0.52, p=0.03), and tended to be inversely related with body fat percentage 
and BMI. We did not fi nd any correlation with fasting insulin or glucose levels, the 
insulin/glucose ratio or HOMA-index. After 1, and 2 years, adiponectin levels increased 
signifi cantly in the GH group and did not change in the control group. In conclusion, 
adiponectin levels were increased, and inversely associated with triglyceride levels, 
in pre-pubertal, not overweight PWS children, although they had a relatively high body 
fat percentage. GH resulted in a signifi cant increase of adiponectin levels, whereas 
no change was found in the control group. This is reassuring with respect to the 
development of insulin resistance during GH treatment in PWS children.
Chapter 9
In the General Discussion, we discuss our fi ndings in relation to current literature. This 
chapter ends with clinical implications and considerations for future research.

Chapter
11
Samenvatting
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Dit proefschrift beschrijft de resultaten van de Nederlandse groeihormoon (GH) 
studie bij kinderen met Prader-Willi syndroom (PWS). In deze studie werden 
verschillende aspecten van het PWS onderzocht, met name anthropometrie, 
psychomotorische ontwikkeling, cognitieve ontwikkeling, gedrag, slaap-gerelateerde 
ademhalingsstoornissen, schildklierfuncties en adiponectine spiegels, alsmede de 
efffecten van GH behandeling hierop.
Hoofdstuk 1
In dit hoofdstuk wordt een overzicht gegeven van de prevalentie, de oorzaak en 
het klinisch beeld van het PWS. Tevens worden de verschillende endocrinologische 
aspecten van het PWS beschreven. Er wordt een overzicht gegeven van de eerdere 
GH studies. Tenslotte worden de doelstellingen, de in- en exclusiecriteria en de opzet 
van de studie uiteengezet.
Hoofdstuk 2
Kinderen met PWS hebben een verminderde lengtegroei en een afwijkende 
lichaamssamenstelling. Zij hebben een relatief hoog vetpercentage en een lage vetvrije 
massa. Uit eerdere studies is gebleken dat tijdens GH behandeling de lengtegroei en 
de lichaamssamenstelling verbeterde. Echter, deze studies waren gedurende maximaal 
één jaar gecontroleerd en er werden relatief kleine patiëntengroepen beschreven. 
Bovendien hadden de meeste patiënten in deze studies ernstig overgewicht. Wij hebben 
daarom een gecontroleerde GH studie uitgevoerd bij 91 pre-pubertaire kinderen met 
het PWS (42 zeer jonge kinderen <3 jaar, 49 kinderen tussen 3-14 jaar). Wij onderzochten 
de effecten van GH op lengtegroei, lichaamssamenstelling en lichaamsproporties. Na 
onafhankelijke loting werden alle kinderen verdeeld in 4 groepen. Twintig zeer jonge 
kinderen en 27 kinderen tussen 3-14 jaar werden behandeld met GH (1 mg/m2/day). Hun 
resultaten werden vergeleken met die van de 22 zeer jonge kinderen en 22 kinderen 
van 3-14 jaar die respectievelijk gedurende 1 en 2 jaar niet met GH behandeld werden 
(de controlegroep). We hebben jaarlijks anthropometrie en lichaamssamenstelling 
(met behulp van een DXA scan) bepaald. Gedurende de 1 (zeer jonge kinderen) en 2 
jaar (kinderen 3-14) gecontroleerde studie vonden we een volledige normalisatie van 
lengte, body mass index (BMI) en hoofdomtrek. Lichaamssamenstelling (uitgedrukt in 
standard deviatie score, SDS, voor leeftijd en geslacht) verbeterde, maar werd niet 
volledig normaal tijdens GH behandeling. De vetvrije massa, nadat gecorrigeerd was 
voor de toegenomen lengte tijdens GH behandeling, was niet toegenomen bij de GH-
behandelde kinderen, maar was afgenomen bij de kinderen in de controlegroep. GH 
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behandeling heeft dus een gunstig effect op de vetvrije massa. Insulin like growth 
factor I (IGF-I) steeg bij de meeste kinderen tot suprafysiologische waarden tijdens 
de behandeling. Uit onze resultaten blijkt dat 2 jaar GH behandeling bij kinderen met 
PWS lengte, alsook BMI en hoofdomtrek normaliseert en hun lichaamssamenstelling en 
lichaamsproporties verbetert. Omdat de IGF-I spiegels fors stijgen bij een aantal PWS 
kinderen, lijkt monitoring van IGF-I spiegels tijdens GH behandeling aangewezen.
Hoofdstuk 3
Eerdere GH-studies bij PWS hebben voornamelijk de effecten van GH op 
antropometrische parameters en lichaamssamenstelling beschreven. Gegevens over 
het effect van GH op de psychomotorische ontwikkeling van zeer jonge kinderen met 
PWS zijn zeer beperkt. Wij onderzochten de psychomotorische ontwikkeling van 43 
zeer jonge kinderen met PWS bij het begin van de studie, 29 van hen werden opnieuw 
geëvalueerd na 1 jaar. De GH groep bestond uit 15 kinderen en de onbehandelde 
controlegroep bestond uit 14 kinderen. We hebben de psychomotorische ontwikkeling 
geëvalueerd met behulp van de Bayley Scales of Infant development (BSID II), bij 
het begin van de studie en na 1 jaar. De gegevens werden omgerekend naar het 
percentage van de verwachte ontwikkeling op basis van leeftijd. De verandering 
(ten opzichte van de normale progressie) in ontwikkeling gedurende het jaar follow-
up werd berekend. De leeftijd (mediaan, interkwartielbereik, ikb) van de GH groep 
was 2.3 jaar (1.7 tot 3.0) en van de controlegroep 1.5 jaar (1.2 tot 2.7) (p=0.17). 
Tijdens het jaar follow-up was zowel voor de motorische ontwikkeling als voor de 
mentale ontwikkeling een signifi cant betere progressie in de behandelgroep dan in de 
controlegroep. De verandering (mediaan, ikb) in de mentale ontwikkeling was +9.3% 
(-5.3 tot 13.3) in de GH-groep en -2.9% (-8.1 tot 4.9) in de controlegroep, (p<0.05). De 
verandering in motorische ontwikkeling was +11.2% (-4.9 tot 22.5) vs. -18.5% (-27.9 tot 
1.8) (p<0.05) voor respectievelijk de GH-groep en de controlegroep. Kinderen met een 
lagere motorische ontwikkelingsleeftijd bij de start van de studie hadden tijdens GH 
een sterkere progressie van hun motoriek dan kinderen met een hogere motorische 
ontwikkelingsleeftijd bij start. Uit onze studie blijkt dat zowel de motorische als 
de mentale ontwikkeling van kinderen met PWS gunstig beïnvloed wordt door GH 
behandeling.
Hoofdstuk 4
Recent zijn een aantal beschrijvingen van onverwacht overlijden van zowel GH-
behandelde als niet-GH-behandelde jonge kinderen met PWS gepubliceerd. Deze 
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onverwachte overlijdens werden dikwijls in verband gebracht met complicaties van 
bovenste luchtweginfecties. Sommige clinici suggereerden een causaal verband tussen 
GH behandeling en onverwacht overlijden. Er zijn echter thans weinig gegevens 
beschikbaar over de effecten van GH behandeling op de ademhaling bij PWS. Wij 
hebben daarom slaap-gerelateerde ademhaling gemeten bij 53 kinderen met PWS (30 
jongens) voor en 6 maanden na start met GH behandeling, door middel van volledige 
polysomnografi e (PSG). Na 6 maanden GH behandeling werd PSG herhaald bij 35 
kinderen. De leeftijd (mediaan, ikb) was 5.4 (2.1 tot 7.2) jaar en BMI was +1.0 SDS (-0.1 
tot 1.7). Apnea Hypopneu Index (AHI) was 5.1/u (2.8 tot 8.7) (normaalwaarden: AHI 
<1/u). Centrale apneus kwamen het meest voor, 2.8/h (1.5 tot 5.4) en obstructieve 
apneus kwamen minder voor. De duur (mediaan, ikb) van de langst gemeten apneu was 
15.0 sec (13.0 tot 28.0). Er was geen verband tussen de totale AHI en leeftijd of BMI, 
maar met toenemende leeftijd daalde het aantal centrale apneus (r=-0.34, p=0.01). 
Na 6 maanden GH behandeling was er geen signifi cante verandering in AHI, van 4.8 
(2.6 tot 7.9) tot 4.0 (2.7 tot 6.2) (p=0.36). Eén patiënt in onze studie is onverwacht 
overleden tijdens een relatief milde bovenste luchtweginfectie. Hij had een bijna-
normale PSG, zowel voor als tijdens GH behandeling. Concluderend hebben kinderen 
met PWS slaap-gerelateerde ademhalingsstoornissen, met een hoge AHI, voornamelijk 
ten gevolge van centrale apneus. Tijdens GH behandeling treedt er geen verergering 
op van slaap-gerelateerde ademhalingsproblemen, maar een (bijna) normale PSG sluit 
een gecompliceerd verloop van een relatief milde bovenste luchtweginfectie niet uit. 
Onze onderzoeksresultaten suggereren dat monitoring tijdens luchtweginfecties bij 
kinderen met PWS overwogen zou moeten worden.
Hoofdstuk 5 
Er zijn aanwijzingen dat bij gezonde zeer jonge kinderen de mentale ontwikkeling 
een omgekeerd verband vertoont met de arousal index, gerelateerd aan snurken. Wij 
onderzochten bij kinderen met PWS de relatie tussen psychomotorische ontwikkeling, 
gemeten met BSID II, en slaap-gerelateerde ademhalingsstoornissen, gemeten met 
PSG. Wij onderzochten een groep van 22 kinderen met PWS. Deze groep had een 
leeftijd (mediaan, ikb) van 1.8 (1.1 tot 3.4) jaar en een BMI SDS van -0.5 (-1.3 tot 
1.6). De mediaan (ikb) voor de mentale en motorische ontwikkeling in deze groep 
kinderen was respectievelijk 73.1% (64.3 tot 79.6) en 55.2% (46.5 tot 63.1), van de 
verwachte ontwikkeling voor de leeftijd. Alle kinderen hadden slaap-gerelateerde 
ademhalingsstoornissen, meestal van centrale oorsprong. Vier kinderen hadden 
obstructief slaapapneu syndroom (OSAS). We vonden geen verband tussen de AHI 
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en de psychomotorische ontwikkeling in de totale groep. De kinderen met OSAS 
hadden echter een signifi cant lagere mentale ontwikkeling dan kinderen zonder OSAS, 
namelijk 65.5% (60.0 tot 70.3) van het normaal te verwachten ontwikkelingsniveau. 
De kinderen met OSAS hadden een BMI SDS van 1.4 (0.1 tot 1.6). Dit is hoger (hoewel 
niet statistisch signifi cant) dan bij kinderen zonder OSAS. Onze resultaten tonen 
geen verband tussen psychomotorische ontwikkeling en centrale slaap-gerelateerde 
ademhalingsstoornissen. Echter, kinderen met OSAS hebben een ernstigere vertraging 
van de mentale ontwikkeling. Op basis van deze resultaten zou screening voor OSAS 
bij jonge kinderen met PWS zinvol zijn. 
Hoofdstuk 6
Gedragsproblemen, cognitieve beperkingen en slaap-gerelateerde ademhalings-
stoornissen zijn veelvoorkomende kenmerken van het PWS. In de algemene populatie 
bestaat er een sterk verband tussen gedragsproblemen, cognitieve beperkingen en 
slaap-gerelateerde ademhalingsproblemen. Wij onderzochten bij de pre-pubertaire 
kinderen met PWS het gedrag, de cognitieve ontwikkeling en het verband met de 
slaap-gerelateerde ademhalingsproblemen. Wij hebben bij 31 pre-pubertaire kinderen 
met PWS in de leeftijd van 4.0-13.2 jaar de cognitie bepaald met behulp van subtesten 
van, voor de leeftijd geschikte, Wechsler intelligentietesten. Het gedrag hebben 
we geëvalueerd met behulp van vragenlijsten voor ouders. Vervolgens hebben we 
gekeken of er een verband bestond tussen de resultaten van deze testen en die van de 
PSG. Alle cognitieve subtesten waren signifi cant lager dan 0 SDS, met de laagste score 
(mediaan, ikb) voor één van de performale subtesten (Blokpatronen), -2.7 SDS (-3.0 tot 
-0.3). Opvallend was dat de cognitieve beperkingen niet harmonisch verdeeld waren. 
Zestig procent van de kinderen scoorden beter op de verbale dan op de performale 
subtesten. Gedragsproblemen werden gerapporteerd voornamelijk op de subschalen 
“emoties/gedrag niet aangepast aan de sociale situatie” en “ongevoeligheid voor 
sociale informatie”. Deze bevindingen zouden veroorzaakt kunnen zijn doordat er 
zich in deze groep een relatief hoog percentage kinderen bevindt met uniparentele 
maternale disomie. Alle kinderen hadden een slaap-gerelateerde ademhalingsstoornis, 
met een (mediaan, ikb) AHI van 4.1/u (2.6 tot 7.9). Op een van de performale subtesten 
werd signifi cant beter gescoord door kinderen met een hogere slaap effi ciëntie index, 
gemeten door middel van PSG. Autistisch aandoend sociaal gedrag was gerelateerd 
aan slaperigheid overdag, zoals gerapporteerd door de ouders. In tegenstelling tot 
onze verwachtingen, hadden kinderen met betere slaap-gerelateerde ademhaling 
meer gedragsproblemen (in het bijzonder problemen met sociaal-gerelateerd 
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gedrag). Concluderend vonden wij bij kinderen met PWS dat gedragsproblemen 
regelmatig voorkwamen, met name autistisch aandoend sociaal gedrag en dat er een 
disharmonische beperking van de cognitie was. Een hogere slaap effi ciëntie index was 
geassocieerd met een betere score op de “Plaatjes ordenen/Onvolledige tekeningen” 
subtest, en slaperigheid overdag was geassocieerd met autistisch aandoend sociaal 
gedrag. Daarentegen konden we het positieve verband tussen slaap-gerelateerde 
ademhalingsstoornissen en gedragsstoornissen, bij PWS niet bevestigen.
Hoofdstuk 7
Bij PWS zijn er een aantal endocrinologische afwijkingen beschreven, onder welke 
GH defi ciëntie en hypogonadotroop hypogonadisme. Echter, er zijn thans heel weinig 
gegevens beschikbaar over de schildklierfuncties bij PWS. Er wordt verondersteld dat 
er een verband is tussen GH behandeling en de schildklierfuncties. GH behandeling 
zou een latente TSH defi ciëntie kunnen openbaren. Daarnaast zou GH behandeling de 
perifere omzetting van T4 naar T3 bevorderen. Wij onderzochten de schildklierfuncties 
bij kinderen met PWS voor en tijdens GH behandeling, in vergelijking met onbehandelde 
patiënten. T4, vrij T4 (vT4), T3, reverse T3 (rT3) en TSH spiegels werden gemeten bij 
75 kinderen met PWS (mediaan (ikb) leeftijd 4.7 (2.7 tot 7.6) jaar). Na een jaar werden 
de spiegels opnieuw bepaald bij 57 kinderen. Vierendertig kinderen werden met GH 
behandeld, en 23 kinderen werden gedurende dit jaar gevolgd als controlegroep. 
Mediaan (ikb) TSH spiegel was -0.1 SDS (-0.5 tot 0.5), T4 spiegel, -0.6 SDS (-1.7 tot 0.0), 
en vT4 spiegel, -0.8 SDS (-1.3 tot -0.3). T4 en vT4 spiegels waren beiden signifi cant 
lager dan 0 SDS en de T3 spiegel was signifi cant hoger dan 0 SDS. Na 1 jaar GH 
behandeling daalde de vT4 spiegel signifi cant, van -0.8 SDS (-1.5 tot -0.2) tot -1.4 SDS 
(-1.6 tot -0.7), terwijl er geen verandering optrad bij de controlegroep. De T3 spiegels 
veranderden niet. Onze resultaten laten zien dat T4 spiegels binnen normale grenzen 
waren bij de meeste kinderen met PWS. Tijdens GH behandeling trad er een daling op 
van de vT4 spiegel, maar TSH bleef volledig normaal. T3 spiegels waren juist relatief 
hoog of normaal. Dit wijst erop dat kinderen met PWS een verhoogde omzetting van 
T4 naar T3 hebben. In het bijzonder tijdens GH behandeling, lijkt het aangewezen om 
schildklierfuncties bij kinderen met PWS te bepalen. 
Hoofdstuk 8
Obesitas en een afwijkende lichaamssamenstelling, met een relatief lage vetvrije 
massa en een relatief hoog lichaamsvetpercentage, zijn veelvoorkomende kenmerken 
van het PWS. Deze factoren vormen een verhoogd risico op de ontwikkeling van 
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insulineresistentie en van cardiovasculaire ziekten. Adiponectine is een hormoon dat 
afgescheiden wordt door de vetcellen en een beschermende werking zou hebben tegen 
het ontstaan van diabetes mellitus en cardiovasculaire ziekten. Wij onderzochten bij 
pre-pubertaire kinderen met PWS (1) adiponectine spiegels, lichaamssamenstelling, 
koolhydraatmetabolisme, en triglyceride spiegels, (2) het verband tussen deze 
parameters en (3) effecten van GH behandeling op deze parameters. Twintig kinderen 
met PWS werden gevolgd in de GH behandelgroep (n=10), of in de controlegroep (n=10) 
gedurende 2 jaar. Wij hebben de adiponectine, glucose, insuline, and triglyceride 
spiegels gemeten bij start van de studie, na 1 jaar en na 2 jaar. Lichaamssamenstelling 
werd bepaald met behulp van een DXA scan. Bij start waren adiponectine spiegels 
(mediaan, ikb) 17.1 mg/l (13.9 tot 23.2) voor de totale groep, wat signifi cant hoger is 
dan bij gezonde kinderen met hetzelfde geslacht en leeftijd, 11.8 mg/l (9.7 tot 12.5) 
(p<0.005). Het lichaamsvetpercentage was signifi cant hoger dan 0 SDS bij de kinderen 
met PWS, 1.8 SDS (1.5 tot 2.1) (p<0.001). Adiponectine spiegels waren omgekeerd 
gerelateerd aan triglyceride spiegels, (r=-0.52, p=0.03), en er was een tendens tot 
een omgekeerde relatie met lichaamsvetpercentage en BMI. We vonden geen verband 
met nuchtere inuline of glucose spiegels, de insuline/glucose ratio of de HOMA-index. 
Na 1 en 2 jaar, stegen adiponectine spiegels signifi cant in de GH group, terwijl er 
geen verandering optrad bij de controlegroep. Onze resultaten toonden dat jonge, 
pre-pubertaire kinderen met PWS hoge adiponectine spiegels hadden en dat deze 
omgekeerd gerelateerd waren aan de triglyceride spiegels. Deze kinderen hadden 
geen ernstig overgewicht, maar wel een verhoogd lichaamsvetpercentage. Tijdens 
GH behandeling trad er een verdere stijging op van de adiponectine spiegels, terwijl 
er geen sprake was van verandering in de controlegroep. Deze bevindingen zijn 
geruststellend voor wat betreft de ontwikkeling van insulineresistentie tijdens GH 
behandeling bij kinderen met PWS. 
Hoofdstuk 9
In de algemene discussie worden de resultaten van de verschillende studies besproken 
en vergeleken met de huidige literatuur. Aan het eind van dit hoofdstuk wordt een 
overzicht gegeven van de klinische implicaties en worden er suggesties gedaan voor 
toekomstig onderzoek.
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